

PATENT

Attorney Docket 4726US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL740532647USDate of Deposit with USPS: January 22, 2001

Person making Deposit: Daniel Thatcher

APPLICATION FOR LETTERS PATENT

for

STREPTOCOCCUS SUI VACCINES AND DIAGNOSTIC TESTS

Inventor:

Hilda E. Smith

Attorney:

Allen C. Turner

Registration No. 33,041

Krista Weber Powell

Registration No. 48, 867

TRASK BRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110

(801) 532-1922

***STREPTOCOCCUS SUI* VACCINES AND DIAGNOSTIC TESTS**

Cross-reference to Related Applications. This application claims priority to, and is a continuation of, International Application No. PCT/NL99/00460, filed on July 19, 1999, designating the United States of America, the contents of which are incorporated herein by this reference, the PCT International Patent Application itself claiming priority from European Patent Office Application Serial No. 98202465.5 filed July 22, 1998 and European Patent Office Application Serial No. 98202467.1 filed July 22, 1998.

Technical Field. The invention relates to *Streptococcus* infections in pigs, vaccines directed against those infections, tests for diagnosing *Streptococcus* infections and bacterial vaccines. More particularly, the invention relates to vaccines directed against *Streptococcus* infections.

Background of the Invention

Streptococcus species, of which a large variety cause infections in domestic animals and man, are often grouped according to Lancefield's groups. Typing according to Lancefield occurs on the basis of serological determinants or antigens that are, among others, present in the capsule of the bacterium, and allows for only an approximate determination. Often, bacteria from different groups show cross-reactivity with each other, while other *Streptococci* can not be assigned a group-determinant at all. Within groups, further differentiation is often possible on the basis of serotyping. These serotypes further contribute to the large antigenic variability of *Streptococci*, a fact that creates an array of difficulties within diagnosis of and vaccination against *Streptococcal* infections.

Lancefield group A *Streptococcus species* (GAS, *Streptococcus pyogenes*), are common in children, causing nasopharyngeal infections and complications thereof. Among animals, cattle are especially susceptible to GAS, and the resulting mastitis.

Group A streptococci are the etiologic agents of streptococcal pharyngitis and impetigo, two of the most common bacterial infections in children, as well as a variety of less common, but potentially life-threatening, infections including soft tissue infections, bacteremia, and pneumonia. In addition, GAS are uniquely associated with the post-infectious autoimmune syndromes of acute rheumatic fever and post streptococcal glomerulonephritis.

Several recent reports suggest that the incidence of both serious infections due to GAS and acute rheumatic fever has

increased during the past decade, focusing renewed interest on defining the attributes or virulence factors of the organism that may play a role in the pathogenesis of these diseases.

GAS produce several surface components and extracellular products that may be important in virulence. The major surface protein, M protein, has been studied in the most detail and has been shown convincingly to play a role in both virulence and immunity. Isolates rich in M protein are able to grow in human blood, a property thought to reflect the capacity of M protein to interfere with phagocytosis, and these isolates tend to be virulent in experimental animals.

Lancefield group B *Streptococcus* (GBS) are most often seen with cattle, causing mastitis, however, human infants are susceptible as well, often with fatal consequences. Group B streptococci (GBS) constitute a major cause of bacterial sepsis and meningitis among human neonates born in the United States and Western Europe and are emerging as significant neonatal pathogens in developing countries as well.

It is estimated that GBS strains are responsible for 10,000 to 15,000 cases of invasive infection in neonates in the United States alone. Despite advances in early diagnosis and treatment, neonatal sepsis due to GBS continues to carry a mortality rate of 15 to 20%. In addition, survivors of GBS meningitis have 30 to 50% incidence of long-term neurologic sequelae. The increasing recognition over the past two decades of GBS as an important pathogen for human infants has generated renewed interest in defining the bacterial and host factors important in virulence of GBS and in the immune response to GBS infection.

Particular attention has focused on the capsular polysaccharide as the predominant surface antigen of the organisms. In a modification of the system originally developed by Rebecca Lancefield, GBS strains are serotyped on the basis of antigen differences in their capsular polysaccharides and the presence or absence of serologically defined C proteins. While GBS isolated from non-human sources

often lack a serologically detectable capsule, a large majority of strains associated with neonatal infection belong to one of four major capsular serotypes, 1a, 1b, II or III. The capsular polysaccharide forms the outermost layer around the exterior of the bacterial cell, superficial to the cell wall. The capsule is distinct from the cell wall-associated group B carbohydrate. It has been suggested that the presence of sialic acid in the capsule of bacteria that cause meningitis is important for these bacteria to breach the blood-brain barrier. Indeed, in *S. agalactiae* sialic acid has shown to be critical for the virulence function of the type III capsule. The capsule of *S. suis* serotype is composed of glucose, galactose, N-acetylglucosamine, rhamnose and sialic acid.

The group B polysaccharide, in contrast to the type-specific capsule, is present on all GBS strains and is the basis for serogrouping of the organisms into Lancefield's group B. Early studies by Lancefield and co-workers showed that antibodies raised in rabbits against whole GBS organisms protected mice against challenge with strains of homologous capsular type, demonstrating the central role of the capsular polysaccharide as a protective antigen. Studies in the 1970s by Baker and Kasper demonstrated that cord blood of human infants with type III GBS sepsis uniformly had low or undetectable levels of antibodies directed against the type III capsule, suggesting that a deficiency of anticapsular antibody was a key factor in susceptibility of human neonates to GBS disease.

Lancefield group C infections, such as those with *S. equi*, *S. zooepidemicus*, *S. dysgalactiae*, and others are mainly seen with horse, cattle and pigs, but can also cross the species barrier to humans. Lancefield group D (*S. bovis*) infections are found with all mammals and some birds, sometimes resulting in endocarditis or septicaemia.

Lancefield groups E, G, L, P, U and V (*S. porcinus*, *S. canis*, *S. dysgalactiae*) are found with various hosts, causing

09767041.032301

neonatal infections, nasopharyngeal infections or mastitis.

Within Lancefield groups R, S, and T, (and with ungrouped types) *S. suis* is found, an important cause of meningitis, septicemia, arthritis and sudden death in young pigs.

5 Incidentally, it can also cause meningitis in man.

Streptococcus suis is an important cause of meningitis, septicemia, arthritis and sudden death in young pigs (4, 46). Incidentally, it can also cause meningitis in man (1). *S. suis* strains are usually identified and classified by their
10 morphological, biochemical and serological characteristics (58, 59, 46). Serological classification is based on the presence of specific antigenic polysaccharides. So far, 35 different serotypes have been described (9, 56, 14). In several European countries, *S. suis* serotype 2 is the most prevalent type
15 isolated from diseased pigs, followed by serotypes 9 and 1. Serological typing of *S. suis* is carried out using different types of agglutination tests. In these tests, isolated and biochemically characterised *S. suis* cells are agglutinated with a panel of 35 specific sera. These methods are very laborious
20 and time-consuming.

Little is known about the pathogenesis of the disease caused by *S. suis*, let alone about its various serotypes such as type 2. Various bacterial components, such as extracellular and cell-membrane associated proteins, fimbriae, haemagglutinins,
25 and haemolysin have been suggested as virulence factors (9, 10, 11, 15, 16, 47, 49). However, the precise role of these protein components in the pathogenesis of the disease remains unclear (37). It is well known that the polysaccharidic capsule of various Streptococci and other gram-positive bacteria plays an
30 important role in pathogenesis (3, 6, 35, 51, 52). The capsule enables these micro-organisms to resist phagocytosis and is therefore regarded as an important virulence factor. Recently, a role of the capsule of *S. suis* in the pathogenesis was suggested as well (5). However, the structure, organisation and
35 functioning of the genes responsible for capsule polysaccharide synthesis (*cps*) in *S. suis* is unknown. Within *S. suis* serotypes

09767041.032901

1 and 2 strains can differ in virulence for pigs (41, 45, 49). Some type 1 and 2 strains are virulent, other strains are not. Because both virulent and non-virulent strains of serotype 1 and 2 strains are fully encapsulated, it may even be that capsule is not a relevant factor required for virulence.

Attempts to control *S. suis* infections or disease are still hampered by the lack of knowledge about the epidemiology of the disease and the lack of effective vaccines and sensitive diagnostics. It is well known and generally accepted that the polysaccharidic capsule of various Streptococci and other gram-positive bacteria plays an important role in pathogenesis. The capsule enables these micro-organisms to resist phagocytosis and is therefore regarded as an important virulence factor.

Compared to encapsulated *S. suis* strains, non-encapsulated *S. suis* strains are phagocytosed by murine polymorphonuclear leucocytes to a greater degree. Moreover, an increase in thickness of capsule was noted for *in vivo* grown virulent strains while no increase was observed for avirulent strains. Therefore, these data again demonstrate the role of the capsule in the pathogenesis for *S. suis* as well.

Ungrouped *Streptococcus* species, such as *S. mutans*, causing caries with humans, *S. uberis*, causing mastitis with cattle, and *S. pneumoniae*, causing major infections in humans, and *Enterococcus faecalis* and *E. faecium*, further contributed to the large group of Streptococci.

Streptococcus pneumoniae (the pneumococcus) is a human pathogen causing invasive diseases, such as pneumonia, bacteraemia, and meningitis. Despite the availability of antibiotics, pneumococcal infections remain common and can still be fatal, especially in high-risk groups, such as young children and elderly people. Particularly in developing countries, many children under the age of five years die each year from pneumococcal pneumonia. *S. pneumoniae* is also the leading cause of otitis media and sinusitis. These infections are less serious, but nevertheless incur substantial medical

costs, especially when leading to complications, such as permanent deafness. The normal ecological niche of the pneumococcus is the nasopharynx of man. The entire human population is colonised by the pneumococcus at one time or another, and at a given time, up to 60% of individuals may be carriers. Nasopharyngeal carriage of pneumococci by man is often accompanied by the development of protection to infection by the same serotype. Most infections do not occur after prolonged carriage but follow the acquisition of recently acquired strains. Many bacteria contain surface polysaccharides which act as a protective layer against the environment. Surface polysaccharides of pathogenic bacteria usually make the bacteria resistant to the defense mechanisms of the host, e.g., the lytic action of serum or phagocytosis. In this respect, the serotype-specific capsular polysaccharide (CP) of *Streptococcus pneumoniae*, is an important virulence factor. Unencapsulated strains are avirulent, and antibodies directed against the CP are protective. Protection is serotype specific; each serotype has its own, specific CP structure. Ninety different capsular serotypes have been identified. Currently, CPs of 23 serotypes are included in a vaccine.

Vaccines directed against *Streptococcus* infections in general aim at utilising an immune response directed against the polysaccharide capsule of the various *Streptococcus* species, especially since the capsule is considered a main virulence factor for these bacteria. The capsule, during infection, provides resistance to phagocytosis and thus promotes the escape of the bacteria from the immune system of the host, protecting the bacteria by elimination by macrophages and neutrophils.

The capsule particularly confers the bacterium resistance to complement-mediated opsonophagocytosis. In addition, some bacteria express capsular polysaccharides (CPs) that mimic host molecules, thereby avoiding the immune system of the host. Also, even when the bacteria have been phagocytosed, intracellular killing is hampered by the presence of a

capsule.

It is in general thought that only when the host has antibodies or other serum-factors directed against capsule antigens, the bacterium will get recognised by the immune system through the anticapsular-antibodies or serum-factors bound to its capsule, and will, through opsonisation, get phagocytosed and killed.

However, these antibodies are serotype-specific, and will often only confer protection against only one of the many serotypes known within a group of *Streptococci*.

For example, current commercially available *S. suis* vaccines, which are in general based on whole-cell-bacterial preparations, or on capsule-enriched fractions of *S. suis*, confer only limited protection against heterologous strains. Also, the current pneumococcal vaccine, licensed in the United States in 1983, consists of purified CPs of 23 pneumococcal serotypes whereas at least 90 CP types exist.

The composition of this pneumococcal vaccine was based on the frequency of the occurrence of disease isolates in the US and cross-reactivity between various serotypes. Although this vaccine protects healthy adults against infections caused by serotypes included in the vaccine, it fails to raise a protective immune response in infants younger than 18 months and it is less effective in elderly people. In addition, the vaccine confers only limited protection in patients with immunodeficiencies and haematology malignancies.

In the light of above, improved vaccines are needed against *Streptococcus* infections. Much attention is being paid at producing CP vaccines by producing the relevant polysaccharides via chemical or recombinant means. However, chemical synthesis of polysaccharides is costly, and capsular polysaccharide synthesis by recombinant means necessitates knowledge about the relevant genes, which are not always available and need to be determined for each and every relevant serotype.

5 The invention provides an isolated or recombinant nucleic acid encoding a capsular (*cps*) gene cluster of *Streptococcus suis*. Biosynthesis of capsule polysaccharides in general has been studied in a number of Gram-positive and Gram-negative bacteria (32). In Gram-negative bacteria, but also in a number of gram-positive bacteria, genes which are involved in the biosynthesis of polysaccharides are clustered at a single locus. *Streptococcus suis* capsular genes as provided by the invention show a common genetic organisation involving three distinct regions. The central region is serotype specific and encodes enzymes responsible for the synthesis and polymerisation of the polysaccharides. This region is flanked by two regions conserved in *Streptococcus suis* which encode proteins for common functions such as transport of the polysaccharide across the cellular membrane. However, in between species, only low homologies exist, hampering easy comparison and detection of seemingly similar genes. Knowing the nucleic acid encoding the flanking regions allows type-specific determination of nucleic acid of the central region of *Streptococcus suis* serotypes, as for example described in the experimental part of the description of the invention.

The invention provides an isolated or recombinant nucleic acid encoding a capsular gene cluster of *Streptococcus suis* or a gene or gene fragment derived thereof. Such a nucleic acid is for example provided by hybridising chromosomal DNA derived from any one of the *Streptococcus suis* serotypes to a nucleic acid encoding a gene derived from a *Streptococcus suis* serotype 1, 2 or 9 capsular gene cluster, as provided by the invention (see for example Tables 4 and 5) and cloning of (type-specific) genes as for example described in the experimental part of the description. At least 14 open reading frames are identified. Most of the genes belong to a single transcriptional unit, identifying a co-ordinate control of these genes, they, and the enzymes and proteins they encode, act in concert to provide the capsule with the relevant polysaccharides. The invention provides *cps* genes and proteins

encoded thereof involved in regulation (CpsA), chain length
determination (CpsB, C), export (CpsC) and biosynthesis (CpsE,
F, G, H, J, K). Although the overall organisation seemed at
first glance to be similar to that of the *cps* and *eps* gene
clusters of a number of Gram-positive bacteria (19, 32, 42),
overall homologies are low (see table 3). The region involved
in biosynthesis is located at the centre of the gene cluster
and is flanked by two regions containing genes with more
common functions.

10 The invention provides an isolated or recombinant nucleic
acid encoding a capsular gene cluster of *Streptococcus suis*
serotype 2 or a gene or gene fragment derived thereof,
preferably as identified in Figure 3. Genes in this gene
cluster are involved in polysaccharide biosynthesis of
15 capsular components and antigens. For a further description of
such genes see for example Table 2 of the description, for
example a *cpsA* gene is provided functionally encoding
regulation of capsular polysaccharide synthesis, whereas *cpsB*
and *cpsC* are functionally involved in chain in chain length
20 determination. Other genes, such as *cpsD*, E, F, G, H, I, J, K
and related genes, are involved in polysaccharide syntheses,
functioning for example as glucosyl- or glycosyltransferase.
The *cpsF*, G, H, I, J genes encode more type-specific proteins
than the flanking genes which are found more-or-less conserved
25 throughout the species and can serve as base for selection of
primers or probes in PCR-amplification or cross-hybridisation
experiments for subsequent cloning.

For example, the invention further provides an isolated or
30 recombinant nucleic acid encoding a capsular gene cluster of
Streptococcus suis serotype 1 or a gene or gene fragment
derived thereof, preferably as identified in Figure 4.

In addition, the invention provides an isolated or
recombinant nucleic acid encoding a capsular gene cluster of
35 *Streptococcus suis* serotype 9 or a gene or gene fragment
derived thereof, preferably as identified in Figure 5.

Furthermore, the invention provides for example a fragment or parts thereof of the *cps* locus, involved in the capsular polysaccharide biosynthesis, of *S. suis*, exemplified in the experimental part for serotype 1, 2 or 9, and allows easy
5 identification or detection of related fragments derived of other serotype of *S. suis*.

The invention provides a nucleic acid probe or primer derived from a nucleic acid according to the invention allowing species or serotype specific detection of
10 *Streptococcus suis*. Such a probe or primer (herein used interchangeably) is for example a DNA, RNA or PNA (peptide nucleic acid) probe hybridising with capsular nucleic acid as provided by the invention. Species specific detection is provided preferably by selecting a probe or primer sequence
15 from a species-specific region (e.g. flanking region) whereas serotype specific detection is provided preferably by selecting a probe or primer sequence from a type-specific region (e.g. central region) of a capsular gene cluster as provided by the invention. Such a probe or primer can be used
20 in a further unmodified form, for example in cross-hybridisation or polymerase-chain reaction (PCR) experiments as for example described in the experimental part of the description of the invention. Herein the invention provides the isolation and molecular characterisation of additional
25 type specific *cps* genes of *S. suis* types 1 and 9. In addition, we describe the genetic diversity of the *cps* loci of serotypes 1, 2 and 9 among the 35 *S. suis* serotypes yet known. Type-specific probes are identified. Also, a type-specific PCR for for example serotype 9 is provided, being a rapid, reliable
30 and sensitive assay, which is used directly on nasal or tonsillar swabs or other samples of infected or carrier animals.

The invention also provides a probe or primer according to the invention further provided with at least one reporter
35 molecule. Examples of reporter molecules are manifold and known in the art, for example a reporter molecule can comprise

0976704.0330

additional nucleic acid provided with a specific sequence (e.g. oligo-dT) hybridising to a corresponding sequence to which hybridisation can easily be detected for example because it has been immobilised to a solid support.

5 Yet other reporter molecules comprise chromophores, e.g. fluorochromes for visual detection, for example by light microscopy or fluorescent in situ hybridisation (FISH) techniques, or comprise an enzyme such as horseradish peroxidase for enzymatic detection, e.g in enzyme-linked
10 assays (EIA). Yet other reporter molecules comprise radioactive compounds for detection in radiation-based-assays.

In a preferred embodiment of the invention, at least one probe or primer according to the invention is provided (labelled) with a reporter molecule and a quencher molecule,
15 providing together with unlabeled probe or primer a PCR-based test allowing rapid detection of specific hybridisation.

The invention further provides a diagnostic test or test kit comprising a probe or primer as provided by the invention. Such a test or test kit, for example a cross-hybridisation
20 test or PCR-based test, is advantageously used in rapid detection and/or serotyping of *Streptococcus suis*.

The invention furthermore provides a protein or fragment thereof encoded by a nucleic acid according to the invention. Examples of such a protein or fragment are for example
25 proteins described in for example Table 2 of the description, for example a cpsA protein is provided functionally encoding regulation of capsular polysaccharide synthesis, whereas cpsB and cpsC are functionally involved in chain in chain length determination. Other proteins or functional fragments thereof
30 as provided by the invention, such as cpsD, E, F, G, H, I, J, K and related proteins, are involved in polysaccharide biosynthesis, functioning for example as glucosyl- or glycosyltransferase in polysaccharide biosynthesis of *Streptococcus suis* capsular antigen.

35 The invention furthermore provides a method to produce a *Streptococcus suis* capsular antigen comprising using a protein

09704090

or functional fragment thereof as provided by the invention, and provides therewith a *Streptococcus suis* capsular antigen obtainable by such a method. A comparison of the predicted amino acid sequences of the *cps2* genes with sequences found in the databases allowed the assignment of functions to the open reading frames. The central region contains the type specific glycosyltransferases and the putative polysaccharide polymerase. This region is flanked by two regions encoding for proteins with common functions, such as regulation and transport of polysaccharide across the membrane.

Biosynthesis of *Streptococcus* capsular polysaccharide antigen using a protein or functional fragment thereof is advantageously used in chemo-enzymatic synthesis and the development of vaccines which offer protection against serotype-specific *Streptococcal* disease, and is also advantageously used in the synthesis and development of multivalent vaccines against *Streptococcal* infections. Such vaccines elicit anticapsular antibodies which confer protection.

Furthermore, the invention provides an acapsular *Streptococcus* mutant for use in a vaccine, a vaccine strain derived thereof and a vaccine derived thereof. Surprisingly, and against the grain of common doctrine, the invention provides use of a *Streptococcus* mutant deficient in capsular expression in a vaccine.

Acapsular *Streptococcus* mutants have long been known in the art and can be found in nature. Griffith (J. Hyg. 27:113-159, 1928) demonstrated that pneumococci could be transformed from one type to another. If he injected live rough (acapsular or unencapsulated) type 2 pneumococci into mice, the mice would survive. If, however, he injected the same dose of live rough type 2 mixed with heat-killed smooth (encapsulated) type 1 into a mouse, the mouse would die, and from the blood he could isolate live smooth type 1 pneumococci. At that time, the significance of this transforming principle was not understood. However, understanding came when it was shown that

DNA constituted the genetic material responsible for phenotypic changes during transformation.

Streptococcus mutants deficient in capsular expression are found in several forms. Some are fully deficient and have
5 no capsule at all, others form a deficient capsule, characterised by a mutation in a capsular gene cluster. Deficiency can for instance include capsular formation wherein the organization of the capsular material has been re-
arranged, as for example demnosrable by electron microscopy.
10 Yet others have a nearly fully developed capsule which is only deficient in a particular sugar component.

Now, after much advance of biotechnology and despite the fact that little is still known about the exact localisation and sequence of genes involved in capsular synthesis in
15 *Streptococci*, it is possible to create mutants of *Streptococci*, for example by homologous recombination or transposon mutagenesis, which has for example been done for GAS (Wessels et al., PNAS 88:8317-8321, 1991), for GBS (Wesels et al., PNAS 86: 8983-8987, 1989), for *S. suis* (Smith, ID-DLO
20 Annual report 1996, page 18-19; Charland et al., Microbiol. 144:325-332, 1998) and for *S. pneumonia* (Kolkman et al., J. Bact. 178:3736-3741, 1996). Such recombinant derived mutants, or isogenic mutants, can easily be compared with the wild-type strains from which they have been derived.

25 In a preferred embodiment, the invention provides use of a recombinant-derived *Streptococcus* mutant deficient in capsular expression in a vaccine. Recombinant techniques useful in producing such mutants are for example homologous recombination, transposon mutagenises, and others, whereby
30 deletions, insertions or (point)-mutations are introduced in the genome. Advantages of using recombinant techniques are the stability of the obtained mutants (especially with homologous recombination and double cross-over techniques), and the knowledge about the exact site of the deletion, mutation or
35 insertion.

In a much preferred embodiment, the invention provides a

096704.0301

stable mutant deficient in capsular expression obtainable for example through homologous recombination or cross over integration events. Examples of such a mutant can be found in the experimental part of this description, for example mutant 5 10cpsB or 10cpsEF is such a stable mutant as provided by the invention.

The invention also provides a *Streptococcus* vaccine strain and vaccine that has been derived from a *Streptococcus* mutant deficient in capsular expression. In general, said 10 strain or vaccine is applicable within the whole range of Streptococcal infections, be it for those with animals or man or with zoonotic infections. It is of course now possible to first select a common vaccine strain and derive a *Streptococcus* mutant deficient in capsular expression thereof 15 for the selection of a vaccine strain and use in a vaccine according to the invention.

In a preferred embodiment, the invention provides use of a *Streptococcus* mutant deficient in capsular expression in a vaccine wherein said *Streptococcus* mutant is selected from 20 the group composed of *Streptococcus* group A, *Streptococcus* group B, *Streptococcus suis* and *Streptococcus pneumoniae*. Herewith the invention provides vaccine strains and vaccines for use with these notoriously heterologous Streptococci, of which a multitude of serotypes exist. With a vaccine as 25 provided by the invention that is derived from a specific *Streptococcus* mutant that deficient in capsular expression, the difficulties relating to lack of heterologous protection can be circumvented since these mutants do not rely on capsular antigens per se to induce protection.

30 In a preferred embodiment, said vaccine strain is selected for its ability to survive or even replicate in an immune-competent host or host cells and thus can persist for a certain period, varying from 1-2 days to more than one or two weeks, in a host, despite its deficient character.

35 Although an immunodeficient host will support replication of a wide range of bacteria that are deficient in one or more

0926704.0301

virulence factors, in general it is considered a characteristic of pathogenicity of Streptococci that they can survive for certain periods or replicate in a normal host or host cells such as macrophages. For example, Williams and
5 Blakemore (Neuropath. Appl. Neurobiol.: 16, 345-356, 1990; Neuropath. Appl. Neurobiol.: 16, 377-392, 1990; J. Infect. Dis.: 162, 474-481, 1990) show that both polymorphonuclear cells and macrophage cells are capable of phagocytosing pathogenic *S. suis* in pigs lacking anti-*S. suis* antibodies,
10 only pathogenic bacteria could survive and multiply inside macrophages and the pig.

In a preferred embodiment, the invention, however, provides a deficient or avirulent mutant or vaccine strain which is capable of surviving at least 4-5 days, preferably at
15 least 8-10 days in said host, thereby allowing the development of a solid immune response to subsequent *Streptococcus* infection,

Due to its persistent but avirulent character, a *Streptococcus* mutant or vaccine strain as provided by the
20 invention is well suited to generate specific and/or long-lasting immune responses against Streptococcal antigens, moreover because possible specific immune responses of the host directed against a capsule are relatively irrelevant because a vaccine strain as provided by the invention is in
25 general not recognised by such antibodies.

In addition, the invention provides a *Streptococcus* vaccine strain according to the invention which strain comprises a mutant capable of expressing a *Streptococcus* virulence factor or antigenic determinant.

30 In a preferred embodiment, the invention provides a *Streptococcus* vaccine strain according to the invention which strain comprises a mutant capable of expressing a *Streptococcus* virulence factor wherein said virulence factor or antigenic determinant is selected from a group of cellular
35 components, such as muramidase-released protein (MRP) extracellular factor (EF) and cell-membrane associated

09767041.04.9901

proteins, 60kDA heat shock protein, pneumococcal surface protein A (Psp A), pneumolysin, C protein, protein M, fimbriae, haemagglutinins and haemolysin or components functionally related thereto.

5 In a much preferred embodiment, the invention provides a *Streptococcus* vaccine strain according to the invention which strain comprises a mutant capable of over-expressing said virulence factor. In this way, the invention provides a vaccine strain for incorporation in a vaccine which
10 specifically causes a host to provide a immune response directed against antigenically important determinants of virulence (listed above), thereby providing specific protection directed against said determinants. Over-expression can for example be achieved by cloning the gene involved
15 behind a strong promoter, which is for example constitutionally expressed in a multicopy system, either in a plasmid or via intergration in a genome.

In yet another embodiment, the invention provides a *Streptococcus* vaccine strain according to the invention which
20 comprises a mutant capable of expressing a non-*Streptococcus* protein. Such a vector-*Streptococcus* vaccine strain allows, when used in a vaccine, protection against other pathogens than *Streptococcus*.

Due to its persistent but avirulent character, a
25 *Streptococcus* vaccine strain or mutant as provided by the invention is well suited to generate specific and long-lasting immune responses, not only against Streptococcal antigens, but also against other antigens when these are expressed by said strain. Especially antigens derived from another pathogen are
30 now expressed without the detrimental effects of said antigen or pathogen which would otherwise have harmed the host.

An example of such a vector is a *Streptococcus* vaccine strain or mutant wherein said antigen is derived from a pathogen, such as *Actinobacillus pleuropneumonia*,
35 *Mycoplasmatae*, *Bordetella*, *Pasteurella*, *E. coli*, *Salmonella*, *Campylobacter*, *Serpulina* and others.

09767041.012301

The invention also provides a vaccine comprising a *Streptococcus* vaccine strain or mutant according to the invention and further comprising a pharmaceutically acceptable carrier or adjuvant. Carriers or adjuvants are well known in the art, examples are phosphate buffered saline, physiological salt solutions, (double-)oil-in-water-emulsions, aluminumhydroxide, Specol, block- or co-polymers, and others.

A vaccine according to the invention can comprise a vaccine strain either in a killed or live form. For example, a killed vaccine comprising a strain having (over)expressed a Streptococcal or heterologous antigen or virulence factor is very well suited for eliciting an immune response. In a preferred embodiment, the invention provides a vaccine wherein said strain is live, due to its persistent but avirulent character, a *Streptococcus* vaccine strain as provided by the invention is well suited to generate specific and long-lasting immune responses.

Now that a Streptococcal vaccine is provided by the invention, the invention also provides a method for controlling or eradicating a Streptococcal disease in a population comprising vaccinating subjects in said population with a vaccine according to the invention.

In a preferred embodiment, a method for controlling or eradicating a Streptococcal disease is provided comprising testing a sample, such as a blood sample, or nasal or throat swab, faeces, urine, or other samples such as can be sampled at or after slaughter, collected from at least one subject, such as an infant or a pig, in a population partly or wholly vaccinated with a vaccine according to the invention for the presence of encapsulated Streptococcal strains or mutants. Since a vaccine strain or mutant according to the invention is not pathogenic, and can be distinguished from wild-type strains by capsular expression, the detection of (fully) encapsulated Streptococcal strains indicates that wild-type infections are still present. Such wild-type infected subjects can than be isolated from the remainder of the population

until the infection has passed away. With domestic animals, such as pigs, it is even possible to remove the infected subject from the population as a whole by culling. Detection of wild-type strains can be achieved via traditional culturing techniques, or by rapid detection techniques such as PCR detection.

In yet another embodiment, the invention provides a method for controlling or eradicating a Streptococcal disease comprising testing a sample collected from at least one subject in a population partly or wholly vaccinated with a vaccine according to the invention for the presence of capsule-specific antibodies directed against Streptococcal strains. Capsule specific antibodies can be detected with classical techniques known in the art, such as used for Lancefield's group typing or serotyping.

A much preferred embodiment of a method provided by the invention for controlling or eradicating a Streptococcal disease in a population comprises vaccinating subjects in said population with a vaccine according to the invention and testing a sample collected from at least one subject in said population for the presence of encapsulated Streptococcal strains and/or for the presence of capsule-specific antibodies directed against Streptococcal strains.

For example, a method is provided according to the invention wherein said Streptococcal disease is caused by *Streptococcus suis*.

The invention also provides a diagnostic assay for testing a sample for use in a method according to the invention comprising at least one means for the detection of encapsulated Streptococcal strains and/or for the detection of capsule-specific antibodies directed against Streptococcal strains.

The invention furthermore provides a vaccine comprising an antigen according to the invention and further comprising a suitable carrier or adjuvant. The immunogenicity of a capsular antigen provided by the invention is for example increased by

linking to a carrier (such as a carrier protein), allowing the recruitment of T-cell help in developing an immune response.

5 The invention further provides a recombinant micro-organism provided with at least a part of a capsular gene cluster derived from *Streptococcus suis*. The invention provides for example a lactic acid bacterium provided with at least a part of a capsular gene cluster derived from *Streptococcus suis*. Various food-grade lactic acid bacteria (Lactococcus lactis, Lactobacillus casei, Lactobacillus
10 plantarium and Streptococcus gordonii) have been used as delivery systems for mucosal immunization. It has now been shown that oral (or mucosal) administration of recombinant L. lactis, Lactobacillus, and Streptococcus gordonii can elicit local IgA and /or IgG antibody responses to an expressed
15 antigen. The use of oral routes for immunization against infective diseases is desirable because oral vaccines are easier to administer, have higher compliance rates, and because mucosal surfaces are the portals of entry for many pathogenic microbial agents. It is within the skill of the
20 artisan to provide such micro-organisms with (additional) genes.

The invention further provides a recombinant *Streptococcus suis* mutant provided with a modified capsular gene cluster. It is within the skill of the artisan to swap
25 genes within a species. In a preferred embodiment, an avirulent *Streptococcus suis* mutant is selected to be provided with at least a part of a modified capsular gene cluster according to the invention.

The invention further provides a vaccine comprising a micro-
30 organism or a mutant provided by the invention. An advantage of such a vaccine over currently used vaccines is that they comprise accurately defined micro-organisms and well-characterised antigens, allowing accurate determination of immune responses against various antigens of choice.

35 The invention is further explained in the experimental part of this description without limiting the invention thereto.

09767041.013901
FOR FTO 29260

Description of the Figures

FIG. 1 illustrates the organization of the *cps2* gene cluster of *S. suis* type 2.

(A) Genetic map of the *cps2* gene cluster. The shadowed arrows represent potential ORFs. Interrupted ORFs indicate the presence of stop codons or frame-shift mutations. Gene designations are indicated below the ORFs. The closed arrows indicate the position of the potential promoter sequences. | indicates the position of the potential transcription regulator sequence. ||| indicates the position of the 100-bp repeated sequence.

(B) Physical map of the *cps2* locus. Restriction sites are as follows: A: *AluI*; C: *ClaI*; E, *EcoRI*; H, *HindIII*; K, *KpnI*; M, *MluI*; N, *NsiI*; P, *PstI*; S, *SnaBI*; Sa: *SacI*; X, *XbaI*.

(C) The DNA fragments cloned in the various plasmids.

FIG. 2 illustrates ethidium bromide stained agarose gel showing PCR products obtained with chromosomal DNA of *S. suis* strains belonging to the serotypes 1,2, ½, 9 and 14 and *cps2J*, *cpsII*, and *cps9H* primer sets as described herein.

(A) *cpsII* primers; (B) *cps2J* primers and (C) *cps9H* primers.

Lanes 1-3: serotype 1 strains; lanes 4-6: serotype 2 strains; lanes 7-9: serotype ½ strains; lanes 10-12: serotype 9 strains and lanes 13-15: serotype 14 strains.

(B) Ethidium bromide stained agarose gel showing PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 2, type 1 or type 9 strains and *cps2J*, *cpsII* and *cpsH* primer sets as described in Materials and Methods. Bacterial DNA suitable for PCR was prepared by using the multiscreen methods as described previously (20).

(A) *cpsII* primers. (B) *cps2J* primers and (C) *cps9H* primers.

Lanes 1-3: PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 1 strains; lanes 4-6: PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 2 strains; lanes 7-9: PCR products obtained with tonsillar swabs collected from pigs carrying *S. suis* type 9 strains; lanes 10-12: PCR products obtained with chromosomal DNA from serotype 9, 2 and 1 strains respectively; lane 13: negative control, no DNA present.

FIG. 3 illustrates the CPS2 nucleotide sequences and corresponding amino acid sequences from the open reading frames.

FIG. 4 illustrates the CPS1 nucleotide sequences and corresponding amino acid sequences

from the open reading frames.

FIG. 5 illustrates the CPS9 nucleotide sequences and corresponding amino acid sequences from the open reading frames.

FIG. 6 illustrates the CPS7 nucleotide sequences and corresponding amino acid sequences from the open reading frames.

FIG. 7 illustrates alignment of the N-terminal parts of Cps2J and Cps2K.

Identical amino acids are marked by bars. The amino acids shown in bold are also conserved in CPS14I Cps14J of *S. pneumoniae* and several other glycosyltransferases (19). The aspartate residues marked by asterisks are strongly conserved.

FIG. 8 illustrates transmission electron micrographs of thin sections of various *S. suis* strains.

- (A) wild type strain 10;
- (B) mutant strain 10cpsB;
- (C) mutant strain 10cpsEF.

Bar = 100 nm

FIG. 9 illustrates the kinetics of phagocytosis of wild type and mutant *S. suis* strains.

(A) Kinetics of phagocytosis of wild type and mutant *S. suis* strains by porcine alveolar macrophages. Phagocytosis was determined as described herein. The Y-axis represents the number of CFU per milliliter in the supernatant fluids as determined by plate counting, the X-axis represents time in minutes.

- wild type strain 10;
- mutant strain 10cpsB;
- Δ mutant strain 10cpsEF.

(B) Kinetics of intracellular killing of wild type and mutant *S. suis* strains by porcine AM. The intracellular killing was determined as described herein. The Y-axis represents the number of CFU per ml in the supernatant fluids after lysis of the macrophages as determined by plate counting, the X-axis represents time in minutes.

- wild type strain 10;
- mutant strain 10cpsB;
- Δ mutant strain 10cpsEF.

FIG. 10 illustrates the nucleotide sequence alignment of the highly conserved 100-bp repeated element.

- 1) 100-bp repeat between *cps2G* and *cps2H*
- 2) 100—bp repeat within “*cps2M*”
- 3) 100—bp repeat between *cps2O* and *cps2P*

FIG. 11 illustrates the *cps2*, *cps9* and *cps7* gene clusters of *S. suis* serotypes 2, 9 and 7.

(A) Genetic organization of the *cps2* gene cluster [84]. The large arrows represent potential ORFs. Gene designations are indicated below the ORFs. Identically filled arrows represent ORFs which showed homology. The small closed arrows indicate the position of the potential promoter sequences. | indicates the position of the potential transcription regulator sequence.

(B) Physical map and genetic organization of the *cps9* gene cluster [15]. Restriction sites are as follows: B: *Bam*HI; P: *Pst*I; H: *Hind*III; X: *Xba*I. The DNA fragments cloned in the various plasmids are indicated. The open arrows represent potential ORFs.

(C) Physical map and genetic organization of the *cps7* gene cluster. Restriction sites are as follows: C: *Clal*; P: *Pst*I; Sc: *Sca*I. The DNA fragments cloned in the various plasmids are indicated. The open arrows represent potential OREs.

FIG. 12 illustrates Ethidium bromide stained agarose gel showing PCR products.

(A) Ethidium bromide stained agarose gel showing PCR products obtained with chromosomal DNA of *S. suis* strains belonging to the serotypes 1, 2, 9 and 7 and the *cps7H* primer set. Strain designations are indicated above the lanes. C: negative control, no DNA present. M: molecular size marker (lambda digested with *Eco*RI and *Hind*III).

(B) Ethidium bromide stained agarose gel showing PCR products obtained with serotype 7 strains collected in different countries and from different organs. Bacterial DNA suitable for PCR was prepared by using the multiscreen method as described herein [89]. Strain designations are indicated above the lanes. M: molecular size marker (lambda digested with *Eco*RI and *Hind*III).

Experimental part

MATERIAL AND METHODS

5

Bacterial strains and growth conditions.

The bacterial strains and plasmids used in this study are listed in Table 1. *S. suis* strains were grown in Todd-Hewitt broth (code CM189, Oxoid), and plated on Columbia agar blood
10 base (code CM331, Oxoid) containing 6% (v/v) horse blood. *E. coli* strains were grown in Luria broth (28) and plated on Luria broth containing 1.5% (w/v) agar. If required, antibiotics were added to the plates at the following concentrations: spectinomycin: 100 ug/ml for *S. suis* and 50
15 ug/ml for *E. coli* and ampicillin, 50 ug/ml.

Serotyping. The *S. suis* strains were serotypes by the slide agglutination test with serotype-specific antibodies (44).

DNA techniques. Routine DNA manipulations were performed as described by Sambrook et al. (36).

20 **Alkaline phosphatase activity.** To screen for PhoA fusions in *E. coli*, plasmid libraries were constructed. Therefore, chromosomal DNA of *S. suis* type 2 was digested with AluI. The 300-500-bp fragments were ligated to SmaI-digested pPHOS2. Ligation mixtures were transformed to the PhoA⁻ *E. coli* strain
25 CC118. Transformants were plated on LB media supplemented with 5-Bromo-4-chloro-3-indolylfosfaat (BCIP, 50 ug/ml, Boehringer, Mannheim, Germany). Blue colonies were purified on fresh LB/BCIP plates to verify the blue phenotype.

DNA sequence analysis. DNA sequences were determined on a 373A
30 DNA Sequencing System (Applied Biosystems, Warrington, GB). Samples were prepared by use of a ABI/PRISM dye terminator cycle sequencing ready reaction kit (Applied Biosystems). Sequencing data were assembled and analyzed using the MacMollyTetra program. Custom-made sequencing primers were
35 purchased from Life Technologies. Hydrophobic stretches within

09267041 013301

proteins were predicted by the method of Klein et al. (17). The BLAST program available on Netscape NavigatorTM was used to search for protein sequences related to the deduced amino acid sequences.

- 5 **Construction of gene-specific knock-out mutants of *S. suis*.** To construct the mutant strains 10cpsB and 10cpsEF we electrotransformed the pathogenic serotype 2 strain 10 (45, 49) of *S. suis* with pCPS11 and pCPS28 respectively. In these plasmids the *cpsB* and *cpsEF* genes were disturbed by the
10 insertion of a spectinomycin-resistance gene. To create pCPS11 the internal 400 bp *Pst*I-*Bam*HI fragment of the *cpsB* gene in pCPS7 was replaced by the *Spc*^R gene. For this purpose pCPS7 was digested with *Pst*I and *Bam*HI and ligated to the 1,200-bp *Pst*I-*Bam*HI fragment, containing the *Spc*^R gen, from pIC-spc. To
15 construct pCPS28 we have used pIC20R. In this plasmid we inserted the *Kpn*I-*Sal*I fragment from pCPS17 (resulting in pCPS25) and the *Xba*I-*Cla*I fragment from pCPS20 (resulting in pCPS27). pCPS27 was digested with *Pst*I and *Xho*I and ligated to the 1,200-bp *Pst*I-*Xho*I fragment, containing the *Spc*^R gene of
20 pIC-spc. The electrotransformation to *S. suis* was carried out as described before (38).

- Southern blotting and hybridization.** Chromosomal DNA was isolated as described by Sambrook et al. (36). DNA fragments were separated on 0.8% agarose gels and transferred to Zeta-Probe GT membranes (Bio-Rad) as described by Sambrook et al.
25 (36). DNA probes were labelled with [(-³²P]dCTP (3000 Ci mmol⁻¹; Amersham) by use of a random primed labelling kit (Boehringer). The DNA on the blots was hybridized at 65°C with appropriate DNA probes as recommended by the supplier of the
30 Zeta-Probe membranes. After hybridization, the membranes were washed twice with a solution of 40 mM sodium phosphate, pH 7.2, 1 mM EDTA , 5% SDS for 30 min at 65°C and twice with a solution of 40 mM sodium phosphate, pH 7.2, 1 mM EDTA, 1% SDS for 30 min at 65°C.

- 35 **PCR.** The primers used in the *cps2J* PCR correspond to the positions 13791-13813 and 14465-14443 in the *S. suis cps2*

locus. The sequences were: 5'-CAAACGCAAGGAATTACGGTATC-3' and 5'-GAGTATCTAAAGAATGCCTATTG-3'. The primers used for the *cps1I* PCR correspond to the positions 4398-4417 and 4839-4821 in the *S. suis* *cps1* sequence. The sequences were: 5'-

5 GGCGGTCTAGCAGATGCTCG-3' and 5'-GCGAACTGTTAGCAATGAC-3'. The primers used in the *cps9H* PCR correspond to the positions 4406-4126 and 4494-4475 in the *S. suis* *cps9* sequence. The sequences were: 5'-GGCTACATATAATGGAAGCCC3' and 5'-CGGAAGTATCTGGGCTACTG-3'.

10 **Construction of gene-specific knock-out mutants of *S. suis*.** To construct the mutant strains 10cpsB and 10cpsEF we electrotransformed the pathogenic serotype 2 strain 10 of *S. suis* with pCPS11 and pCPS28 respectively. In these plasmids the *cpsB* and *cpsEF* genes were disturbed by the
15 insertion of a spectinomycin-resistance gene. To create pCPS11 the internal 400 bp *PstI*-*BamHI* fragment of the *cpsB* gene in pCPS7 was replaced by the *Spc^R* gene. For this purpose pCPS7 was digested with *PstI* and *BamHI* and ligated to the 1,200-bp *PstI*-*BamHI* fragment, containing the *Spc^R* gen, from pIC-spc. To
20 construct pCPS28 we have used pIC20R. In this plasmid we inserted the *KpnI*-*SalI* fragment from pCPS17 (resulting in pCPS25) and the *XbaI*-*ClaI* fragment from pCPS20 (resulting in pCPS27). pCPS27 was digested with *PstI* and *XhoI* and ligated to the 1,200-bp *PstI*-*XhoI* fragment, containing the *Spc^R* gene of
25 pIC-spc. The electrotransformation to *S. suis* was carried out as described before (38).

Phagocytosis assay. Phagocytosis assays were performed as described by Leij et al. (23). Briefly, to opsonize the cells, 10^7 *S. suis* cells were incubated with 6% SPF-pig serum for 30
30 min at 37°C in a head-over-head rotor at 6 rpm. 10^7 AM and 10^7 opsonized *S. suis* cells were combined and incubated at 37°C under continuous rotation at 6 rpm. At 0, 30, 60 and 90 min, 1-ml samples were collected and mixed with 4 ml of ice-cold EMEM to stop phagocytosis. Phagocytes were removed by centrifugation
35 for 4 min at 110 x g and 4°C. The number of colony forming units (CFU) in the supernatants was determined. Control

experiments were carried out simultaneously by combining 10^7 opsonized *S. suis* cells with EMEM (without AM).

Killing assays. AM (10^7 /ml) and opsonized *S. suis* cells (10^7 /ml) were mixed 1 : 1 and incubated for 10 min at 37°C under continuous rotation at 6 rpm. Ice-cold EMEM was added to stop further phagocytosis and killing. To remove extracellular *S. suis* cells, phagocytes were washed twice (4 min, 110 x g, 4°C) and resuspended in 5 ml EMEM containing 6% SPF serum. The tubes were incubated at 37°C under rotation at 6 rpm. After 0, 15, 30, 60 and 90 min, samples were collected and mixed with ice-cold EMEM to stop further killing. The samples were centrifuged for 4 min at 110 x g at 4°C and the phagocytic cells were lysed in EMEM containing 1% saponine for 20 min at room temperature. The number of CFU in the suspensions was determined.

Pigs. Germfree pigs, cross-breeds of Great Yorkshire and Dutch landrace, were obtained from sows by caesarian sections. The surgery was performed in sterile flexible film isolators. Pigs were allotted to groups, each consisting of 4 pigs, and were housed in sterile stainless steel incubators.

Experimental infections. Pigs were inoculated intranasally with *S. suis* type 2 as described before. To predispose the pigs for infection with *S. suis*, five-day old pigs were inoculated intranasally with about 10^7 CFU of *Bordetella bronchiseptica* strain 92932. Two days later the pigs were inoculated intranasally with *S. suis* type 2 (10^6 CFU). Pigs were monitored twice daily for clinical signs of disease, such as fever, nervous signs and lameness. Blood samples were collected three times a week from each pig. White blood cells were counted with a cell counter. To monitor infection with *S. suis* and *B. bronchiseptica* and to check for absence of contaminants, we collected swabs of nasopharynx and feces daily. The swabs were plated directly onto Columbia agar containing 6% horse blood. After three weeks the pigs were killed and examined for pathological changes. Tissue specimens from the central nervous system, serosae, and joints were examined bacteriologically and

histologically as described before (45, 49). Colonization of the serosae was scored positively when *S. suis* was isolated from the pericardium, thoracic pleura or the peritoneum. Colonization of the joints was scored positively when *S. suis* was isolated from one or more joints (12 joints per animal were scored).

Vaccination and challenge

One week old pigs were vaccinated intravenously with a dosage of 106 cfu of the *S. suis* strains 10cpsEF or 10cpsB. Three weeks later the pigs were challenged intravenously with the pathogenic serotype 2 strain 10 (107 cfu). Disease monitoring, haematological, serological and bacteriological examinations as well as post-mortum examinations were as described before under experimental infections.

Electron Microscopy. Bacteria were prepared for electron microscopy as described by Wagenaar et al. (50). Shortly, bacteria were mixed with agarose MP (Boehringer) of 37° C to a concentration of 0.7%. The mixture was immediately cooled on ice. Upon gelifying, samples were cut into 1 to 1.5 mm slices and incubated in a fixative containing 0.8% glutaraldehyde and 0.8% osmiumtetroxide. Subsequently, the samples were fixed and stained with uranyl acetate by microwave stimulation, dehydrated and imbedded in eponaraldite resin. Ultra-thin sections were counterstained with lead citrate and examined with a Philips CM 10 electron microscope at 80 kV.

Isolation of porcine alveolar macrophages (AM). Porcine AM were obtained from the lungs of specific pathogen free (SPF) pigs. Lung lavage samples were collected as described by van Leengoed et al. (43). Cells were suspended in EMEM containing 6% (v/v) SPF-pig serum and adjusted to 10⁷ cells per ml.

RESULTS

Identification of the *cps* locus.

The *cps* locus of *S. suis* type 2 was identified by making use of a strategy developed for the genetic identification of exported proteins (13, 31). In this system we made use of a plasmid (pPHOS2) containing a truncated alkaline phosphatase gene (13). The gene lacked the promoter sequence, the translational start site and the signal sequence. The truncated gene is preceded by a unique *Sma*I restriction site. Chromosomal DNA of *S. suis* type 2, digested with *Alu*I, was randomly cloned in this restriction site. Because translocation of *PhoA* across the cytoplasmic membrane of *E. coli* is required for enzymatic activity, the system can be used to select for *S. suis* fragments containing a promoter sequence, a translational start site and a functional signal sequence. Among 560 individual *E. coli* clones tested, 16 displayed a dark blue phenotype when plated on media containing BCIP. DNA sequence analysis of the inserts from several of these plasmids were performed (results not shown) and the deduced amino acid sequences were analyzed. The hydrophobicity profile of one of the clones (pPHOS7, results not shown) showed that the N-terminal part of the sequence resembled the characteristics of a typical signal peptide: a short hydrophilic N-terminal region is followed by a hydrophobic region of 38 amino acids. These data indicate that the *phoA* system was successfully used for the selection of *S. suis* genes encoding exported proteins. Moreover, the sequences were analyzed for similarities present in the databases. The sequence of pPHOS7 showed a high similarity (37% identity) with the protein encoded by the *cps14C* gene of *Streptococcus pneumoniae* (19). This strongly suggests that pPHOS7 contains a part of the *cps* operon of *S. suis* type 2.

Cloning of the flanking *cps* genes. In order to clone the flanking *cps* genes of *S. suis* type 2 the insert of pPHOS7 was used as a probe to identify chromosomal DNA fragments which contain flanking *cps* genes. A 6-kb *Hind*III fragment was

identified and cloned in pKUN19. This yielded clone pCPS6 (Fig. 1C). Sequence analysis of the insert of pCPS6 revealed that pCPS6 most probably contained the 5'-end of the *cps* locus, but still lacked the 3'-end. Therefore, sequences of the 3' -end of pCPS6 were in turn used as a probe to identify chromosomal fragments containing *cps* sequences located further downstream. These fragments were also cloned in pKUN19, resulting in pCPS17. Using the same system of chromosomal walking we subsequently generated the plasmid pCPS18, pCPS20, pCPS23 and pCPS26, containing downstream *cps* sequences.

Analysis of the *cps* operon. The complete nucleotide sequence of the cloned fragments was determined (figure 4). Examination of the compiled sequence revealed the presence of at least 13 potential open reading frame (Orfs), which were designated as Orf 2Y, Orf2X and Cps2A-Cps2K (Fig. 1A). Moreover, a 14th, incomplete, Orf (Orf 2Z) was located at the 5'-end of the sequence. Two potential promoter sequences were identified. One was located 313 bp (locations 1885-1865 and 1884-1889) upstream of Orf2X. The other potential promoter sequence was located 68 bp upstream of Orf2Y (locations 2241-2236 and 2216-2211). Orf2Y is expressed in opposite orientation. Between Orfs 2Y and 2Z the sequence contained a potential stem-loop structure, which could act as a transcription terminator. Each Orf is preceded by a ribosome-binding site and the majority of the Orfs are very closely linked. The only significant intergenic gap was found between Cps2G and Cps2H (389 nucleotides). However, no obvious promoter sequences or potential stem-loop structures were found in this region. These data suggest that Orf2X and Cps2A-Cps2K are arranged as an operon.

An overview of all Orfs with their properties is shown in Table 2. The majority of the predicted gene products is related to proteins involved in polysaccharide biosynthesis. Orf2Z showed some similarity with the YitS protein of *Bacillus subtilis*. YitS was identified during the sequence analysis of the complete genome of *B. subtilis*. The function of the protein

is unknown.

Orf2Y showed similarity with YcxD protein of *B. subtilis* (53). Based on the similarity between YcxD and MocR of *Rhizobium meliloti* (33), YcxD was suggested to be a regulatory protein.

Orf2X showed similarity with the hypothetical YAAA proteins of *Haemophilus influenzae* and *E. coli*. The function of these proteins is unknown.

The gene products encoded by the *cps2A*, *cps2B*, *cps2C* and *cps2D* genes showed approximate similarity with the CpsA, CpsC, CpsD and CpsB proteins of several serotypes of *Streptococcus pneumoniae* (19), respectively. This suggest similar functions for these proteins. Hence, Cps2A may have a role in the regulation of the capsular polysaccharide synthesis. Cps2B and Cps2C could be involved in the chain length determination of the type 2 capsule and Cps2C can play an additional role in the export of the polysaccharide. The Cps2D protein of *S. suis* is related to the CpsB protein of *S. pneumoniae* and to proteins encoded by genes of several other Gram-positive bacteria involved in polysaccharide or exopolysaccharide synthesis, but their function is unknown (19).

The protein encoded by *cps2E* gene showed similarity to several bacterial proteins with glycosyl transferase activities: Cps14E and Cps19fE of *S. pneumoniae* serotypes 14 and 19F (18, 19, 29), CpsE of *Streptococcus salvarius* (X94980) and CpsD of *Streptococcus agalactiae* (34). Recently, Kolkman et al. (18) showed that Cps14E is a glucosyl-1-phosphate transferase that links glucose to a lipid carrier, the first step in the biosynthesis of the *S. pneumoniae* type 14 repeating unit. Based on these data a similar function may be fulfilled by Cps2E of *S. suis*.

The protein encoded by the *cps2F* gene showed similarity to the protein encoded by the *rfbU* gene of *Salmonella enteritica*. (25). This similarity is most pronounced in the C-terminal regions of these proteins. The *rfbU* gene was shown to encoded mannosyltransferase activity (25).

The *cps2G* gene encoded a protein that showed moderate similarity with the *rfbF* gene product of *Campylobacter hyoilei* (22), the *epsF* gene product of *S. thermophilus* (40) and the *capM* gene product of *S. aureus* (24). On the basis of
5 similarity the *rfbF*, *epsF* and *capM* genes are suggested to encoded galactosyltransferase activities. Hence, a similar glycosyl transferase activity could be fulfilled by the *cps2G* gene product.

The *cps2H* gene encodes a protein that is similar to the N-
10 terminal region of the *lgtD* gene product of *Haemophilus influenzae* (U32768). Moreover, the hydrophobicity plots of Cps2H and LgtD looked very similar in these regions (data not shown). Based on sequence similarity the *lgtD* gene product was suggested to have glycosyl transferase activity (U32768).

15 The gene product encoded by the *cps2I* gene showed some similarity with a protein of *Actinobacillus actinomycetemcomitans* (AB002668). This protein is part of the gene cluster responsible for the serotype-b-specific antigen of *A. actinomycetemcomitans*. The function of the protein is unknown.

20 The gene products encoded by the *cps2J* and *cps2K* genes showed significant similarities to the Cps14J protein of *S. pneumoniae*. The *cps14J* gene of *S. pneumoniae* was shown to encode a β -1,4-galactosyltransferase activity. In *S. pneumoniae* CpsJ is responsible for the addition of the fourth
25 (i.e. last) sugar in the synthesis of the *S. pneumoniae* serotype 14 polysaccharide (20). Even some similarity was found between Cps2J and Cps2K (Fig. 2, 25.5% similarity). This similarity was most pronounced in the N-terminal regions of the proteins. Recently, two small conserved regions were identified
30 in the N-terminus of Cps14J and Cps14I and their homologues (20). These regions were predicted to be important for catalytic activity. Both regions, DXS and DXDD (Fig. 2), were also found in Cps2J and Cps2K.

Distribution of the *cps2* genes in other *S. suis* serotypes. To examine the relationship between the *cps2* genes and *cps* genes in the other *S. suis* serotypes, we performed cross-hybridization experiments. DNA fragments of the individual

5 *cps2* genes were amplified by PCR, labelled with ^{32}P , and used to probe Southern blots of chromosomal DNA of the reference strains of the 35 different *S. suis* serotypes. Large variation in the hybridization patterns were observed (Table 4). As a positive control we used a probe specific for 16S rRNA. The

10 16S rRNA probe hybridized with all serotypes tested. However, none of the other genes tested were common in all serotypes. Based on the genetic organization of the genes we previously suggested that *orfX* and *cpsA-cpsK* genes are part of one operon and that the protein encoded by these genes are all involved

15 in polysaccharide biosynthesis. *OrfY* and *OrfZ* are not a part of this operon, and their role in the polysaccharide biosynthesis is unclear. Based on sequence similarity data, *OrfY* may be involved in regulation of the *cps2* genes. *OrfZ* is proposed to be unrelated to polysaccharide biosynthesis.

20 Probes specific for the *orfZ*, *orfY*, *orfX*, *cpsA*, *cpsB*, *cpsC* and *cpsD* genes hybridized with most other serotypes. This suggests that the protein encoded by these genes are not type-specific, but may perform more common functions in biosynthesis of the capsular polysaccharide. This confirms previous data which

25 showed that the *cps2A-cps2D* genes showed strong similarity to *cps* genes of several serotype of *Streptococcus pneumoniae*. Based on this similarity *Cps2A* is possibly a regulatory protein, whereas *Cps2B* and *Cps2C* may play a role in length determination and export of polysaccharide. The *cps2E* gene

30 hybridized with DNA of serotypes 1, 2, 14 and 1/2. The *cps2E* gene showed a strong similarity to the *cps14E* gene of *S. pneumoniae* (18). This enzyme was shown to have a glucosyl-1-phosphate activity and catalyzed the transfer of glucose to a lipid carrier (18). These data indicate that a

35 glycosyltransferase closely related to *Cps14E* may be responsible for the first step in the biosynthesis of

09757041.013304

polysaccharide in the *S. suis* serotypes 1, 2, 14 and 1/2. The *cps2F*, *cps2G*, *cps2H*, *cps2I* and *cps2J* genes hybridized with chromosomal DNA of serotypes 2 and 1/2 only. The *cps2G* gene showed an additional weak hybridization signal with DNA of serotype 34. In agglutination tests serotype 1/2 showed agglutination with sera specific for serotype 2 as well as with sera specific for serotype 1. This suggests that serotype 1/2 shares antigenic determinants with both types 1 and 2. The hybridization data confirmed these data. All putative glycosyltransferases present in serotype 2 are also present in serotype 1/2. The *cps2K* gene showed a similar hybridization pattern as the *cps2E* gene. Hybridization was observed with DNA of serotypes 1, 2, 14 and 1/2. Taken together these hybridization data show that the *cps2* gene cluster can be divided in three regions: a central region containing the type-specific genes is flanked by two regions containing common genes for various serotypes.

Cloning of the type-specific *cps* genes of serotypes 1 and 9.

To clone the type-specific *cps* genes of *S. suis* serotype 1 we used the *cps2E* gene as a probe to identify chromosomal DNA fragments of type 1 which contain flanking *cps* genes. A 5 kb *EcoRV* fragment was identified and cloned in pKUN19. This yielded pCPS1-1 (Fig. 1B). This fragment was in turn used as a probe to identify an overlapping 2.2 kb *HindIII* fragment. pKUN19 containing this *HindIII* fragment was designated pCPS1-2. The same strategy was followed to identify and clone the type-specific *cps* genes of serotype 9. In this case, we used the *cps2D* gene as a probe. A 0.8 kb *HindIII*-*XbaI* fragment was identified and cloned, yielding pCPS9-1 (Fig. 1C). This fragment was in turn used as a probe to identify a 4 kb *XbaI* fragment. pKUN19 containing this 4 kb *XbaI* fragment was designated pCPS9-2.

Analysis of the cloned *cps1* genes. The complete nucleotide sequence of the inserts of pCPS1-1 and pCPS1-2 was determined (figure 5). Examination of the sequence revealed the presence of five complete and two incomplete Orfs (Fig.1B). Each Orf is preceded by a ribosome-binding site. In accord with data obtained for the *cps2* genes of serotype 2, the majority of the Orfs is very closely linked. The only significant gap (718 bp) was found between Cps1G and Cps1H. No obvious promoter sequences or potential stem-loop structures could be found in this region. This suggests that, as in serotype 2, the *cps* genes in serotype 1 are arranged in an operon.

An overview of the Orfs and their properties is shown in Table 2. As expected on the basis of the hybridization data (Table 4), the protein encoded by the *cps1E* gene was related to Cps2E of *S. suis* type 2 (identity of 86%). The fragment cloned in pCPS1-1 lacked the coding region for the first 7 amino acids of the *cps1E* gene.

The protein encoded by the *cps1F* and *cps1G* genes showed strong similarity to the Cps14F and Cps14G proteins of *Streptococcus pneumoniae* serotype 14, respectively (20). The function of the Cps14F is not completely clear, but it has been suggested that Cps14F can enhance role in glycosyltransferase activity. The *cps14G* gene of *S. pneumoniae* was shown to encode β -1,4-galactosyltransferase activity. In *S. pneumoniae* type 14 this activity is required for the second step in the biosynthesis of the oligosaccharide subunit (20). Based on the similarity data found similar glycosyltransferase and enhancing activities are suggested for the *cps 1G* and *cps1F* genes of *S. suis* type 1.

The protein encoded by the *cps1H* gene showed similarity to the Cps14H protein of *S. pneumoniae* (20). Based on sequence similarity Cps14H was proposed to be the polysaccharide polymerase (20).

The protein encoded by the *cps1I* gene showed some similarity with the Cps14J protein of *S. pneumoniae* (19). The *cps14J* gene was shown to encode a β -1,4-galactosyltransferase

activity, responsible for the addition of the fourth (i.e. last) sugar in the synthesis of the *S. pneumoniae* serotype 14 polysaccharide.

Between Cps1G and Cps1H a gap of 718 bp was found. This region revealed three small Orfs. The three Orfs were expressed in three different reading frames and were not preceded by potential ribosome binding sites, nor contained potential start sites. However, the three potential gene products encoded by this region showed some similarity with three successive regions of the C-terminal part of the EpsK protein of *Streptococcus thermophilus* (27% identity, 40). The region related to the first 82 amino acids is lacking.

Analysis of the cloned cps9 genes. We also determined the complete nucleotide sequence of the inserts of pCPS9-1 and pCPS9-2 (figure 6). Examination of the sequence revealed the presence of three complete and two incomplete Orfs (Fig.1C). As in serotypes 1 and 2, all Orfs are preceded by a ribosome-binding site and are very closely coupled. As suggested by the hybridization data (Table 4) the Cps2D and Cps9D proteins were highly related (Table 2). Based on sequence comparisons pCPS9-1 lacked the first 27 amino acids of the Cps9D protein.

The protein encoded by the *cps9E* gene showed some similarity with the CapD protein of *Staphylococcus aureus* serotype 1 (24). Based on sequence similarity data the Cap1D protein was suggested to be an epimerase or a dehydratase involved in the synthesis of N-acetylfructosamine or N-acetylgalactosamine (63).

Cps9F showed some similarity to the CapM proteins of *S. aureus* serotypes 5 and 8 (61, 64, 65). Based on sequence similarity data Cap5M and Cap8M are proposed to be glycosyltransferases (63).

The protein encoded by the *cps9G* gene showed some similarity with a protein of *Actinobacillus actinomycetemcomitans* (AB002668_4). This protein is part of a gene cluster responsible for the serotype-b specific antigens

of *Actinobacillus actinomycetemcomitans*. The function of the protein is unknown.

The protein encoded by the *cps9H* gene showed some similarity with the *rfbB* gene of *Yersinia enterocolitica* (68).

5 The RfbB protein was shown to be essential for O-antigen synthesis, but the function of the protein in the synthesis of the O:3 lipopolysaccharide is unknown.

Serotype 1 and serotype 9 specific *cps* genes. To determine
10 whether the cloned fragments in pCPS1-1, pCPS1-2, pCPS9-1 and pCPS9-2 contained the type-specific genes for serotype 1 and 9, respectively, cross hybridization experiments were performed. DNA fragments of the individual *cps1* and *cps9* genes were amplified by PCR, labelled with ³²P, and used to probe
15 Southern blots of chromosomal DNA of the reference strains of the 35 different *S. suis* serotypes. The results are shown in Table 5. Based on the data obtained with the *cps2E* probe (Table 4), the *cps1E* probe was expected to hybridize with chromosomal DNA of *S. suis* serotypes 1,2, 14, 27 and 1/2. The
20 *cps1H*, *cps9E* and *cps9F* probes hybridized with most other serotypes. However, the *cps1F* and *cps1G* and *cps1I* probes hybridized with chromosomal DNA of serotypes 1 and 14 only. The *cps9G* and *cps9H* probe hybridized with serotype 9 only. These data suggest that the *cps9G* and *cps9H* probes are
25 specific for serotype 9 and therefore could be useful tools for the development of rapid and sensitive diagnostic tests for *S. suis* type 9 infections.

Type specific PCR. So far, the probes were tested on the 35
30 different reference strains only. To test the diagnostic value of the type-specific *cps* probes further, several other *S. suis* serotype 1, 2, 1/2, 9 and 14 strains were used. Moreover, since a PCR based method would be even more rapid and sensitive than a hybridization test, we tested whether we
35 could use a PCR for the serotyping of the *S. suis* strains. The

09767041 032201

oligonucleotide primer sets were chosen within the *cps2J*,
cps1I and *cps9H* genes. Amplified fragments of 675 bp, 380 bp
and 390 bp were expected respectively. The results show that
5 using *cps2J* primers; 380 bp fragments were amplified on type 1
and 14 strains using *cps1I* primers and 390 bp fragments were
amplified on type 9 strains using *cps9H* primers.

Construction of mutants impaired in capsule production. To
10 evaluate the role of the capsule of *S. suis* type 2 in the
pathogenesis, we constructed two isogenic mutants in which
capsule production was disturbed. To construct mutant 10cpsB,
pCPS11 was used. In this plasmid a part of the *cps2B* gene was
replaced by the spectinomycin-resistance gene. To construct
15 mutant strain 10cpsEF the plasmid pCPS28 was used. In pCPS28
the 3'-end of *cps2E* gene as well as the 5'-end of *cps2F* gene
were replaced by the spectinomycin-resistance gene. pCPS11 and
pCPS28 were used to electrotransform strain 10 of *S. suis* type
2 and spectinomycin-resistant colonies were selected. Southern
20 blotting and hybridization experiments were used to select
double cross over integration events (results not shown).
To test whether the capsular structure of the strains 10cpsB
and 10cpsEF was disturbed, we used a slide agglutination test
using a suspension of the mutant strains in hyperimmune anti-*S.*
25 *suis* type 2 serum (44). The results showed that even in the
absence of serotype specific antisera, the bacteria
agglutinated. This indicates that in the mutant strains the
capsular structure was disturbed. To confirm this, thin
sections of wild type and mutant strains were compared by
30 electron microscopy. The results showed that compared to the
wild type (Fig. 3A) the amount of capsule produced by the
mutant strains was greatly reduced (Figs. 3B and 3C). Almost no
capsular material could be detected on the surface of the
mutant strains.

Capsular mutants are sensitive to phagocytosis and killing by porcine alveolar macrophages (PAM).

The capsular mutants were tested for their ability to resist phagocytosis by PAM in the presence of porcine SPF serum. The wild type strain 10 seemed to be resistant to phagocytosis under these conditions (Fig. 4A). In contrast, the mutant strains were efficiently ingested by macrophages (Fig. 4A). After 90 min. more than 99.7% (strain 10cpsB) and 99.8% (strain 10cpsEF) of the mutant cells were ingested by the macrophages. Moreover, as shown in Fig. 4B the ingested strains were efficiently killed by the macrophages. 90-98% of all ingested cells were killed within 90 min. No differences could be observed between wild type and mutant strains. These data indicate that the capsule of *S. suis* type 2 efficiently protects the organism from uptake by macrophages *in vitro*.

Capsular mutants are less virulent for germfree piglets. The virulence properties of the wild-type and mutant strains were tested after experimental infection of newborn germfree pigs (45, 49). Table 1 shows that specific and nonspecific signs of disease could be observed in all pigs inoculated with the wild type strain. Moreover, all pigs inoculated with the wild type strain died during the course of the experiment or were killed because of serious illness or nervous disorders (Table 3). In contrast, the pigs inoculated with strains 10cpsB and 10cpsEF showed no specific signs of disease and all pigs survived until the end of the experiment. The temperature of the pigs inoculated with the wild type strain increased 2 days after inoculation and remained high until day 5 (Table 3). The temperature of the pigs inoculated with the mutant strains sometimes exceeded the 40°C, however, we could observe significant differences in the fever index [i.e % of observations in an experimental group during which pigs showed fever (>40°C)] between pigs inoculated with wild type and mutant strains. All pigs showed increased numbers of polymorphonuclear leucocytes (PMLs) (>10 x 10⁹ PMLs per litre)

09757044.043204
T022T0 "T022T0
(Table 3). However, in pigs inoculated with the mutant strains the percentage of samples with increased numbers of PMLs was considerably lower. *S. suis* strains and *B. bronchiseptica* could be isolated from the nasopharynx and feces swab samples of all
5 pigs from 1 day post-infection until the end of the experiment (Table 3). Postmortem, the wild type strain could frequently be isolated from the central nervous system (CNS), kidney, heart, liver, spleen, serosae, joints and tonsils. Mutant strains could easily be recovered from the tonsils, but were never
10 recovered from the kidney, liver or spleen. Interestingly, low numbers of the mutant strains were isolated from the CNS, the serosae, the joints, the lungs and the heart. Taken together, these data strongly indicated that mutant *S. suis* strains, impaired in capsule production, are not virulent for young
15 germfree pigs.

We describe the identification and the molecular characterisation of the *cps* locus, involved in the capsular polysaccharide biosynthesis, of *S. suis*. Most of the genes seemed to belong to a single transcriptional unit, suggesting a
20 co-ordinate control of these genes. We assign functions to most of the gene products. We thereby identified regions involved in regulation (Cps2A), chain length determination (Cps2B, C), export (Cps2C) and biosynthesis (Cps2E, F, G, H, J, K). The region involved in biosynthesis is located at the centre of the
25 gene cluster and is flanked by two regions containing genes with more common functions. The incomplete *orf2Z* gene was located at the 5'-end of the cloned fragment. Orf2Z showed some similarity with the YitS protein of *B. subtilis*. However, because the function of the YitS protein is unknown this did
30 not give us any information about the possible function of Orf2Z. Because the *orf2Z* gene is not a part of the *cps* operon, a role of this gene in polysaccharide biosynthesis is not expected. The Orf2Y protein showed some similarity with the YcxD protein of *B. subtilis* (53). The YcxD protein was suggested
35 to be a regulatory protein. Similarly, Orf2Y may be involved in the regulation of polysaccharide biosynthesis. The Orf2X

protein showed similarity with the YAAA proteins of *H. influenzae* and *E. coli*. The function of these proteins is unknown. In *S. suis* type 2 the *orf2X* gene seemed to be the first gene in the *cps2* operon. This suggests a role of Orf2X in the polysaccharide biosynthesis. In *H. influenzae* and *E. coli*, however, these proteins are not associated with capsular gene clusters. The analysis of isogenic mutants impaired in the expression of Orf2X should give more insight in the presumed role of Orf2X in the polysaccharide biosynthesis of *S. suis* type 2.

The gene products encoded by the *cps2E*, *cps2F*, *cps2G*, *cps2H*, *cps2J* and *cps2K* genes showed little similarity with glycosyltransferases of several Gram-positive or Gram-negative bacteria (18, 19, 20, 22, 25). The *cps2E* gene product shows some similarity with the Cps14E protein of *S. pneumoniae* (18, 19). Cps14E is a glucosyl-1-phosphate transferase that links glucose to a lipid carrier (18). In *S. pneumoniae* this is the first step in the biosynthesis of the oligosaccharide repeating unit. The structure of the *S. suis* serotype 2 capsule contains glucose, galactose, rhamnose, N-acetyl glucoseamine and sialic acid in a ratio of 3:1:1:1:1 (7). Based on these data we conclude that Cps2E of *S. suis* has glucosyltransferase activity, and is involved in the linkage of the first sugar to the lipid carrier.

The C-terminal region of the *cps2F* gene product showed some similarity with the RfbU of *Salmonella enteritica*. RfbU was shown to have mannosyltransferase activity (24). Because mannosyl is not a component of the *S. suis* type 2 polysaccharide a mannosyltransferase activity is not expected in this organism. Nevertheless, *cps2F* encodes a glycosyltransferase with another sugar specificity.

Cps2G showed moderate similarity to a family of gene products suggested to encode galactosyltransferase activities (22, 24, 40). Hence a similar activity is shown for Cps2G.

Cps2H showed some similarity with LgtD of *H. influenzae* (U32768). Because LgtD was proposed to have glycosyltransferase

activity , a similar activity is fulfilled by Cps2H.

Cps2J and Cps2K showed similarity to Cps14J of *S. pneumoniae* (20). Cps2J showed similarity with Cps14I of *S. pneumoniae* as well. Cps14I was shown to have N-acetyl glucosaminyltransferase activity, whereas Cps14J has a β -1,4-galactosyltransferase activity (20). In *S. pneumoniae* Cps14I is responsible for the addition of the third sugar and Cps14J for the addition of the last sugar in the synthesis of the type 14 repeating unit (20). Because the capsule of *S. suis* type 2 contains galactose as well as N-acetyl glucosamine components, galactosyltransferase as well as N-acetyl glucoaminyltransferase activities could be envisaged for the cps2J and cps2K gene products, respectively. As was observed for Cps14I and Cps14J, the N-termini of Cps2J and Cps2K showed a significant degree of sequence similarity. Within the N-terminal domains of Cps14I and Cps14J, two small regions were identified, which were also conserved in several other glycosyltransferases (22). Within these two regions, two Asp residues were proposed to be important for catalytic activity. The two conserved regions, DXS and DXDD, were also found in Cps2J and Cps2K.

The function of Cps2I remains unclear. Cps2I showed some similarity with a protein of *A. actinomycetemcomitans*. Although this protein part is of the gene cluster responsible for the serotype-B-specific antigens, the function of the protein is unknown.

We further describe the identification and characterization of the cps genes specific for *S. suis* serotypes 1, 2 and 9. After the entire cps2 locus of *S. suis* serotype 2 was cloned and characterized, functions for most of the cps2 gene products could be assigned by sequence homologies. Based on these data the glycosyltransferase activities, required for type specificity, could be located in the centre of the operon. Cross-hybridization experiments, using the individual cps2 genes as probes on chromosomal DNAs of the 35 different serotypes, confirmed this idea. The regions containing the

type-specific genes of serotypes 1 and 9 could be cloned and characterized, showing that an identical genetic organization of the *cps* operons of other *S. suis* serotypes exists. The *cps1E*, *cps1F*, *cps1G*, *cps1H*, and *cps1I* genes revealed a striking similarity with *cps14E*, *cps14F*, *cps14G*, *cps14H* and *cps14J* genes of *S. pneumoniae*. Interestingly, *S. pneumoniae* serotype 14 is the serotype most commonly associated with pneumococcal infections in young children (54), whereas *S. suis* serotype 1 strains are most commonly isolated from piglets younger than 8 weeks (46). In *S. pneumoniae* the *cps14E*, *cps14G*, *cps14I* and *cps14J* encode the glycosyltransferases required for the synthesis of the type 14 tetrameric repeating unit, showing that the *cps1E*, *cps1G* and *cps1I* genes encoded glycosyltransferases. The precise functions of these genes as well as the substrate specificities of the enzymes can be established. In *S. pneumoniae* the *cps14E* gene was shown to encode a glucosyl-1-phosphate transferase catalyzing the transfer of glucose to a lipid carrier. Moreover, *cpsE*-like genes were found in *S. pneumoniae* serotypes 9N, 13, 14, 15B, 15C, 18F, 18A and 19F (60). *CpsE* mutants were constructed in the serotypes 9N, 13, 14 and 15B. All mutant strains lacked glucosyltransferase activity (60). Moreover, in all these *S. pneumoniae* serotypes the *cpsE* gene seemed to be responsible for the addition of glucose to the lipid carrier. Based on these data we suggest that in *S. suis* type 1 the *cps1E* gene may fulfil a similar function. The structure of the *S. suis* type 1 capsule is unknown, but it is composed of glucose, galactose, N-acetyl glucosamine, N-acetyl galactosamine and sialic acid in a ratio of 1: 2.4: 1: 1:1.4 (5). Therefore a role of a *cpsE*-like glucosyltransferase activity can easily be envisaged. *CpsE* like sequences were also found in serotypes 2, 1/2 and 14.

For polysaccharide biosynthesis in *S. pneumoniae* type 14, transfer of the second sugar of the repeating unit to the first lipid-linked sugar is performed by the gene products of *cps14F* and *cps14G* (20). Similar to *Cps14F* and *Cps14G*, the *S.*

suis type 1 proteins Cps1F and Cps1G may act as one glycosyltransferase performing the same reaction. Cps14F and Cps14G of *S. pneumoniae* showed similarity to the N-terminal half and C-terminal half of the SpsK protein of *Sphingomonas* (20, 67), respectively. This suggests a combined function for both proteins. Moreover, *cps14F* and *cps14G* like sequences were found in several serotypes of *S. pneumoniae* and these genes always seemed to exist together (60). The same was observed for *S. suis* type 1. The *cps1F* and *cps1G* probes hybridized with type 1 and type 14 strains.

According to the similarity found between the *cps1H* gene and the *cps14H* gene of *S. pneumoniae* (20), *cps1H* is expected to encode a polysaccharide polymerase.

The protein encoded by the *cps1I* gene showed some similarity with the Cps14J protein of *S. pneumoniae* (19). The *cps14J* gene was shown to encode a β -1,4-galactosyltransferase activity, responsible for the addition of the fourth (i.e. last) sugar in the synthesis of the *S. pneumoniae* serotype 14 polysaccharide. In *S. suis* type 2 the proteins encoded by the *cps2J* and *cps2K* genes showed similarity to the Cps14J protein. However, no significant homologies were found between Cps2J, Cps2K and Cps1I. In the N-terminal regions of Cps14J and Cps14I two small conserved regions, DXS and DXDD, were identified (19). These regions seemed to be important for catalytic activity (13). At the same positions in the sequence Cps2I contained the regions DXS and DXED.

In the region between Cps1G and Cps1H three small Orfs were identified. Since the Orfs were expressed in three different reading frames, and did not contain potential start sites, expression is not expected. However, the three potential gene products encoded by this region showed some similarity with three successive regions of the C-terminal part of the EpsK protein of *Streptococcus thermophilus* (27% identity, 40). The region related to the first 82 amino acids is lacking. The EpsK protein was suggested to play a role in the export of the exopolysaccharide by rendering the polymerized

exopolysaccharide more hydrophobic through a lipid modification. These data could suggest that the sequences in the region between *Cps1G* and *Cps1H* originated from *epsK*-like sequence. Hybridization experiments showed that this *epsK*-like region is also present in other serotype 1 strains as well as in serotype 14 strains (results not shown).

The function of most of the cloned serotype 9 genes can be established. Based on sequence similarity data the *cps9E* and *cps9F* genes could be glycosyltransferases (61, 24, 63, 64, 65). Moreover, the *cps9G* and *cps9H* genes showed similarity to genes located in regions involved in polysaccharide biosynthesis, but the function of these genes is unknown (68).

Cross-hybridization experiments using the individual *cps2*, *cps1* and *cps9* genes as probes showed that the *cps9G* and *cps9H* probes specifically hybridized with serotype 9 strains. Therefore, these are useful as tools for the identification of *S. suis* type 9 strains both for diagnostic purposes as well as in epidemiological and transmission studies. We previously developed a PCR method which can be used to detect *S. suis* strains in nasal and tonsil swabs of pigs (62). The method was for example used to identify pathogenic (EF-positive) strains of *S. suis* serotype 2. During the last years, beside *S. suis* type 2 strains, serotype 9 strains are frequently isolated from organs of diseased pigs. However, until now a rapid and sensitive diagnostic test was not available for type 9 strains. Therefore, the type 9 specific probes or the type 9 specific PCR is of great diagnostic value. The *cps1F*, *cps1G* and *cps1I* probes hybridized with serotype 1 as well as with serotype 14 strains. In coagglutination tests type 1 strains react with the anti-type 1 as well as with the anti-type 14 antisera (56). This suggests the presence of common epitopes between these serotypes. On the other hand type 1 strains agglutinated only with anti-type 1 serum (56,57), indicating that it is possible to detect differences between those serotypes.

The *cps2F*, *cps2G*, *cps2H*, *cps2I* and *cps2J* probes hybridized

with serotypes 2 and 1/2 only. Serotype 34 showed a weak hybridizing signal with the *cps2G* probe. As shown in agglutination tests type 1/2 strains react with sera directed against type 1 as well as with sera directed against type 2 strains (46). Therefore, type 1/2 shared antigens with both types 1 and 2. Based on the hybridization patterns of serotype 1/2 strains with the *cps1* and *cps2* specific genes, serotype 1/2 seemed to be more closely related to type 2 strains than to type 1 strains. In our current studies we identify type-specific genes, primers or probes which are used for the discrimination of serotypes 1, 14 and 2 and 1/2 and others of the 35 serotypes yet known. Furthermore, type-specific genes, primers or probes can now easily be developed for yet unknown serotypes, once they become isolated.

Cloning and characterization of a further part of the *cps2* locus.

Based on the established sequence 11 genes, designated *cps2L* to *cps2T*, *orf2U* and *orf2V*, were identified. A gene homologous to genes involved in the polymerization of the repeating oligosaccharide unit (*cps2O*) as well as genes involved in the synthesis of sialic acid (*cps2P* to *cps2T*) were identified. Moreover, hybridization experiments showed that the genes involved in the sialic acid synthesis are present in *S. suis* serotype 1, 2, 14, 27 and 1/2. The "*cps2M*" and "*cps2N*" regions showed similarity to proteins involved in the polysaccharide biosynthesis of other gram-positive bacteria. However, these regions seemed to be truncated or were non-functional as the result of frame-shift or point mutations. At its 3'-end the *cps2* locus contained two insertional elements ("*orf2U*" and "*orf2V*") both of which seemed to be non-functional.

To clone the remaining part of the *cps2* locus, sequences of the 3'-end of pCPS26 (Fig. 1C) were used to identify a chromosomal fragment containing *cps2* sequences located further downstream. This fragment was cloned in pKUN19 resulting in pCPS29. Using a similar approach we subsequently isolated the

plasmids pCPS30 and pCPS34 containing downstream cps2 sequences (Fig. 1C).

Analysis of the cps2 operon.

5 The complete nucleotide sequence of the cloned fragments was determined. Examination of the compiled sequence revealed the presence of : a sequence encoding the C-terminal part of Cps2K, six apparently functional genes (designated cps20-cps2T) and the remnants of 5 different ancestral genes
10 (designated "cps2L", "cps2M", "cps2N" , "orf2U" and "orf2V"). The latter genes seemed to be truncated or incomplete as the result of the presence of stop codons or frame-shift mutations (Fig. 1A). Neither potential promoter sequences nor potential stem-loop structures could be identified within the sequenced
15 region. A ribosome-binding site precedes each ORF and the majority of the ORFs is very closely linked. Three intergenic gaps were found: one between "cps2M" and "cps2N" (176 nucleotides), one between cps2O and cps2P (525 nucleotides), and one between cps2T and "orf2U" (200 nucleotides). These and
20 our above data show that Orf2X and Cps2A-Orf2T are part of a single operon.

 A list of all loci and their properties is shown in Table 4. The "cps2L" region contained three potential ORFs, of 103, 79 and 152 amino acids, respectively, which were only
25 separated from each other by stop codons. Only the first ORF is preceded by a potential ribosomal binding site and contained a methionine start codon. This suggests that "cps2L" originates from an ancestral cps2L gene, which coded for a protein of 339 amino acids. The function of this hypothetical
30 Cps2L protein remains unclear so far: no significant homologies were found between Cps2L and proteins present in the data libraries. It is not clear whether the first ORF of the "cps2L" region is expressed into a protein of 103 amino acids. The "cps2M " region showed homology to the N-terminal
35 134 amino acids of the NeuA proteins of Streptococcus agalactiae and Escherichia coli (AB017355, 32). However,

09767041.013301

although the "cps2 M" region contained a potential ribosome binding site, a methionine start codon was absent. Compared with the *S. agalactiae* sequence, the ATG start codon was replaced by a lysin encoding AAG codon. Moreover, the region homologous to the first 58 amino acids of the *S. agalactiae* NeuA (identity 77%) was separated from the region homologous to amino acids 59-134 of NeuA by a repeated DNA sequence of 100-bp (see later). In addition, the region homologous to amino acids 59 to 95 of NeuA (identity 32%) and the region homologous to the amino acids 96 to 134 of NeuA (identity 50%) were present in different reading frames. Therefore, the partial and truncated NeuA homologue is probably nonfunctional in *S. suis*. The "cps2N" region showed homology to CpsJ of *S. agalactiae* (accession no. AB017355). However, sequences homologous to the first 88 amino acids of CpsJ were lacking in *S. suis*. Moreover, the homologous region was present in two different reading frames. The protein encoded by the cps20 gene showed homology to proteins of several streptococci involved in the transport of the oligosaccharide repeating unit (accession no. AB017355), suggesting a similar function for Cps20. The proteins encoded by the cps2P, cps2S and cps2T genes showed homology to the NeuB, NeuD and NeuA proteins of *S. agalactiae* and *E. coli* (accession no AB017355). Because the "cps2M" region also showed homology to NeuA of *E. coli*, the *S. suis* cps2 locus contains a functional neuA gene (cps2T) as well as a nonfunctional ("cps2M") gene. The mutual homology between these two regions showed an identity of 77% at the amino acid level over amino acids 1-58 and 49% over the amino acids 59-134. Cps2Q and Cps2R showed homology to the N-terminal and C-terminal parts of the NeuC protein of *S. agalactiae* and *E. coli*, respectively. This suggests that the function of the *S. agalactiae* NeuC protein in *S. suis* is likely fulfilled by two different proteins. In *E. coli* the neu genes are known to be involved in the synthesis of sialic acid. NeuNAc is synthesized from N-acetylmannosamine and phosphoenolpyruvate by NeuNAc synthetase. Subsequently, NeuNAc

is converted to CMP-NeuNAc by the enzyme CMP-NeuNAc synthetase. CMP-NeuNAc is the substrate for the synthesis of polysaccharide. In *E. coli* K1 NeuB is the NeuNAc synthetase, NeuA is the CMP-NeuNAc synthetase. NeuC has been implicated in the NeuNAc synthesis, but its precise role is not known. The precise role of NeuD is not known. A role of the Cps2P-Cps2T proteins in the synthesis of sialic acid can easily be envisaged, since the capsule of *S. suis* serotype 2 is rich in sialic acid. In *S. agalactiae* sialic acid has been shown to be critical to the virulence function of the type III capsule. Moreover, it has been suggested that the presence of sialic acid in capsule of bacteria which can cause meningitis may be important for the capacity of these bacteria to breach the blood-brain barrier. So far, however, the requirement of the sialic acid for virulence of *S. suis* remains unclear.

"Orf2U" and "Orf2V" showed homology to proteins located on two different insertional elements. "Orf2U" is homologous to IS1194 of *Streptococcus thermophilus*, whereas "Orf2V" showed homology to a putative transposase of *Streptococcus pneumoniae*. This putative transposase was recently found to be associated with the type 2 capsular locus of *S. pneumoniae*. Compared with the original insertional elements in *S. thermophilus* and *S. pneumoniae*, both "Orf2U" and "Orf2V" are likely to be non-functional due to frame shift mutations within their coding regions.

A striking observation was the presence of a sequence of 100 bp (Fig. 9) which was repeated three times within the cps2 operon. The sequence is highly conserved (between 94% and 98%) and was found in the intergenic regions between cps2G and cps2H, within "cps2M" and between cps2O and cps2P. No significant homologies were found between this 100-bp direct repeat sequence and sequences present in the data libraries, suggesting that the sequence is unique for *S. suis*.

Distribution of the cps2 sequences among the 35 *S. suis* serotypes. To examine the presence of sialic acid encoding genes in other *S. suis* serotypes, we performed cross-

hybridization experiments. DNA fragments of the individual
cps2 genes were amplified by PCR, radiolabelled with ³²P and
hybridized to chromosomal DNA of the reference strains of the
35 different *S. suis* serotypes. As a positive control we used
5 a probe specific for *S. suis* 16S rRNA. The 16S rRNA probe
hybridized with almost equal intensities to all serotypes
tested (Table 4). The "cps2L" sequence hybridized with DNA of
serotype 1, 2, 14 and 1/2. The "cps2M", cps2O, cps2P, cps2Q,
cps2R, cps2S and cps2T genes hybridized with DNA of serotype
10 1, 2, 14, 27 and 1/2. Because the cps2P-cps2T genes are most
probably involved in the synthesis of sialic acid these
results suggest that sialic acid is also a part of the capsule
in the *S. suis* serotype 1, 2, 14, 27 and 1/2. This is in
agreement with the finding that the serotypes 1, 2 and 1/2
15 possess a capsule that is rich in sialic acid. Although the
chemical compositions of the capsules of serotype 14 and 27
are unknown, recent agglutination studies using sialic acid-
binding lectins suggested the presence of sialic acid in *S.*
suis serotype 14, but not in serotype 27. In these studies,
20 sialic acid was also detected in serotypes 15 and 16. Since
the latter observation is not in agreement with our
hybridization studies, it might be that other genes, not
homologous to the cps2P-cps2T genes, are responsible for the
sialic acid synthesis in serotypes 15 and 16.

25 A probe based on "cps2N" sequences hybridized with DNA from
serotypes 1, 2, 14 and 1/2. A probe specific for "orf2U"
hybridized with serotypes 1, 2, 7, 14, 24, 27, 32, 34, and
1/2, whereas a probe specific for "orf2V" hybridized with many
different serotypes. In addition, we prepared a probe specific
30 for the 100-bp direct repeat sequence. This probe hybridized
with the serotypes 1, 2, 13, 14, 22, 24, 27, 29, 32, 34 and
1/2 (Table 4). To analyze the number of copies of the direct
repeat sequence within the *S. suis* serotype 2 chromosome, a
Southern blot hybridization and analysis was performed.
35 Therefore, chromosomal DNA of *S. suis* serotype 2 was digested
with NcoI and hybridized with a ³²P-labelled direct repeat

sequence. Only one hybridizing fragment, containing the three direct repeats present on the *cps2* locus, was found (results not shown). This indicates that the 100-bp direct repeat sequence is only associated with the *cps2* locus. In *S.*

5 *pneumoniae* a 115-bp long repeated sequence was found to be associated with the capsular genes of serotypes 1, 3, 14 and 19F. In *S. pneumoniae* this 115-bp sequence was also found in the vicinity of other genes involved in pneumococcal virulence (hyaluronidase and neuraminidase genes). A regulatory role of
10 the 115-bp sequence in co-ordinate control of these virulence-related genes was suggested.

To study the role of the capsule in resistance to phagocytosis and in virulence, we constructed two isogenic mutants in which capsule synthesis was disturbed. In 10cpsB,
15 the *cps2B* gene was disturbed by the insertion of an antibiotic-resistance gene, whereas in 10cpsEF parts of the *cps2E* and *cps2F* genes were replaced. Both mutant strains seemed to be completely unencapsulated. Because the *cps 2* genes seemed to be part of an operon polar effects cannot be
20 excluded. Therefore these data did not give any information about the role of Cps2B, Cps2E or Cps2F in the polysaccharide biosynthesis. However, the results clearly show that the capsular polysaccharide of *S. suis* type 2 is a surface component with antiphagocytic activity. *In vitro* wild type
25 encapsulated bacteria are ingested by phagocytes at a very low frequency, whereas the mutant unencapsulated bacteria are efficiently ingested by porcine macrophages. Within 2 hours, over 99.6% of mutant bacteria were ingested and over 92% of the ingested bacteria were killed. Intracellularly, wild type
30 as well as mutant strains seemed to be killed with the same efficiency. This suggests that the loss of capsular material is associated with loss of capacity to resist uptake by macrophages. This loss of resistance to *in vitro* phagocytosis was associated with a substantial attenuation of the virulence
35 in germfree pigs. All pigs inoculated with the mutant strains survived the experiment and did not show any specific clinical

096704.01300
T022F0.040260

signs of disease. Only some aspecific clinical signs of disease could be observed. Moreover, mutant bacteria could be reisolated from the pigs. This supports the idea that, as in other pathogenic Streptococci, the capsule of *S. suis* acts as an important virulence factor. Transposon mutants prepared by Charland impaired in the capsule production showed a reduced virulence in pigs and mice. To construct these mutants the type 2 reference strain S735 was used. We previously showed that this strain is only weakly virulent for young pigs. Moreover, the insertion site of the transposon is unsolved so far.

As a further example herein a rapid PCT test for *Streptococcus suis* type 7 is described.

Recent epidemiological studies on *Streptococcus suis* infections in pigs indicated that, besides serotypes 1, 2 and 9, serotype 7 is also frequently associated with diseased animals. For the latter serotype, however, no rapid and sensitive diagnostic methods are available. This hampers prevention and control programs. Here we describe the development of a type-specific PCR test for the rapid and sensitive detection of *S. suis* serotype 7. The test is based on DNA sequences of capsular (*cps*) genes specific for serotype 7. These sequences could be identified by cross-hybridization of several individual *cps* genes with the chromosomal DNAs of 35 different *S. suis* serotypes.

Streptococcus suis is an important cause of meningitis, septicemia, arthritis and sudden death in young pigs [69,70]. It can, however, also cause meningitis in man [71]. Attempts to control the disease are still hampered by the lack of sufficient knowledge about the epidemiology of the disease and the lack of effective vaccines and sensitive diagnostics.

S. suis strains can be identified and classified by their morphological, biochemical and serological characteristics [70, 73, 74]. Serological classification is based on the

presence of specific antigenic determinants. Isolated and biochemically characterized *S. suis* cells are agglutinated with a panel of specific sera. These typing methods are very laborious and time-consuming and can only be performed on isolated colonies. Moreover, it has been reported that nonspecific cross-reactions may occur among different types of *S. suis* [75, 76].

So far, 35 different serotypes have been described [7, 78, 79]. *S. suis* serotype 2 is the most prevalent type isolated from diseased pigs, followed by serotypes 9, and 1. However, recently serotype 7 strains were also frequently isolated from diseased pigs [80, 81, 82]. This suggests that infections with *S. suis* serotype 7 strains seemed to be an increasing problem. Moreover, the virulence of *S. suis* serotype 7 strains was confirmed by experimental infection of young pigs [83].

Recently, rapid and sensitive PCR assays specific for serotypes 2 (and 1/2), 1 (and 14) and 9 were developed [84]. These assays were based the cps loci of *S. suis* serotypes 2, 1 and 9 [84, 85]. However, until now no rapid and sensitive diagnostic test is available for *S. suis* serotype 7. Herein we describe the development of a PCR test for the rapid and sensitive detection of *S. suis* serotype 7 strains. The test is based on DNA sequences which form a part of the cps locus of *S. suis* serotype 7. Compared with the serological serotyping methods the PCR assay was a rapid, reliable and sensitive assay. Therefore, this test, in combination with the PCR tests which we previously developed for serotype 1, 2 and 9, will undoubtedly contribute to a more rapid and reliable diagnosis of *S. suis* and may facilitate control and eradication programs.

Materials and Methods

Bacterial strains, growth conditions and serotyping.

The bacterial strains and plasmids used in this study are
5 listed in Table 7. The *S. suis* reference strains were obtained
from M. Gottschalk, Canada. *S. suis* strains were grown in
Todd-Hewitt broth (code CM189, Oxoid), and plated on Columbia
agar blood base (code CM331, Oxoid) containing 6% (v/v) horse
10 blood. *E. coli* strains were grown in Luria broth [86] and
plated on Luria broth containing 1.5% (w/v) agar. If required,
ampicillin was added to the plates. The *S. suis* strains were
serotyped by the slide agglutination test with serotype-
specific antibodies [70].

15 DNA techniques.

Routine DNA manipulations and PCR reactions were performed
as described by Sambrook et al. [88]. Blotting and
hybridization was performed as described previously [84,86].

20 DNA sequence analysis.

DNA sequences were determined on a 373A DNA Sequencing
System (Applied Biosystems, Warrington, GB). Samples were
prepared by use of a ABI/PRISM dye terminator cycle sequencing
ready reaction kit (Applied Biosystems). Custom-made
25 sequencing primers were purchased from Life Technologies.
Sequencing data were assembled and analyzed using the
McMollyTetra program. The BLAST program was used to search for
protein sequences homologous to the deduced amino acid
sequences.

30

PCR.

The primers used for the *cps7H* PCR correspond to the
positions 3334-3354 and 3585-3565 in the *S. suis* *cps7* locus.
The sequences were:

35 5'-AGCTCTAACACGAAATAAGGC-3' and 5'-GTCAAACACCCTGGATAGCCG-3'.

The reaction mixtures contained 10 mM Tris-HCl, pH 8.3; 1.5 mM

MgCl₂; 50 mM KCl; 0.2 mM of each of the four deoxynucleotide triphosphates; 1 microM of each of the primers and 1U of AmpliTaq Gold DNA polymerase (Perkin Elmer Applied Biosystems, New Jersey). DNA amplification was carried out in a Perkin Elmer 9600 thermal cycler and the program consisted of an incubation for 10 min at 95°C and 30 cycles of 1 min at 95°C, 2 min at 56°C and 2 min at 72°C.

Results and discussion

Cloning of the serotype 7-specific cps genes.

To isolate the type-specific cps genes of *S. suis* serotype 7 we used the cps9E gene of serotype 9 as a probe to identify chromosomal DNA fragments of type 7 containing homologous DNA sequences [84]. A 1.6-kb PstI fragment was identified and cloned in pKUN19. This yielded pCPS7-1 (Fig. 11C). In turn, this fragment was used as a probe to identify an overlapping 2.7 kb ScaI-ClaI fragment. pGEM7 containing the latter fragment was designated pCPS7-2 (Fig. 11C).

Analysis of the cloned cps7 genes.

The complete nucleotide sequences of the inserts of pCPS7-1, pCPS7-2 were determined. Examination of the cps7 sequence revealed the presence of two complete and two incomplete open reading frames (ORFs) (Fig. 11C). All ORFs are preceded by a ribosome-binding site. In accord with the data obtained for the cps1, cps2 and cps9 genes of serotypes 1, 2 and 9, respectively, the type 7 ORFs are very closely linked to each other. The only significant intergenic gap was that found between cps7E and cps7F (443 nucleotides). No obvious promoter sequences or potential stem-loop structures were found in this region. This suggests that, as in serotype 1, 2 and 9, the cps genes in serotype 7 form part of an operon.

An overview of the ORFs and their properties is shown in Table 8. As expected on the basis of the hybridization data [84], the Cps9E and Cps7E proteins showed a high similarity

(identity 99%, Table 8). Based on sequence comparisons between Cps9E and Cps7E, the PstI fragment of pCPS7-1 lacks the region encoding the first 371 codons of Cps7E. The C-terminal part of the protein encoded by the cps7F gene showed some similarity
5 with the BplG protein of Bordetella pertussis [88], as well as with the C-terminal part of S. suis Cps2E [85]. Both BplG and Cps2E were suggested to have glycosyltransferase activity and are probably involved in the linkage of the first sugar to the lipid carrier [85,88]. The protein encoded by the cps7G
10 gene showed similarity with the BlpF protein of Bordetella pertussis [88]. BlpF is likely to be involved in the biosynthesis of an amino sugar, suggesting a similar function for Cps7G. The protein encoded by the cps7H gene showed similarity with the WbdN protein of E. coli [89] as well as
15 with the N-terminal part of the Cps2K protein of S. suis [81]. Both WbdN and Cps2K were suggested to have glycosyltransferase activity [85, 89].

Serotype 7 specific cps genes.

20 To determine whether the cloned fragments in pCPS7-1 and pCPS7-2 contained serotype 7-specific DNA sequences, cross hybridization experiments were performed. DNA fragments of the individual cps7 genes were amplified by PCR, labelled with 32P, and used to probe spot blots of chromosomal DNA of the
25 reference strains of 35 different S. suis serotypes. The results are summarized in Table 9. As expected, based on the data obtained with the cps9E probe [84], the cps7E probe hybridized with chromosomal DNA of many different S. suis serotypes. The cps7F and cps7G probes showed hybridization
30 with chromosomal DNA of S. suis serotypes 4, 5, 7, 17, and 23. However, the cps7H probe hybridized with chromosomal DNA of serotype 7 only, indicating that this gene is specific for serotype 7.

Type specific PCR.

We tested whether we could use PCR instead of hybridization for the typing of the *S. suis* serotype 7 strains. For that purpose we selected an oligonucleotide primer set within the *cps7H* gene with which an amplified fragment of 251-bp was expected. In addition, we included in our analysis several *S. suis* serotype 7 strains, other than the reference strain. These strains were obtained from different countries and were isolated from different organs (Table 7). The results show that indeed a fragment of about 250-bp was amplified with all type 7 strains used (Fig. 12B), whereas no PCR products were obtained with serotype 1, 2 and 9 strains (Fig. 12A). This suggests that the PCR test, as described here, is a rapid diagnostic tool for the identification of *S. suis* serotype 7 strains. Until now such a diagnostic test was not available for serotype 7 strains. Together with the recently developed PCR assays for serotype 1, 2, 1/2, 14 and 9, this assay may be an important diagnostic tool to detect pigs carrying serotype 2, 1/2, 1, 14, 9 and 7 strains and may facilitate control and eradication programs.

2025 RELEASE UNDER E.O. 14176

<110> Smith, Hilda

<130> 2183-4726

<151> 1999-07-19

<151> 1998-07-22

<150> EP98202467.1

<151> 1998-07-22

<160> 53

<170> PatentIn version 3.0

 $\langle 210 \rangle$ 1

<211> 23

<212> DNA

<213> Artificial

 $\langle 220 \rangle$

<223> Primer

 $\langle 400 \rangle$ 1

caaacgcaag gaattacggt atc

<210> 2

<211> 23

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 2

gagtatctaa agaatgccta ttg

23

<210> 3

<211> 20

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 3

ggcggcttag cagatgctcg

20

<210> 4

<211> 19

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 4
gcgaactgtt agcaatgac

19

<210> 5

<211> 21

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 5
ggctacatat aatggaagcc c

21

<210> 6

<211> 20

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 6
cggaagtatc tgggctactg

20

<210> 7

<211> 21

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 7

agctctaaca cgaaataagg c

21

<210> 8

<211> 21

<212> DNA

<213> Artificial

<220>

<223> primer

<400> 8

gtcaaacacc ctggatagcc g

21

<210> 9

<211> 6992

<212> DNA

<213> Streptococcus suis

<220>

<221> misc_feature

<222> (1)..(6992)

<223> CPS 2

<400> 9

atcgccaaac gaaattggca ttatttgata tgatagcagt tgcaatttct gcaatcttaa 60
 caagtcatat accaaatgct gattfaaac gtcttggaat tttatcata atgatggttc 120
 attatttgc atttttata tctcgtatgc cagtgaatt tgagtataga ggtaatctga 180
 tagagttga aaaaacattt aactatagta taatattgc aattttctt acggcagtat 240
 cattttgtt ggagaataat ttcgcacttt caagacgtgg tgccgtgtat ttcacattaa 300
 taaacttctg ttggtatac ctatttaacg taattattaa gcagttaag gatagcttcc 360
 tatttcgac aatctatcaa aaaaagacga ttctaattac aacggctgaa cgatgggaaa 420
 atatgcaagt tttattgaa tcacataaac aaattcaaaa aaatcttgtt gcattggtag 480
 ttttaggtac agaaatagat aaaattaatt taccattacc gctctattat tctgtggaag 540
 aagctataga gtttcaaca agggaagtgg tcgaccacgt cttataaat ctaccaagtg 600
 agttttaga cgtaaagcaa ttcgttcag attttgagtt gttaggtatt gatgtaagcg 660
 ttgatattaa ttcattcggt ttactgcgt tgaaaaacaa aaaaatccaa ctgctaggtg 720
 accatagcat tgtaactttt tccacaaatt ttataagcc tagtcatac atgatgaaac 780
 gacttttga tatactcgga gcggtagtcg ggtaattat ttgtgtata gtttctattt 840
 tgtagttcc aattattcgt agagatggtg gaccggctat tttgctcag aaacgagttg 900
 gacagaatgg acgcataatt acattctaca agtttcgac gatgtatgtt gatgctgagg 960
 agcgcaaaaa agacttgctc agccaaaacc agatgcaagg gtgggtatgt tttaaatgg 1020
 gaaaaacgat cctagaatta ctccaattgg acatttcata cgcaaaaaca agtttagacg 1080
 agtaccaca gttttataat gtttaattg gcgatagag tctagttggt acacgtccac 1140
 ctacagtga tgaattgaa aaatatactc ctggtcaaaa gagacgattg agttttaaac 1200
 cagggattac aggtctctgg caggtagtg gtcgtagtaa taccacagac ttcgacgacg 1260

tagttcggtt ggacttagca tacattgata attggactat ctggtcagat attaaaattt 1320
 tattaagac agtgaaagt gtattgtga gagagggaag taagtaaaag tatatgaaag 1380
 ttgtttggt cggttcttca gggggacatt tgactcactt gtatttgta aaaccgtttt 1440
 ggaaggaaga agaacgtttt tgggtaacat ttgataaaga ggatgcaaga agtcttttga 1500
 agaatgaaaa aatgtatcca tgttactttc caacaaatcg caatctcatt aatttagtga 1560
 aaaatacttt cttagctttc aaaattttac gtgatgagaa accagatgtt attatttcat 1620
 ctggtgcggc cgttgctgtc cccttctttt acatcggaag actatttgga gcaaagacga 1680
 tttatattga agtatttgat cgagttaata aatctacatt aactggaaaa ctagtttatt 1740
 ccgtaacaga tatttttatt gttcagtggg aagaaatgaa gaaggtatat cctaaatcta 1800
 ttaactggg gagtattttt taatgatttt tgaacagta ggaactcatg aacaacagtt 1860
 taatcgattg ataaaagaga ttgatttatt gaaaaaaaaat ggaagtataa ccgacgaaat 1920
 atttattcaa acaggatatt ctgactatat tccagaatat tgcaagtata aaaaatttct 1980
 cagttacaaa gaaatggaac aatatattaa caaatcagaa gtagttattt gccacggagg 2040
 ccccgctact ttatgaatt cattatccaa aggaaaaaaaa caattattgt ttcttagaca 2100
 aaaaaagtat ggtgaacatg taaatgatca tcaagtagag ttgtaagaa gaattttaca 2160
 agataataat attttattta tagaaaatat agatgatttg ttgaaaaaa ttattgaagt 2220
 ttctaagcaa actaacttta catcaaataa taattttttt tgtgaaagat taaaacaaat 2280
 agtgaaaaaa tttaatgagg atcaagaaaa tgaataataa aaaagatgca tatttgataa 2340
 tggtttatca taatttttct cagattttac tggagaggga tacagatatt atcatcttct 2400
 ctgaggagaa tgcacacat tagttccttc agaatacctg tataattatt ttaaatattc 2460
 tcaggattta tatgttgaat ttacaaaaga tgagcaaaaa tataaagaaa ataggatata 2520
 tgaacgagtt aaatgttaca gattatttcc taatatatca gaaaaaacta ttgataatgt 2580

actgtttaga attttattaa gaatgtatcg agcttttgaa tactatttac aaagattgtt 2640
 gttlattgat agaataaaaa acatgggtcta agaataagat ttgggttctaa ttgggtttcg 2700
 ctccacatg atttgtggc aattctttta tcaaatgaaa acgaaacagc ttatttattt 2760
 aagtaatcta aatgtccaga tgaactattt atacagacaa ttatagaaaa atatgaattt 2820
 tcaaatagat tatctaaata tggaaattta agatatataa agtggaaaaa atcaacatct 2880
 tctcctattg tctttacaga tgattctatt gatgaattgc taaatgcaag aaatttaggt 2940
 tttttattg ctagaaagt aaaaatagaa aataaatcta aatttaaaga aattattact 3000
 aaaaaataaa atagttgatt ttgtgagagt aatgtatgtt taaattattt aaatatgacc 3060
 cggaatattt tattttaag tacttctggt tgattattt tattccagag caaaagtatg 3120
 tattttatt aattttatg aatttaattt tatttcatat aaaattttg aaaactaagc 3180
 taatattaaa aaatgaaatt ttattgtttt tattatggtc tatattatgt ttgtttcag 3240
 tagtcacaag tatgtttgtt gaaataaatt ttgaaagatt attgcagat ttactgctc 3300
 ccataatttg gattattgca ataatgtatt ataatttga ttcatttata aatattgatt 3360
 ataaaaaatt aaaaaatagt atcttttta gtttttagt ttatttaggt atatctgcat 3420
 tgtatattat tcaaatggg aaagatattg tatttttaga cagacacctt ataggactag 3480
 actatcttat aacaggcgtc aaaacaaggt tggttggctt tatgaactat cctacgttaa 3540
 ataccactac aattatagtt tcaattccgt taatctttgc acttataaaa aataaaatgc 3600
 aacaattttt ttcttgtgt ctgctttta taccgatcta tttaagtga tcgagaattg 3660
 gtagtttatt gctagcaata ttaattatat gcttgttatg gagatatata ggtggaaaat 3720
 ttgcttggat aaaaaagcta atagtaatat ttgtaatact acttattatt taaatactg 3780
 aattgcttta ccatgaaatt ttggctgttt ataattctag agaatcaagt aacgaagcta 3840
 gatttattat ttatcaagga agtattgata aagtattaga aaacaatatt ttatttggat 3900

atggaatatc cgaatattca gttacgggaa ctgggctcgg aagtcattca ggctatatat 3960
catttttta taaatcagga atagtgggt tgattttact gatgtttct ttttttatg 4020
ttataaaaaa aagttaagga gtaaatgggg aaacagcact attttattt acatcattag 4080
ccatatattt catatatgaa acaatagatc cgattattat tatattagta ctattctttt 4140
cttcaatagg tatttggaat aatataaatt ttaaaaagga tatggagaca aaaaatgaat 4200
gatttaattt cagtattgt accaatttat aatgtccaag attatcttga taaatgtatt 4260
aacagtatta ttaaccaa acataactaat ttagagggtta ttctcgtaaa tgatggaagt 4320
actgatgatt ctgagaaaaa ttgcttaa ac tatatgaaga acgatggaag aattaaatat 4380
tacaagaaaa ttaatggcgg tctagcagat gctcgaaatt tcggactaga acatgcaaca 4440
ggtaaatata ttgcttttgc gattctgat gactatatag aagttgcaat gtgcagaga 4500
atgcatgata atataactga gtataatgcc gatatagcag agatagattt ttgtttagta 4560
gacgaaaacg ggtatacaaa gaaaaaaaga aatagtaatt tcatgtctt aacgagagaa 4620
gagactgtaa aagaattttt gtcaggatct aatatagaaa ataatgtttg gtgcaagctt 4680
tattcacgag atattataaa agatataaaa ttccaaatta ataatagaag tattggtgag 4740
gatttgcttt ttaatttgga ggtcttgaac aatgtaacac gtgtagtagt tgatactaga 4800
gaatattatt ataattatgt cattcgtaac agttcgctta ttaatcagaa attctctata 4860
aataatattg atttagtcac aagattggag aattaccctt ttaagttaa aagagagttt 4920
agtcattatt ttgatgcaaa agttattaaa gagaagggtta aatgtttaaa caaatgtat 4980
tcaacagatt gtttgataa tgagttcttg ccaatattag agtcttatcg aaaagaaata 5040
cgtagatatc catttattaa agcgaaaaga tatttatcaa gaaagcattt agttacgttg 5100
tatttgatga aattttcgcc taaactatat gtaatgttat ataagaaatt tcaaaagcag 5160
tagaggtaaa aatggataaa attagtgtta ttgtccagt ttataatgta gataaatatt 5220

taagtagttg tatagaaagc attattaatc aaaattataa aaatatagaa atattattga 5280
 tagatgatgg ctctgtagat gattctgcta aaatatgcaa ggaatatgca gaaaaagata 5340
 aaagagtaaa aatttttttc actaatcata gtggagtatc aaatgctaga aatcatggaa 5400
 taaagcggag tacagctgaa tatattatgt ttgttgactc tgatgatgtt gttgatagta 5460
 gattagtaga aaaattatat ttaatatta taaaaagtag aagtgattta tctggttgtt 5520
 tgtacgctac ttttcagaa aatataaata atttgaagt gaataatcca aatattgatt 5580
 ttgaagcaat taataccgtg caggacatgg gagaaaaaaa tttatgaat ttgtatataa 5640
 ataattttt ttctactcct gtttgtaaac tatataagaa aagatacata acagatcttt 5700
 ttcaagagaa tcaatggta ggagaagatt tacttttaa tctgcattat ttaaagaata 5760
 tagatagagt tagttatttg actgaacatc tttatttta taggagaggt atactaagta 5820
 cagtaaattc tttaaagaa ggtgtgtttt tgcaattgga aaatttgcaa aaacaagtga 5880
 tagtattgtt taagcaaata tatggtgagg attttgacgt atcaattgtt aaagatacta 5940
 tacgttgga agtattttat tatagcttac taatgtttaa atacggaaaa cagtctattt 6000
 ttgacaaatt ttaattttt agaaatcttt ataaaaata ttattttaac ttgtaaaag 6060
 tatctaaca aaattctttg tctaaaaatt ttgtataag aattgttcg aacaaagttt 6120
 ttaaaaaaat attatggta taataggaag atatcatgga tactattagt aaaatttcta 6180
 taattgtacc tatatataat gtagaaaaat atttatctaa atgtatagat agcattgtaa 6240
 atcagacctt caaacatata gagattcttc tggatgaatga cggtagtacg gataattcgg 6300
 aagaaatttg ttagcatat gcgaagaaag atagtcgcat tcgtattttt aaaaagaga 6360
 acggcgggct atcagatgcc cgtaattatg gcataagtcg cgccaagggt gactacttag 6420
 cttttataga ctcatgatg tttattcatt cggagtcat ccaacgttta cacgaagcaa 6480
 ttgagagaga gaatgccctt gtggcagttg ctggttatga taggtagat gcttcggggc 6540

$\langle 210 \rangle$ 10

<211> 239

<212> PRT

<213> Streptococcus suis

 $\langle 220 \rangle$

<221> misc_feature

<223> ORF2Z

<400> 10

Ser Leu Asp Ile Asp His Met Met Glu Val Met Glu Ala Ser Lys Ser
1 5 10 15

Ala Ala Gly Ser Ala Cys Pro Ser Pro Gln Ala Tyr Gln Ala Ala Phe
20 25 30

Glu Gly Ala Glu Asn Ile Ile Val Val Thr Ile Thr Gly Gly Leu Ser
35 40 45

Gly Ser Phe Asn Ala Ala Arg Val Ala Arg Asp Met Tyr Ile Glu Glu
50 55 60

His Pro Asn Val Asn Ile His Leu Ile Asp Ser Leu Ser Ala Ser Gly
65 70 75 80

Glu Met Asp Leu Leu Val His Gln Ile Asn Arg Leu Ile Ser Ala Gly
85 90 95

Leu Asp Phe Pro Gln Val Val Glu Ala Ile Thr His Tyr Arg Glu His
100 105 110

Ser Lys Leu Leu Phe Val Leu Ala Lys Val Asp Asn Leu Val Lys Asn
115 120 125

Gly Arg Leu Ser Lys Leu Val Gly Thr Val Val Gly Leu Leu Asn Ile
130 135 140

Arg Met Val Gly Glu Ala Ser Ala Glu Gly Lys Leu Glu Leu Leu Gln
145 150 155 160

Lys Ala Arg Gly His Lys Lys Ser Val Thr Ala Ala Phe Glu Glu Met
165 170 175

Lys Lys Ala Gly Tyr Asp Gly Gly Arg Ile Val Met Ala His Arg Asn
180 185 190

Asn Ala Lys Phe Phe Gln Gln Phe Ser Glu Leu Val Lys Ala Ser Phe
195 200 205

Pro Thr Ala Val Ile Asp Glu Val Ala Thr Ser Gly Leu Cys Ser Phe
210 215 220

Tyr Ala Glu Glu Gly Gly Leu Leu Met Gly Tyr Glu Val Lys Ala
225 230 235

<210> 11

<211> 244

<212> PRT

<213> Streptococcus suis

Glu Phe Glu Gln Val Phe Ser Pro Gln Ile Gln Lys Arg Leu Val Lys
165 170 175

Ile Leu Phe Met Glu Glu Lys Ala Gly Gln Leu Lys Val His Ser Thr
180 185 190

Ile Ser Lys Lys Gly Arg Gly Arg Leu Leu Ser Trp Leu Ala Lys Asn
195 200 205

Asn Ile Gln Glu Leu Ser Asp Ile Gln Asp Phe Lys Val Asp Gly Phe
210 215 220

Glu Tyr Cys Thr Ser Glu Ser Thr Ala Asn Gln Leu Thr Phe Ile Arg
225 230 235 240

Ser Ile Lys Met

<210> 12

<211> 481

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2A

<400> 12

Met Lys Lys Arg Ser Gly Arg Ser Lys Ser Ser Lys Phe Lys Leu Val
1 5 10 15

Asn Phe Ala Leu Leu Gly Leu Tyr Ser Ile Thr Leu Cys Leu Phe Leu
20 25 30

Val Thr Met Tyr Arg Tyr Asn Ile Leu Asp Phe Arg Tyr Leu Asn Tyr
35 40 45

Ile Val Thr Leu Leu Leu Val Gly Val Ala Val Leu Ala Gly Leu Leu
50 55 60

Met Trp Arg Lys Lys Ala Arg Ile Phe Thr Ala Leu Leu Leu Val Phe
65 70 75 80

Ser Leu Val Ile Thr Ser Val Gly Ile Tyr Gly Met Gln Glu Val Val
 85 90 95

Lys Phe Ser Thr Arg Leu Asn Ser Asn Ser Thr Phe Ser Glu Tyr Glu
 100 105 110

Met Ser Ile Leu Val Pro Ala Asn Ser Asp Ile Thr Asp Val Arg Gln
 115 120 125

Leu Thr Ser Ile Leu Ala Pro Ala Glu Tyr Asp Gln Asp Asn Ile Thr
 130 135 140

Ala Leu Leu Asp Asp Ile Ser Lys Met Glu Ser Thr Gln Leu Ala Thr
145 150 155 160

Ser Pro Gly Thr Ser Tyr Leu Thr Ala Tyr Gln Ser Met Leu Asn Gly
 165 170 175

Glu Ser Gln Ala Met Val Phe Asn Gly Val Phe Thr Asn Ile Leu Glu
 180 185 190

Asn Glu Asp Pro Gly Phe Ser Ser Lys Val Lys Lys Ile Tyr Ser Phe
 195 200 205

Lys Val Thr Gln Thr Val Glu Thr Ala Thr Lys Gln Val Ser Gly Asp
 210 215 220

Ser Phe Asn Ile Tyr Ile Ser Gly Ile Asp Ala Tyr Gly Pro Ile Ser
225 230 235 240

Thr Val Ser Arg Ser Asp Val Asn Ile Ile Met Thr Val Asn Arg Ala
 245 250 255

Thr His Lys Ile Leu Leu Thr Thr Thr Pro Arg Asp Ser Tyr Val Ala
 260 265 270

Phe Ala Asp Gly Gly Gln Asn Gln Tyr Asp Lys Leu Thr His Ala Gly
 275 280 285

Ile Tyr Gly Val Asn Ala Ser Val His Thr Leu Glu Asn Phe Tyr Gly

290 295 300

Ile Asp Ile Ser Asn Tyr Val Arg Leu Asn Phe Ile Ser Phe Leu Gln
305 310 315 320

Leu Ile Asp Leu Val Gly Gly Ile Asp Val Tyr Asn Asp Gln Glu Phe
325 330 335

Thr Ser Leu His Gly Asn Tyr His Phe Pro Val Gly Gln Val His Leu
340 345 350

Asn Ser Asp Gln Ala Leu Gly Phe Val Arg Glu Arg Tyr Ser Leu Thr
355 360 365

Gly Gly Asp Asn Asp Arg Gly Lys Asn Gln Glu Lys Val Ile Ala Ala
370 375 380

Leu Ile Lys Lys Met Ser Thr Pro Glu Asn Leu Lys Asn Tyr Gln Ala
385 390 395 400

Ile Leu Ser Gly Leu Glu Gly Ser Ile Gln Thr Asp Leu Ser Leu Glu
405 410 415

Thr Ile Met Ser Leu Val Asn Thr Gln Leu Glu Ser Gly Thr Gln Phe
420 425 430

Thr Val Glu Ser Gln Ala Leu Thr Gly Thr Gly Arg Ser Asp Leu Ser
435 440 445

Ser Tyr Ala Met Pro Gly Ser Gln Leu Tyr Met Met Glu Ile Asn Gln
450 455 460

Asp Ser Leu Glu Gln Ser Lys Ala Ala Ile Gln Ser Val Leu Val Glu
465 470 475 480

Lys

<210> 13

<211> 229

<212> PRT

$\langle 220 \rangle$

<223> CPS2B

Met Asn Asn Gln Glu Val Asn Ala Ile Glu Ile Asp Val Leu Phe Leu
1 5 10 15

Leu Thr Ala Gly Leu Ala Phe Val Tyr Ser Ser Phe Leu Val Thr Pro
35 40 45

Ala Gly Ala Gly Leu Thr Asn Gln Glu Leu Gln Ala Gly Thr Tyr Leu
65 70 75 80

Val Ala Thr Glu Leu Asn Leu Lys Glu Ser Leu Lys Glu Lys Ile Ser
100 105 110

Ala Asp Pro Asn Glu Ala Ala Arg Ile Ala Asn Ser Leu Arg Thr Phe
130 135 140

Ala Val Gln Lys Val Val Glu Val Thr Lys Val Ser Asp Val Thr Thr
145 150 155 160

Leu Glu Glu Ala Val Pro Ala Glu Glu Pro Thr Thr Pro Asn Thr Lys
 165 170 175

Arg Asn Ile Leu Leu Gly Leu Leu Ala Gly Gly Ile Leu Ala Thr Gly
 180 185 190

Leu Val Leu Val Met Glu Val Leu Asp Asp Arg Val Lys Arg Pro Gln
 195 200 205

Asp Ile Glu Glu Val Met Gly Leu Thr Leu Leu Gly Ile Val Pro Asp
 210 215 220

Ser Lys Lys Leu Lys
 225

<210> 14

<211> 225

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2C

<400> 14

Met Ala Met Leu Glu Ile Ala Arg Thr Lys Arg Glu Gly Val Asn Lys
 1 5 10 15

Thr Glu Glu Tyr Phe Asn Ala Ile Arg Thr Asn Ile Gln Leu Ser Gly
 20 25 30

Ala Asp Ile Lys Val Val Gly Ile Thr Ser Val Lys Ser Asn Glu Gly
 35 40 45

Lys Ser Thr Thr Ala Ala Ser Leu Ala Ile Ala Tyr Ala Arg Ser Gly

50

55

60

Tyr Lys Thr Val Leu Val Asp Ala Asp Ile Arg Asn Ser Val Met Pro
 65 70 75 80

Gly Phe Phe Lys Pro Ile Thr Lys Ile Thr Gly Leu Thr Asp Tyr Leu
 85 90 95

Ala Gly Thr Thr Asp Leu Ser Gln Gly Leu Cys Asp Thr Asp Ile Pro
 100 105 110

Asn Leu Thr Val Ile Glu Ser Gly Lys Val Ser Pro Asn Pro Thr Ala
 115 120 125

Leu Leu Gln Ser Lys Asn Phe Glu Asn Leu Leu Ala Thr Leu Arg Arg
 130 135 140

Tyr Tyr Asp Tyr Val Ile Val Asp Cys Pro Pro Leu Gly Leu Val Ile
 145 150 155 160

Asp Ala Ala Ile Ile Ala Gln Lys Cys Asp Ala Met Val Ala Val Val
 165 170 175

Glu Ala Gly Asn Val Lys Cys Ser Ser Leu Lys Lys Val Lys Glu Gln
 180 185 190

Leu Glu Gln Thr Gly Thr Pro Phe Leu Gly Val Ile Leu Asn Lys Tyr
 195 200 205

Asp Ile Ala Thr Glu Lys Tyr Ser Glu Tyr Gly Asn Tyr Gly Lys Lys
 210 215 220

Ala

225

<210> 15

<211> 243

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2D

<400> 15

Met Ile Asp Ile His Ser His Ile Ile Phe Gly Val Asp Asp Gly Pro
 1 5 10 15

Lys Thr Ile Glu Glu Ser Leu Ser Leu Ile Ser Glu Ala Tyr Arg Gln
 20 25 30

Gly Val Arg Tyr Ile Val Ala Thr Ser His Arg Arg Lys Gly Met Phe
 35 40 45

Glu Thr Pro Glu Lys Ile Ile Met Ile Asn Phe Leu Gln Leu Lys Glu
 50 55 60

Ala Val Ala Glu Val Tyr Pro Glu Ile Arg Leu Cys Tyr Gly Ala Glu
 65 70 75 80

Leu Tyr Tyr Ser Lys Asp Ile Leu Ser Lys Leu Glu Lys Lys Lys Val
 85 90 95

Pro Thr Leu Asn Gly Ser Cys Tyr Ile Leu Leu Glu Phe Ser Thr Asp
 100 105 110

Thr Pro Trp Lys Glu Ile Gln Glu Ala Val Asn Glu Met Thr Leu Leu
 115 120 125

Gly Leu Thr Pro Val Leu Ala His Ile Glu Arg Tyr Asp Ala Leu Ala
 130 135 140

Phe Gln Ser Glu Arg Val Glu Lys Leu Ile Asp Lys Gly Cys Tyr Thr
 145 150 155 160

Gln Val Asn Ser Asn His Val Leu Lys Pro Ala Leu Ile Gly Glu Arg
 165 170 175

FOREFOLD "F029250"

Ala Lys Glu Phe Lys Lys Arg Thr Arg Tyr Phe Leu Glu Gln Asp Leu
 180 185 190

Val His Cys Val Ala Ser Asp Met His Asn Leu Tyr Ser Arg Pro Pro
 195 200 205

Phe Met Arg Glu Ala Tyr Gln Leu Val Lys Lys Glu Tyr Gly Glu Asp
 210 215 220

Arg Ala Lys Ala Leu Phe Lys Lys Asn Pro Leu Leu Ile Leu Lys Asn
 225 230 235 240

Gln Val Gln

<210> 16

<211> 459

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2E

<400> 16

Met Asn Ile Glu Ile Gly Tyr Arg Gln Thr Lys Leu Ala Leu Phe Asp
 1 5 10 15

Met Ile Ala Val Thr Ile Ser Ala Ile Leu Thr Ser His Ile Pro Asn
 20 25 30

Ala Asp Leu Asn Arg Ser Gly Ile Phe Ile Ile Met Met Val His Tyr
 35 40 45

Phe Ala Phe Phe Ile Ser Arg Met Pro Val Glu Phe Glu Tyr Arg Gly

50 55 60
 Asn Leu Ile Glu Phe Glu Lys Thr Phe Asn Tyr Ser Ile Ile Phe Val
 65 70 75 80
 Ile Phe Leu Met Ala Val Ser Phe Met Leu Glu Asn Asn Phe Ala Leu
 85 90 95
 Ser Arg Arg Gly Ala Val Tyr Phe Thr Leu Ile Asn Phe Val Leu Val
 100 105 110
 Tyr Leu Phe Asn Val Ile Ile Lys Gln Phe Lys Asp Ser Phe Leu Phe
 115 120 125
 Ser Thr Thr Tyr Gln Lys Lys Thr Ile Leu Ile Thr Thr Ala Glu Leu
 130 135 140
 Trp Glu Asn Met Gln Val Leu Phe Glu Ser Asp Ile Leu Phe Gln Lys
 145 150 155 160
 Asn Leu Val Ala Leu Val Ile Leu Gly Thr Glu Ile Asp Lys Ile Asn
 165 170 175
 Leu Pro Leu Pro Leu Tyr Tyr Ser Val Glu Glu Ala Ile Gly Phe Ser
 180 185 190
 Thr Arg Glu Val Val Asp Tyr Val Phe Ile Asn Leu Pro Ser Glu Tyr
 195 200 205
 Phe Asp Leu Lys Gln Leu Val Ser Asp Phe Glu Leu Leu Gly Ile Asp
 210 215 220
 Val Gly Val Asp Ile Asn Ser Phe Gly Phe Thr Val Leu Lys Asn Lys
 225 230 235 240
 Lys Ile Gln Met Leu Gly Asp His Ser Ile Val Thr Phe Ser Thr Asn
 245 250 255
 Phe Tyr Lys Pro Ser His Ile Trp Met Lys Arg Leu Leu Asp Ile Leu
 260 265 270
 Gly Ala Val Val Gly Leu Ile Ile Ser Gly Ile Val Ser Ile Leu Leu
 275 280 285

$\langle 220 \rangle$

<221> misc_feature

<223> CPS2F

<400> 17

Met Arg Thr Val Tyr Ile Ile Gly Ser Lys Gly Ile Pro Ala Lys Tyr
1 5 10 15

Gly Gly Phe Glu Thr Phe Val Glu Lys Leu Thr Glu Tyr Gln Lys Asp
20 25 30

Lys Ser Ile Asn Tyr Phe Val Ala Cys Thr Arg Glu Asn Ser Ala Lys
35 40 45

Ser Asp Ile Thr Gly Glu Val Phe Glu His Asn Gly Ala Thr Cys Phe
50 55 60

Asn Ile Asp Val Pro Asn Ile Gly Ser Ala Lys Ala Ile Leu Tyr Asp
65 70 75 80

Ile Met Ala Leu Lys Lys Ser Ile Glu Ile Ala Lys Asp Arg Asn Asp
85 90 95

Thr Ser Pro Ile Phe Tyr Ile Leu Ala Cys Arg Ile Gly Pro Phe Ile
100 105 110

Tyr Leu Phe Lys Lys Gln Ile Glu Ser Ile Gly Gly Gln Leu Phe Val
115 120 125

Asn Pro Asp Gly His Glu Trp Leu Arg Glu Lys Trp Ser Tyr Pro Val
130 135 140

Arg Gln Tyr Trp Lys Phe Ser Glu Ser Leu Met Leu Lys Tyr Ala Asp
145 150 155 160

Leu Leu Ile Cys Asp Ser Lys Asn Ile Glu Lys Tyr Ile His Glu Asp
165 170 175

Tyr Arg Lys Tyr Ala Pro Glu Thr Ser Tyr Ile Ala Tyr Gly Thr Asp
180 185 190

Leu Asp Lys Ser Arg Leu Ser Pro Thr Asp Ser Val Val Arg Glu Trp
195 200 205

Tyr Lys Glu Lys Glu Ile Ser Glu Asn Asp Tyr Tyr Leu Val Val Gly
210 215 220

Arg Phe Val Pro Glu Asn Asn Tyr Glu Val Met Ile Arg Glu Phe Met
225 230 235 240

Lys Ser Tyr Ser Arg Lys Asp Phe Val Leu Ile Thr Asn Val Glu His
245 250 255

Asn Ser Phe Tyr Glu Lys Leu Lys Lys Glu Thr Gly Phe Asp Lys Asp
260 265 270

Lys Arg Ile Lys Phe Val Gly Thr Val Tyr Asn Gln Glu Leu Leu Lys
275 280 285

Tyr Ile Arg Glu Asn Ala Phe Ala Tyr Phe His Gly His Glu Val Gly
290 295 300

Gly Thr Asn Pro Ser Leu Leu Glu Ala Leu Ser Ser Thr Lys Leu Asn
305 310 315 320

Leu Leu Leu Asp Val Gly Phe Asn Arg Glu Val Gly Glu Glu Gly Ala
325 330 335

Lys Tyr Trp Asn Lys Asp Asn Leu His Arg Val Ile Asp Ser Cys Glu
340 345 350

Gln Leu Ser Gln Glu Gln Ile Asn Asp Met Asp Ser Leu Ser Thr Lys
355 360 365

Gln Val Lys Glu Arg Phe Ser Trp Asp Phe Ile Val Asp Glu Tyr Glu
370 375 380

Lys Leu Phe Lys Gly
385

<210> 18

<211> 385

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2G

<400> 18

Met Lys Lys Ile Leu Tyr Leu His Ala Gly Ala Glu Leu Tyr Gly Ala
1 5 10 15

Asp Lys Val Leu Leu Glu Leu Ile Lys Gly Leu Asp Lys Asn Glu Phe
20 25 30

Glu Ala His Val Ile Leu Pro Asn Asp Gly Val Leu Val Pro Ala Leu
35 40 45

Arg Glu Val Gly Ala Gln Val Glu Val Ile Asn Tyr Pro Ile Leu Arg
50 55 60

Arg Lys Tyr Phe Asn Pro Lys Gly Ile Phe Asp Tyr Phe Ile Ser Tyr
65 70 75 80

His His Tyr Ser Lys Gln Ile Ala Gln Tyr Ala Ile Glu Asn Lys Val
85 90 95

Asp Ile Ile His Asn Asn Thr Thr Ala Val Leu Glu Gly Ile Tyr Leu
100 105 110

Lys Arg Lys Leu Lys Leu Pro Leu Leu Trp His Val His Glu Ile Ile
115 120 125

Val Lys Pro Lys Phe Ile Ser Asp Ser Ile Asn Phe Leu Met Gly Arg
130 135 140

Phe Ala Asp Lys Ile Val Thr Val Ser Gln Ala Val Ala Asn His Ile
145 150 155 160

Lys Gln Ser Pro His Ile Lys Asp Asp Gln Ile Ser Val Ile Tyr Asn
165 170 175

Gly Val Asp Asn Lys Val Phe Tyr Gln Ser Asp Ala Arg Ser Val Arg
180 185 190

Glu Arg Phe Asp Ile Asp Glu Glu Ala Leu Val Ile Gly Met Val Gly
195 200 205

Arg Val Asn Ala Trp Lys Gly Gln Gly Asp Phe Leu Glu Ala Val Ala
210 215 220

Pro Ile Leu Glu Gln Asn Pro Lys Ala Ile Ala Phe Ile Ala Gly Ser
225 230 235 240

Ala Phe Glu Gly Glu Glu Trp Arg Val Val Glu Leu Glu Lys Lys Ile
245 250 255

Ser Gln Leu Lys Val Ser Ser Gln Val Arg Arg Met Asp Tyr Tyr Ala
260 265 270

Asn Thr Thr Glu Leu Tyr Asn Met Phe Asp Ile Phe Val Leu Pro Ser
275 280 285

Thr Asn Pro Asp Pro Leu Pro Thr Val Val Leu Lys Ala Met Ala Cys
290 295 300

Gly Lys Pro Val Val Gly Tyr Arg His Gly Gly Val Cys Glu Met Val
305 310 315 320

Lys Glu Gly Val Asn Gly Phe Leu Val Thr Pro Asn Ser Pro Leu Asn
325 330 335

Leu Ser Lys Val Ile Leu Gln Leu Ser Glu Asn Ile Asn Leu Arg Lys
340 345 350

Lys Ile Gly Asn Asn Ser Ile Glu Arg Gln Lys Glu His Phe Ser Leu
355 360 365

Lys Ser Tyr Val Lys Asn Phe Ser Lys Val Tyr Thr Ser Leu Lys Val
370 375 380

Tyr

Lys Ile His Tyr Val Asn Trp Gln Trp Phe Val Met Thr Lys Lys Asp
115 120 125

Asp Ile Asn Asp Ser Phe Ile Pro Arg Arg Met Gln Tyr Cys Phe Glu
130 135 140

Lys Pro Val Trp His His Ser Asp Gly Lys Pro Val Thr Lys Cys Ile
145 150 155 160

Ile Ser Ala Lys Tyr Tyr Lys Lys Met Asn Leu Lys Leu Ser Met Gly
165 170 175

His His Thr Val Phe Gly Asn Pro Asn Val Arg Ile Glu His His Asn
180 185 190

Asp Leu Lys Phe Ala His Tyr Arg Ala Ile Ser Gln Glu Gln Leu Ile
195 200 205

Tyr Lys Thr Ile Cys Tyr Thr Ile Arg Asp Ile Ala Thr Met Glu Asn
210 215 220

Asn Ile Glu Thr Ala Gln Arg Thr Asn Gln Met Ala Leu Ile Glu Ser
225 230 235 240

Gly Val Asp Met Trp Glu Thr Ala Arg Glu Ala Ser Tyr Ser Gly Tyr
245 250 255

Asp Cys Asn Val Ile His Ala Pro Ile Asp Leu Ser Phe Cys Lys Glu
260 265 270

Asn Ile Val Ile Lys Tyr Asn Glu Leu Ser Arg Glu Thr Val Ala Glu
275 280 285

Arg Val Met Lys Thr Gly Arg Glu Met Ala Val Arg Ala Tyr Asn Val
290 295 300

Glu Arg Lys Gln Lys Glu Lys Lys Phe Leu Lys Pro Ile Ile Phe Val
305 310 315 320

Leu Asp Gly Leu Lys Gly Asp Glu Tyr Ile His Pro Asn Pro Ser Asn
325 330 335

His Leu Thr Ile Leu Thr Glu Met Tyr Asn Val Arg Gly Leu Leu Thr
340 345 350

Asp Asn His Gln Ile Lys Phe Leu Lys Val Asn Tyr Arg Leu Ile Ile

355 360 365
 Thr Pro Asp Phe Ala Lys Phe Leu Pro His Glu Phe Ile Val Val Pro
 370 375 380
 Asp Thr Leu Asp Ile Glu Gln Val Lys Ser Gln Tyr Val Gly Thr Gly
 385 390 395 400
 Val Asp Leu Ser Lys Ile Ile Ser Leu Lys Glu Tyr Arg Lys Glu Ile
 405 410 415
 Gly Phe Ile Gly Asn Leu Tyr Ala Leu Leu Gly Phe Val Pro Asn Met
 420 425 430
 Leu Asn Arg Ile Tyr Leu Tyr Ile Gln Arg Asn Gly Ile Ala Asn Thr
 435 440 445
 Ile Ile Lys Ile Lys Ser Arg Leu
 450 455
 <210> 20
 <211> 410
 <212> PRT
 <213> Streptococcus suis
 <220>
 <221> misc_feature
 <223> CPS2I
 <400> 20
 Met Gln Ala Asp Arg Arg Lys Thr Phe Gly Lys Met Arg Ile Arg Ile
 1 5 10 15
 Asn Asn Leu Phe Phe Val Ala Ile Ala Phe Met Gly Ile Ile Ile Ser

20 25 30
 Asn Ser Gln Val Val Leu Ala Ile Gly Lys Ala Ser Val Ile Gln Tyr
 35 40 45
 Leu Ser Tyr Leu Val Leu Ile Leu Cys Ile Val Asn Asp Leu Leu Lys
 50 55 60
 Asn Asn Lys His Ile Val Val Tyr Lys Leu Gly Tyr Leu Phe Leu Ile
 65 70 75 80
 Ile Phe Leu Phe Thr Ile Gly Ile Cys Gln Gln Ile Leu Pro Ile Thr
 85 90 95
 Thr Lys Ile Tyr Leu Ser Ile Ser Met Met Ile Ile Ser Val Leu Ala
 100 105 110
 Thr Leu Pro Ile Ser Leu Ile Lys Asp Ile Asp Asp Phe Arg Arg Ile
 115 120 125
 Ser Asn His Leu Leu Phe Ala Leu Phe Ile Thr Ser Ile Leu Gly Ile
 130 135 140
 Lys Met Gly Ala Thr Met Phe Thr Gly Ala Val Glu Gly Ile Gly Phe
 145 150 155 160
 Ser Gln Gly Phe Asn Gly Gly Leu Thr His Lys Asn Phe Phe Gly Ile
 165 170 175
 Thr Ile Leu Met Gly Phe Val Leu Thr Tyr Leu Ala Tyr Lys Tyr Gly
 180 185 190
 Ser Tyr Lys Arg Thr Asp Arg Phe Ile Leu Gly Leu Glu Leu Phe Leu
 195 200 205
 Ile Leu Ile Ser Asn Thr Arg Ser Val Tyr Leu Ile Leu Leu Leu Phe
 210 215 220
 Leu Phe Leu Val Asn Leu Asp Lys Ile Lys Ile Glu Gln Arg Gln Trp
 225 230 235 240
 Ser Thr Leu Lys Tyr Ile Ser Met Leu Phe Cys Ala Ile Phe Leu Tyr
 245 250 255

Tyr Phe Phe Gly Phe Leu Ile Thr His Ser Asp Ser Tyr Ala His Arg
 260 265 270

Val Asn Gly Leu Ile Asn Phe Phe Glu Tyr Tyr Arg Asn Asp Trp Phe
 275 280 285

His Leu Met Phe Gly Ala Ala Asp Leu Ala Tyr Gly Asp Leu Thr Leu
 290 295 300

Asp Tyr Ala Ile Arg Val Arg Arg Val Leu Gly Trp Asn Gly Thr Leu
 305 310 315 320

Glu Met Pro Leu Leu Ser Ile Met Leu Lys Asn Gly Phe Ile Gly Leu
 325 330 335

Val Gly Tyr Gly Ile Val Leu Tyr Lys Leu Tyr Arg Asn Val Arg Ile
 340 345 350

Leu Lys Thr Asp Asn Ile Lys Thr Ile Gly Lys Ser Val Phe Ile Ile
 355 360 365

Val Val Leu Ser Ala Thr Val Glu Asn Tyr Ile Val Asn Leu Ser Phe
 370 375 380

Val Phe Met Pro Ile Cys Phe Cys Leu Leu Asn Ser Ile Ser Thr Met
 385 390 395 400

Glu Ser Thr Ile Asn Lys Gln Leu Gln Thr
 405 410

<210> 21

<211> 332

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<400> 21

Leu Arg Glu Cys Leu Asp Ser Ile Ile Ser Gln Ser Tyr Thr Asn Leu
20 25 30

Glu Ile Leu Leu Ile Asp Asp Gly Ser Ser Asp Ser Ser Thr Asp Ile
35 40 45

Cys Leu Glu Tyr Ala Glu Gln Asp Gly Arg Ile Lys Leu Phe Arg Leu
50 55 60

Pro Asn Gly Gly Val Ser Asn Ala Arg Asn Tyr Gly Ile Lys Asn Ser
65 70 75 80

Thr Ala Asn Tyr Ile Met Phe Val Asp Ser Asp Asp Ile Val Asp Gly
85 90 95

Asn Ile Val Glu Ser Leu Tyr Thr Cys Leu Lys Glu Asn Asp Ser Asp
100 105 110

Leu Ser Gly Gly Leu Leu Ala Thr Phe Asp Gly Asn Tyr Gln Glu Ser
115 120 125

Glu Leu Gln Lys Cys Gln Ile Asp Leu Glu Glu Ile Lys Glu Val Arg
130 135 140

Asp Leu Gly Asn Glu Asn Phe Pro Asn His Tyr Met Ser Gly Ile Phe
145 150 155 160

Asn Ser Pro Cys Cys Lys Leu Tyr Lys Asn Ile Tyr Ile Asn Gln Gly
165 170 175

Phe Asp Thr Glu Gln Trp Leu Gly Glu Asp Leu Leu Phe Asn Leu Asn
180 185 190

Tyr Leu Lys Asn Ile Lys Lys Val Arg Tyr Val Asn Arg Asn Leu Tyr
195 200 205

Phe Ala Arg Arg Ser Leu Gln Ser Thr Thr Asn Thr Phe Lys Tyr Asp
 210 215 220

Val Phe Ile Gln Leu Glu Asn Leu Glu Glu Lys Thr Phe Asp Leu Phe
 225 230 235 240

Val Lys Ile Phe Gly Gly Gln Tyr Glu Phe Ser Val Phe Lys Glu Thr
 245 250 255

Leu Gln Trp His Ile Ile Tyr Tyr Ser Leu Leu Met Phe Lys Asn Gly
 260 265 270

Asp Glu Ser Leu Pro Lys Lys Leu His Ile Phe Lys Tyr Leu Tyr Asn
 275 280 285

Arg His Ser Leu Asp Thr Leu Ser Ile Lys Arg Thr Ser Ser Val Phe
 290 295 300

Lys Arg Ile Cys Lys Leu Ile Val Ala Asn Asn Leu Phe Lys Ile Phe
 305 310 315 320

Leu Asn Thr Leu Ile Arg Glu Glu Lys Asn Asn Asp
 325 330

<210> 22

<211> 332

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2K

<400> 22

Met Ile Asn Ile Ser Ile Ile Val Pro Ile Tyr Asn Val Glu Gln Tyr
1 5 10 15

Leu Ser Lys Cys Ile Asn Ser Ile Val Asn Gln Thr Tyr Lys His Ile
20 25 30

Glu Ile Leu Leu Val Asn Asp Gly Ser Thr Asp Asn Ser Glu Glu Ile
35 40 45

Cys Leu Ala Tyr Ala Lys Lys Asp Ser Arg Ile Arg Tyr Phe Lys Lys
50 55 60

Glu Asn Gly Gly Leu Ser Asp Ala Arg Asn Tyr Gly Ile Ser Arg Ala
65 70 75 80

Lys Gly Asp Tyr Leu Ala Phe Ile Asp Ser Asp Asp Phe Ile His Ser
85 90 95

Glu Phe Ile Gln Arg Leu His Glu Ala Ile Glu Arg Glu Asn Ala Leu
100 105 110

Val Ala Val Ala Gly Tyr Asp Arg Val Asp Ala Ser Gly His Phe Leu
115 120 125

Thr Ala Glu Pro Leu Pro Thr Asn Gln Ala Val Leu Ser Gly Arg Asn
130 135 140

Val Cys Lys Lys Leu Leu Glu Ala Asp Gly His Arg Phe Val Val Ala
145 150 155 160

Trp Asn Lys Leu Tyr Lys Lys Glu Leu Phe Asp Phe Arg Phe Glu Lys
165 170 175

Gly Lys Ile His Glu Asp Glu Tyr Phe Thr Tyr Arg Leu Leu Tyr Glu
180 185 190

Leu Glu Lys Val Ala Ile Val Lys Glu Cys Leu Tyr Tyr Tyr Val Asp
195 200 205

Arg Glu Asn Ser Ile Ile Thr Ser Ser Met Thr Asp His Arg Phe His
210 215 220

Cys Leu Leu Glu Phe Gln Asn Glu Arg Met Asp Phe Tyr Glu Ser Arg

<210> 23

<211> 467

<212> PRT

<213> Streptococcus suis

 $\langle 220 \rangle$

<221> misc_feature

<223> CPS20

 $\langle 220 \rangle$

<221> misc_feature

<222> (1)..(467)

<223> Xaa may be any amino acid

<400> 23

Met Ser Lys Lys Ser Ile Val Val Ser Gly Leu Val Tyr Thr Ile Gly
1 5 10 15

Thr Ile Leu Val Gln Gly Leu Ala Phe Ile Thr Leu Pro Ile Tyr Thr
20 25 30

Arg Val Ile Ser Gln Glu Val Tyr Gly Gln Phe Ser Leu Tyr Asn Ser
35 40 45

Trp Val Gly Leu Val Gly Leu Phe Ile Gly Leu Gln Leu Gly Gly Ala
50 55 60

Phe Gly Pro Gly Trp Val His Phe Arg Glu Lys Phe Asp Asp Phe Val
65 70 75 80

Ser Thr Leu Met Val Ser Ser Ile Ala Phe Phe Leu Pro Ile Phe Gly
85 90 95

Leu Ser Phe Leu Leu Ser Gln Pro Leu Ser Leu Leu Phe Gly Leu Pro
100 105 110

Asp Trp Val Val Pro Leu Ile Phe Leu Gln Ser Leu Met Ile Val Val
115 120 125

Gln Gly Phe Phe Thr Thr Tyr Leu Val Gln Arg Gln Gln Ser Met Trp
130 135 140

Thr Leu Pro Leu Ser Val Leu Ser Ala Val Ile Asn Thr Ala Leu Ser
145 150 155 160

Leu Phe Leu Thr Phe Pro Met Glu Asn Asp Phe Ile Ala Arg Val Met
165 170 175

Ala Asn Pro Ala Thr Thr Gly Val Leu Ala Cys Val Ser Xaa Trp Phe
180 185 190

Ser Gln Lys Lys Asn Gly Leu His Phe Arg Lys Asp Tyr Leu Arg Tyr

195 200 205

Gly Leu Ser Ile Ser Ile Pro Leu Ile Phe His Gly Leu Gly His Asn
210 215 220

Val Leu Asn Gln Phe Asp Arg Ile Met Leu Gly Lys Met Leu Thr Leu
225 230 235 240

Ser Asp Val Ala Leu Tyr Ser Phe Gly Tyr Thr Leu Ala Ser Ile Leu
245 250 255

Gln Ile Val Phe Ser Ser Leu Asn Thr Val Trp Cys Pro Trp Tyr Phe
260 265 270

Glu Lys Lys Arg Gly Ala Asp Lys Asp Leu Leu Ser Tyr Val Arg Tyr
275 280 285

Tyr Leu Ala Ile Gly Leu Phe Val Thr Phe Gly Phe Leu Thr Ile Tyr
290 295 300

Pro Arg Leu Ala Met Leu Leu Gly Gly Ser Glu Tyr Arg Phe Ser Met
305 310 315 320

Gly Phe Ile Pro Met Ile Ile Val Gly Val Phe Phe Val Phe Leu Tyr
325 330 335

Ser Phe Pro Ala Asn Ile Gln Phe Tyr Ser Gly Asn Thr Lys Phe Leu
340 345 350

Pro Ile Gly Thr Phe Ile Ala Gly Val Leu Asn Ile Ser Val His Phe
355 360 365

Val Leu Ile Pro Thr Lys Asn Leu Trp Cys Cys Phe Ala Thr Thr Ala
370 375 380

Ser Tyr Leu Leu Leu Leu Val Leu His Tyr Phe Val Ala Lys Lys Lys
385 390 395 400

Tyr Ala Tyr Asp Glu Val Ala Ile Ser Thr Phe Val Lys Val Ile Ala
405 410 415

Leu Val Val Val Tyr Thr Gly Leu Met Thr Val Phe Val Gly Ser Ile
420 425 430

Trp Ile Arg Trp Ser Leu Gly Ile Ala Val Leu Val Val Tyr Ala Ile
 435 440 445

Tyr Phe Arg Lys Glu Leu Thr Val Ala Leu Asn Thr Phe Arg Glu Lys
 450 455 460

Arg Ser Lys
 465

<210> 24

<211> 338

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2P

<400> 24

Met Val Tyr Ile Ile Ala Glu Ile Gly Cys Asn His Asn Gly Asp Val
 1 5 10 15

His Leu Ala Arg Lys Met Val Glu Val Ala Val Asp Cys Gly Val Asp
 20 25 30

Ala Val Lys Phe Gln Thr Glu Lys Ala Asp Leu Leu Ile Ser Lys Tyr
 35 40 45

Ala Pro Lys Ala Glu Tyr Gln Lys Ile Thr Thr Gly Glu Ser Asp Ser
 50 55 60

Gln Leu Glu Met Thr Arg Arg Leu Glu Leu Ser Phe Glu Glu Tyr Leu
 65 70 75 80

Asp Leu Arg Asp Tyr Cys Leu Glu Lys Gly Val Asp Val Phe Ser Thr
 85 90 95

Pro Glu Asp Glu Glu Ser Leu Asp Phe Leu Ile Ser Thr Asp Met Pro
100 105 110

Val Tyr Lys Ile Pro Ser Gly Glu Ile Thr Asn Leu Pro Tyr Leu Glu
115 120 125

Lys Ile Gly Arg Gln Ala Lys Lys Val Ile Leu Ser Thr Gly Met Ala
130 135 140

Val Met Asp Glu Ile His Gln Ala Val Lys Ile Leu Gln Glu Asn Gly
145 150 155 160

Thr Thr Asp Ile Ser Ile Leu His Cys Thr Thr Glu Tyr Pro Thr Pro
165 170 175

Tyr Pro Ala Leu Asn Leu Asn Val Leu His Thr Leu Lys Lys Glu Phe
180 185 190

Pro Asn Leu Thr Ile Gly Tyr Ser Asp His Ser Val Gly Ser Glu Val
195 200 205

Pro Ile Ala Ala Ala Ala Met Gly Ala Glu Leu Ile Glu Lys His Phe
210 215 220

Thr Leu Asp Asn Glu Met Glu Gly Pro Asp His Lys Ala Ser Ala Thr
225 230 235 240

Pro Asp Ile Leu Ala Ala Leu Val Lys Gly Val Arg Ile Val Glu Gln
245 250 255

Ser Leu Gly Lys Phe Glu Lys Glu Pro Glu Glu Val Glu Val Arg Asn
260 265 270

Lys Ile Val Ala Glu Lys Ser Ile Val Ala Lys Lys Ala Ile Ala Lys
275 280 285

Gly Glu Val Phe Thr Glu Glu Asn Ile Thr Val Lys Arg Pro Gly Asn
290 295 300

Gly Ile Ser Pro Met Glu Trp Tyr Lys Val Leu Gly Gln Val Ser Glu
305 310 315 320

Gln Asp Phe Glu Glu Asp Gln Asn Ile Cys His Ser Ala Phe Glu Asn

325 330 335

Gln Met

<210> 25

<211> 170

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2Q

<400> 25

Met Lys Lys Ile Cys Phe Val Thr Gly Ser Arg Ala Glu Tyr Gly Ile
1 5 10 15

Met Arg Arg Leu Leu Ser Tyr Leu Gln Asp Asp Pro Glu Met Glu Leu
20 25 30

Asp Leu Val Val Ala Thr Met His Leu Glu Glu Lys Tyr Gly Met Thr
35 40 45

Val Lys Asp Ile Glu Ala Asp Lys Arg Arg Ile Val Lys Arg Ile Pro
50 55 60

Leu His Leu Thr Asp Thr Ser Lys Gln Thr Ile Val Lys Ser Leu Ala
65 70 75 80

Thr Leu Thr Glu Gln Leu Thr Val Leu Phe Glu Glu Val Gln Tyr Asp
85 90 95

Leu Val Leu Ile Leu Gly Asp Arg Tyr Glu Met Leu Pro Val Ala Asn
100 105 110

Ala Ala Leu Leu Tyr Asn Ile Pro Ile Cys His Ile His Gly Gly Glu

115 120 125
 Lys Thr Met Gly Asn Phe Asp Glu Ser Ile Arg His Ala Ile Thr Lys
 130 135 140

Met Ser His Leu His Leu Thr Ser Thr Asp Glu Phe Arg Asn Arg Val
 145 150 155 160

Ile Gln Leu Gly Glu Asn Pro Thr Met Tyr
 165 170

<210> 26

<211> 184

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2R

<400> 26

Met Glu Leu Gly Ile Asp Phe Ala Glu Asp Tyr Tyr Val Val Leu Phe
 1 5 10 15

His Pro Val Thr Leu Glu Asp Asn Thr Ala Glu Glu Gln Thr Gln Ala
 20 25 30

Leu Leu Asp Ala Leu Lys Glu Asp Gly Ser Gln Cys Leu Ile Ile Gly
 35 40 45

Ser Asn Ser Asp Thr His Ala Asp Lys Ile Met Glu Leu Met His Glu
 50 55 60

Phe Val Lys Gln Asp Ser Asp Ser Tyr Ile Phe Thr Ser Leu Pro Thr
 65 70 75 80

Arg Tyr Tyr His Ser Leu Val Lys His Ser Gln Gly Leu Ile Gly Asn

85 90 95
 Ser Ser Ser Gly Leu Ile Glu Val Pro Ser Leu Gln Val Pro Thr Leu
 100 105 110
 Asn Ile Gly Asn Arg Gln Phe Gly Arg Leu Ser Gly Pro Ser Val Val
 115 120 125
 His Val Gly Thr Ser Lys Glu Ala Ile Val Gly Gly Leu Gly Gln Leu
 130 135 140
 Arg Asp Val Ile Asp Phe Thr Asn Pro Phe Glu Gln Pro Asp Ser Ala
 145 150 155 160
 Leu Gln Gly Tyr Arg Ala Ile Lys Glu Phe Leu Ser Val Gln Ala Ser
 165 170 175
 Thr Met Lys Glu Phe Tyr Asp Arg
 180
 <210> 27
 <211> 208
 <212> PRT
 <213> Streptococcus suis
 <220>
 <221> misc_feature
 <223> CPS2S
 <400> 27
 Met Lys Lys Val Ala Phe Leu Gly Ala Gly Thr Phe Ser Asp Gly Val
 1 5 10 15
 Leu Pro Trp Leu Asp Arg Thr Arg Tyr Glu Leu Ile Gly Tyr Phe Glu
 20 25 30
 Asp Lys Pro Ile Ser Asp Tyr Arg Gly Tyr Pro Val Phe Gly Pro Leu
 35 40 45

Gln Asp Val Leu Thr Tyr Leu Asp Asp Gly Lys Val Asp Ala Val Phe
50 55 60

Val Thr Ile Gly Asp Asn Val Lys Arg Lys Glu Ile Phe Asp Leu Leu
65 70 75 80

Ala Lys Asp His Tyr Asp Ala Leu Phe Asn Ile Ile Ser Glu Gln Ala
85 90 95

Asn Ile Phe Ser Pro Asp Ser Ile Lys Gly Arg Gly Val Phe Ile Gly
100 105 110

Phe Ser Ser Phe Val Gly Ala Asp Ser Tyr Val Tyr Asp Asn Cys Ile
115 120 125

Ile Asn Thr Gly Ala Ile Val Glu His His Thr Thr Val Glu Ala His
130 135 140

Cys Asn Ile Thr Pro Gly Val Thr Ile Asn Gly Leu Cys Arg Ile Gly
145 150 155 160

Glu Ser Thr Tyr Ile Gly Ser Gly Ser Thr Val Ile Gln Cys Ile Glu
165 170 175

Ile Ala Pro Tyr Thr Thr Leu Gly Ala Gly Thr Val Val Leu Lys Ser
180 185 190

Leu Thr Glu Ser Gly Thr Tyr Val Gly Val Pro Ala Arg Lys Ile Lys
195 200 205

<210> 28

<211> 410

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2T

Met Glu Pro Ile Cys Leu Ile Pro Ala Arg Ser Gly Ser Lys Gly Leu
1 5 10 15

Thr Ile Arg Ala Ala Ile Glu Ser Gly Cys Phe Lys Lys Glu Asn Ile
35 40 45

Gly Val Gln Val Leu Met Arg Pro Ala Asp Leu Ala Thr Asp Phe Thr
65 70 75 80

Gln Val Phe Val Leu Leu Gln Val Thr Ser Pro Leu Arg Ser Gly Lys
100 105 110

Val Val Ser Phe Thr Lys Val Asp Lys Ser Pro Thr Leu Phe Ser Thr
130 135 140

Leu Asp Glu Asn Gly Phe Ala Lys Asp Ile Ala Gly Leu Gly Gly Ser
145 150 155 160

Tyr Arg Arg Gln Asp Glu Lys Thr Leu Tyr Tyr Pro Asn Gly Ala Ile
165 170 175

Tyr Ile Ser Ser Lys Gln Ala Tyr Leu Ala Asp Lys Thr Tyr Phe Ser
180 185 190

Glu Lys Thr Ala Ala Tyr Val Met Thr Lys Glu Asp Ser Ile Asp Val
195 200 205

Asp Asp His Phe Asp Phe Thr Gly Val Ile Gly Arg Ile Tyr Phe Asp
210 215 220

Tyr Gln Arg Arg Glu Gln Gln Asn Lys Pro Phe Tyr Lys Arg Glu Leu
225 230 235 240

Lys Arg Leu Cys Glu Gln Arg Val His Asp Ser Leu Val Ile Gly Asp
 245 250 255

Ser Arg Leu Leu Ala Leu Leu Leu Asp Gly Phe Asp Asn Ile Ser Ile
 260 265 270

Gly Gly Met Thr Ala Ser Thr Ser Leu Glu Asn Gln Gly Leu Phe Leu
 275 280 285

Ala Thr Pro Ile Lys Lys Val Leu Leu Ser Leu Gly Val Asn Asp Leu
 290 295 300

Ile Thr Asp Tyr Pro Leu His Met Ile Glu Asp Thr Ile Arg Gln Leu
305 310 315 320

Met Glu Ser Leu Val Ser Lys Ala Glu Gln Val Glu Val Thr Thr Ile
 325 330 335

Ala Tyr Thr Leu Phe Arg Asp Ser Val Ser Asn Glu Glu Thr Val Gln
 340 345 350

Leu Asn Asp Val Ile Val Gln Ser Ala Ser Glu Leu Gly Ile Ser Val
 355 360 365

Ile Asp Leu Asn Glu Val Val Glu Lys Glu Ala Met Leu Asp Tyr Gln
 370 375 380

Tyr Thr Asn Asp Gly Leu His Phe Asn Gln Ile Gly Gln Glu Arg Val
385 390 395 400

Asn Gln Leu Ile Leu Thr Ser Leu Thr Arg
 405 410

<210> 29

<211> 6992

<212> DNA

<213> Streptococcus suis

<221> misc_feature

<400> 29

caagtcatat accaaatgct gatttaaadc gttctggaat tttatcata atgatggtc 120

tagagtttga aaaaacattt aactatagta taatatttgc aatttttctt acggcagtat 240

taaacttcgt ttggtatac ctatttaacg taattattaa gcagttaag gatagcttc 360

atatgcaagt tttatttgaa tcacataaac aaattcaaaa aaatcttggt gcattggtag 480

aagctataga gttttcaaca aggggaagtgg tcgaccacgt ctttataaat ctaccaagtg 600

ttgatattaa ttcattcggt ttactgcgt tgaaaaacaa aaaaatccaa ctgctaggtg 720

gacttttggga tataactcgga gcggtagtcg ggtaattat ttgtggtata gtttctattt 840

gacagaatgg acgcatattt acattctaca agtttcgatc gatgtatgtt gatgctgagg 960

gaaaaacgat cctagaatta ctccaattgg acatttcata cgcaaaaaca agtttagac 1080

gaaaaacgat cctagaatta ctccaattgg acatttcata cgcaaaaaca agtttagac 1080

agttaccaca gttttataat gttttaattg gcgatatgag tctagttggt acacgtccac 1140
 ctacagttga tgaatttgaa aaatatactc ctggtcaaaa gagacgattg agttttaaac 1200
 cagggattac aggtctctgg caggttagtg gtcgtagtaa taccacagac ttcgacgacg 1260
 tagttcggtt ggacttagca tacattgata attggactat ctggtcagat attaaaattt 1320
 tattaaagac agtgaaagtt gtattgttga gagagggaag taagtaaaag tatatgaaag 1380
 tttgtttggt cggttcttca gggggacatt tgactcactt gtatttgta aaaccgtttt 1440
 ggaaggaaga agaacgtttt tgggtaacat ttgataaaga ggatgcaaga agtcttttga 1500
 agaatgaaaa aatgtaacca tgttactttc caacaaatcg caatctcatt aatttagtga 1560
 aaaatacttt cttagctttc aaaattttac gtgatgagaa accagatgtt attatttcat 1620
 ctggtgcggc cgttgctgtc cccttctttt acatcggaag actatttgga gcaaagacga 1680
 tttatattga agtatttgat cgagttaata aatctacatt aactggaaaa ctagtttatt 1740
 ccgtaacaga tatttttatt gttcagtggg aagaaatgaa gaaggatat cctaaatcta 1800
 ttaactggg gagtattttt taatgatttt tgaacagta ggaactcatg aacaacagtt 1860
 taatcgattg ataaaagaga ttgatttatt gaaaaaaaaat ggaagtataa ccgacgaaat 1920
 atttattcaa acaggatatt ctgactatat tccagaatat tgcaagtata aaaaatttct 1980
 cagttacaaa gaaatggaac aatatattaa caaatcagaa gtagttattt gccacggagg 2040
 ccccgctact tttatgaatt cattatccaa aggaaaaaaaa caattattgt ttcttagaca 2100
 aaaaaagtat ggtgaacatg taaatgatca tcaagtagag tttgtaagaa gaattttaca 2160
 agataataat attttattta tagaaaatat agatgatttg tttgaaaaaa ttattgaagt 2220
 ttctaagcaa actaacttta catcaataa taattttttt tgtgaaagat taaacaaat 2280
 agttgaaaaa ttaatgagg atcaagaaaa tgaataataa aaaagatgca tatttgataa 2340
 tggcttatca taatttttct cagattttac tggagaggga tacagatatt atcatcttct 2400

ctcaggagaa tgcacaccat tagttccctc agaataacctg tataattatt ttaaatttc 2460
 tcaggattta tatgttgaat ttacaaaaga tgagcaaaaa tataaagaaa ataggatata 2520
 tgaacgagtt aaatgttaca gattatttcc taatatatca gaaaaaacta ttgataatgt 2580
 actgtttaga atttattaa gaatgtatcg agcttttgaa tactatttac aaagattgtt 2640
 gtttattgat agaataaaaa acatggtcta agaataagat ttggttctaa ttgggtttcg 2700
 ctccacatg atttgtggc aattcttta tcaaatgaaa acgaaacagc ttattattt 2760
 aagtaatcta aatgtccaga tgaactattt atacagacaa ttatagaaaa atatgaattt 2820
 tcaaatagat tatctaaata tggaaattta agatatataa agtggaaaaa atcaacatct 2880
 tctctattg tctttacaga tgattctatt gatgaattgc taaatgcaag aaatttaggt 2940
 tttttattg ctgaaagtt aaaaatagaa aataaatcta aatttaaaga aattattact 3000
 aaaaaataaa atagttgatt ttgtgagagt aatgtatgtt taaattattt aaatagacc 3060
 cggaatattt ttttttaag tacttctggt tgattattt tattccagag caaaagtatg 3120
 tatttttatt aattttatg aatttaattt tatttcatat aaaattttg aaaactaagc 3180
 taatattaaa aaatgaaatt ttattgttt tattatggct tatattatgt ttgtttcag 3240
 tagtcacaag tatgtttgtt gaaataaatt ttgaaagatt attgcagat ttactgctc 3300
 ccataattg gattattgca ataattgatt ataattgta ttcatttata aatattgatt 3360
 ataaaaaatt aaaaaatagt atcttttta gtttttagt tttattaggt atatctgcat 3420
 tgtatattat tcaaatggg aaagatattg tatttttaga cagacacctt ataggactag 3480
 actatcttat aacaggcgctc aaaacaaggt tgggtggctt tatgaactat cctacgttaa 3540
 ataccactac aattatagtt tcaattccgt taactttgc actataaaa aataaaatgc 3600
 aacaatttt tttctgtgt ctgctttta taccgatcta ttaagtga tcgagaattg 3660
 gtagtttacc gctagcaata ttaattatat gcttggtatg gagatatata ggtggaaaat 3720

ttgcttgat aaaaaagcta atagtaatat ttgtaatact acttattatt ttaaatactg 3780
 aattgcttta ccatgaaatt ttggctgttt ataattctag agaatcaagt aacgaagcta 3840
 gatttattat ttatcaagga agtattgata aagtattaga aaacaatatt ttatttgat 3900
 atggaatgc cgaatattca gttacgggaa ctgggctcgg aagtcattca ggctatatat 3960
 catttttta taaatcagga atagttgggt tgattttact gatgtttct ttttttatg 4020
 ttataaaaa aagttatgga gtaaatgggg aaacagcact attttattt acatcattag 4080
 ccatatttt catatatgaa acaatagatc cgattattat tatattagta ctattcttt 4140
 ctcaatagg tatttggaat aatataaatt ttaaaaagga tatggagaca aaaaatgaat 4200
 gattaattt cagttattgt accaatttat aatgtccaag attatctga taaatgtatt 4260
 aacagtatta ttaaccaaac atatacta atagaggta ttctcgtaa tgatggaagt 4320
 actgatgatt ctgagaaaat ttgcttaa ac tatatgaaga acgatggaag aattaaatat 4380
 tacaagaaaa ttaatggcgg tctagcagat gctcgaaatt tcggactaga acatgcaaca 4440
 ggtaaatata ttgcttttgc cgattctgat gactatatag aagttgcaat gttcgagaga 4500
 atgcatgata atataactga gtataatgcc gatatagcag agatagattt ttgttagta 4560
 gacgaaaacg ggtatacaaa gaaaaaaga aatagtaatt ttcattgctt aacgagagaa 4620
 gagactgtaa aagaatttt gtcaggatct aatatagaaa ataattgttg gtgcaagctt 4680
 tattcacgag atattataaa agatataaaa ttccaaatta ataatagaag tattggtgag 4740
 gatttgcttt ttaatttgga ggtcttgaac aatgtaacac gtgtagtagt tgatactaga 4800
 gaatattatt ataattatgt cattcgtaac agttcgctta ttaacagaa attctctata 4860
 aataatattg atttagtcac aagattggag aattaccct ttaagttaa aagagagttt 4920
 agtcattatt ttgatgcaa agttattaaa gagaaggta aatgtttaaa caaatgtat 4980
 tcaacagatt gtttgataa tgagttcttg ccaatattag agtcctatcg aaaagaaata 5040

cgtagatc catttattaa agcgaaaaga tatttatcaa gaaagcattt agttacgttg 5100
 tatttgatga aatttcgcc taaactatat gtaatgttat ataagaaatt tcaaaagcag 5160
 tagaggtaaa aatggataaa attagtgtta ttgtccagt ttataatga gataaatatt 5220
 taagtagttg tatagaaagc attattaatc aaaattataa aaatatagaa atattattga 5280
 tagatgatgg ctctgtagat gattctgcta aaatatgcaa ggaatagca gaaaaagata 5340
 aaagagtaaa aattttttc actaatcata gtggagtatc aaatgctaga aatcatggaa 5400
 taaagcggag tacagctgaa tatattatgt ttgttgactc tgatgatgtt gttgatagta 5460
 gattagtaga aaaattatat tttaattata taaaaagtag aagtgattta tctggttgtt 5520
 tgtacgtac ttttcagaa aatataaata atttgaagt gaataatcca aatattgatt 5580
 ttgaagcaat taataccgtg caggacatgg gagaaaaaaa tttatgaat ttgtatataa 5640
 ataattttt ttctactcct gttgtaaac tatataagaa aagatacata acagatcttt 5700
 ttcaagagaa tcaatggta ggagaagatt tactttttaa tctgcattat ttaaagaata 5760
 tagatagagt tagttatttg actgaacatc ttattttta taggagaggt atactaagta 5820
 cagtaaattc ttttaagaa ggtgtgttt tgcaattgga aaatttgcaa aaacaagtga 5880
 tagtattgtt taagcaaata tatggtgagg atttgacgt atcaattgtt aaagatacta 5940
 tacgttgga agtattttat tatagcttac taatgtttaa atacggaaaa cagtctattt 6000
 ttgacaaatt tttaattttt agaaatcttt ataaaaata ttattttaa ttgttaaag 6060
 tatctaaca aaattctttg tctaaaaatt ttgtataag aattgttcg aacaaagttt 6120
 ttaaaaaat attatggta taataggaag atatcatgga tactattagt aaaatttcta 6180
 taattgtacc tatatataat gtagaaaaat atttatctaa atgtatagat agcattgtaa 6240
 atcagacctt caaacatata gagattcttc tggatgaatga cggtagtacg gataattcgg 6300
 aagaaatttg tttagcatat gcgaagaaag atagtcgcat tcgtattttt aaaaagaga 6360

acggcgggct atcagatgcc cgtaattatg gcataagtcg cgccaagggt gactacttag 6420
 cttttataga ctcagatgat ttattcatt cggagttcat ccaacgttta cacgaagcaa 6480
 ttgagagaga gaatgccctt gtggcagttg ctggttatga tagggtagat gcttcggggc 6540
 atttctaac agcagagccg ctctctacaa atcaggctgt tctgagcggc aggaatgttt 6600
 gtaaaaagct gctagaggcg gatggtcatc gctttgtggt ggctgtaat aaactctata 6660
 aaaaagaact attgaagat tttegatttg aaaagggtaa gattcatgaa gatgaatact 6720
 tcacttatcg ctgctctat gagttagaaa aagtgcaat agttaaggag tgcttgact 6780
 attatgttga ccgagaaaat agtatcaciaa ctctagcat gactgacat cgttccatt 6840
 gcctactgga attcaaaaat gaacgaatgg acttctatga aagtagagga gataaagagc 6900
 tcttactaga gtgttatcgt tcatttttag cctttgctgt ttgttttta ggcaaatata 6960
 atcattgggt gagcaaacag caaaagaagc tt 6992

<210> 30

<211> 454

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1E

<400> 30

Arg Gln Thr Lys Leu Ala Leu Phe Asp Met Ile Ala Val Ala Ile Ser
 1 5 10 15

Ala Ile Leu Thr Ser His Ile Pro Asn Ala Asp Leu Asn Arg Ser Gly
20 25 30

Ile Phe Ile Ile Met Met Val His Tyr Phe Ala Phe Phe Ile Ser Arg
35 40 45

Met Pro Val Glu Phe Glu Tyr Arg Gly Asn Leu Ile Glu Phe Glu Lys
50 55 60

Thr Phe Asn Tyr Ser Ile Ile Phe Ala Ile Phe Leu Thr Ala Val Ser
65 70 75 80

Phe Leu Leu Glu Asn Asn Phe Ala Leu Ser Arg Arg Gly Ala Val Tyr
85 90 95

Phe Thr Leu Ile Asn Phe Val Leu Val Tyr Leu Phe Asn Val Ile Ile
100 105 110

Lys Gln Phe Lys Asp Ser Phe Leu Phe Ser Thr Ile Tyr Gln Lys Lys
115 120 125

Thr Ile Leu Ile Thr Thr Ala Glu Arg Trp Glu Asn Met Gln Val Leu
130 135 140

Phe Glu Ser His Lys Gln Ile Gln Lys Asn Leu Val Ala Leu Val Val
145 150 155 160

Leu Gly Thr Glu Ile Asp Lys Ile Asn Leu Ser Leu Pro Leu Tyr Tyr
165 170 175

Ser Val Glu Glu Ala Ile Glu Phe Ser Thr Arg Glu Val Val Asp His
180 185 190

Val Phe Ile Asn Leu Pro Ser Glu Phe Leu Asp Val Lys Gln Phe Val
195 200 205

Ser Asp Phe Glu Leu Leu Gly Ile Asp Val Ser Val Asp Ile Asn Ser
210 215 220

Phe Gly Phe Thr Ala Leu Lys Asn Lys Lys Ile Gln Leu Leu Gly Asp
225 230 235 240

His Ser Ile Val Thr Phe Ser Thr Asn Phe Tyr Lys Pro Ser His Ile

<210> 31

<211> 149

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1F

<400> 31

Met Lys Val Cys Leu Val Gly Ser Ser Gly Gly His Leu Thr His Leu
1 5 10 15

Tyr Leu Leu Lys Pro Phe Trp Lys Glu Glu Glu Arg Phe Trp Val Thr
20 25 30

Phe Asp Lys Glu Asp Ala Arg Ser Leu Leu Lys Asn Glu Lys Met Tyr
35 40 45

Pro Cys Tyr Phe Pro Thr Asn Arg Asn Leu Ile Asn Leu Val Lys Asn
50 55 60

Thr Phe Leu Ala Phe Lys Ile Leu Arg Asp Glu Lys Pro Asp Val Ile
65 70 75 80

Ile Ser Ser Gly Ala Ala Val Ala Val Pro Phe Phe Tyr Ile Gly Lys
85 90 95

Leu Phe Gly Ala Lys Thr Ile Tyr Ile Glu Val Phe Asp Arg Val Asn
100 105 110

Lys Ser Thr Leu Thr Gly Lys Leu Val Tyr Pro Val Thr Asp Ile Phe
115 120 125

Ile Val Gln Trp Glu Glu Met Lys Lys Val Tyr Pro Lys Ser Ile Asn
130 135 140

Leu Gly Ser Ile Phe
145

<210> 32

<211> 164

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1G

<400> 32

Met Ile Phe Val Thr Val Gly Thr His Glu Gln Gln Phe Asn Arg Leu
 1 5 10 15

Ile Lys Glu Ile Asp Leu Leu Lys Lys Asn Gly Ser Ile Thr Asp Glu
 20 25 30

Ile Phe Ile Gln Thr Gly Tyr Ser Asp Tyr Ile Pro Glu Tyr Cys Lys
 35 40 45

Tyr Lys Lys Phe Leu Ser Tyr Lys Glu Met Glu Gln Tyr Ile Asn Lys
 50 55 60

Ser Glu Val Val Ile Cys His Gly Gly Pro Ala Thr Phe Met Asn Ser
 65 70 75 80

Leu Ser Lys Gly Lys Lys Gln Leu Leu Phe Pro Arg Gln Lys Lys Tyr
 85 90 95

Gly Glu His Val Asn Asp His Gln Val Glu Phe Val Arg Arg Ile Leu
 100 105 110

Gln Asp Asn Asn Ile Leu Phe Ile Glu Asn Ile Asp Asp Leu Phe Glu
 115 120 125

Lys Ile Ile Glu Val Ser Lys Gln Thr Asn Phe Thr Ser Asn Asn Asn
 130 135 140

Phe Phe Cys Glu Arg Leu Lys Gln Ile Val Glu Lys Phe Asn Glu Asp
 145 150 155 160

Gln Glu Asn Glu

<210> 33

<211> 388

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1H

<400> 33

Met Phe Lys Leu Phe Lys Tyr Asp Pro Glu Tyr Phe Ile Phe Lys Tyr
 1 5 10 15

Phe Trp Leu Ile Ile Phe Ile Pro Glu Gln Lys Tyr Val Phe Leu Leu
 20 25 30

Ile Phe Met Asn Leu Ile Leu Phe His Ile Lys Phe Leu Lys Thr Lys
 35 40 45

Leu Ile Leu Lys Asn Glu Ile Leu Leu Phe Leu Leu Trp Ser Ile Leu
 50 55 60

Cys Phe Val Ser Val Val Thr Ser Met Phe Val Glu Ile Asn Phe Glu
 65 70 75 80

Arg Leu Phe Ala Asp Phe Thr Ala Pro Ile Ile Trp Ile Ile Ala Ile
 85 90 95

Met Tyr Tyr Asn Leu Tyr Ser Phe Ile Asn Ile Asp Tyr Lys Lys Leu
 100 105 110

09767041.01301

Lys Asn Ser Ile Phe Phe Ser Phe Leu Val Leu Leu Gly Ile Ser Ala
115 120 125

Leu Tyr Ile Ile Gln Asn Gly Lys Asp Ile Val Phe Leu Asp Arg His
130 135 140

Leu Ile Gly Leu Asp Tyr Leu Ile Thr Gly Val Lys Thr Arg Leu Val
145 150 155 160

Gly Phe Met Asn Tyr Pro Thr Leu Asn Thr Thr Thr Ile Ile Val Ser
165 170 175

Ile Pro Leu Ile Phe Ala Leu Ile Lys Asn Lys Met Gln Gln Phe Phe
180 185 190

Phe Leu Cys Leu Ala Phe Ile Pro Ile Tyr Leu Ser Gly Ser Arg Ile
195 200 205

Gly Ser Leu Ser Leu Ala Ile Leu Ile Ile Cys Leu Leu Trp Arg Tyr
210 215 220

Ile Gly Gly Lys Phe Ala Trp Ile Lys Lys Leu Ile Val Ile Phe Val
225 230 235 240

Ile Leu Leu Ile Ile Leu Asn Thr Glu Leu Leu Tyr His Glu Ile Leu
245 250 255

Ala Val Tyr Asn Ser Arg Glu Ser Ser Asn Glu Ala Arg Phe Ile Ile
260 265 270

Tyr Gln Gly Ser Ile Asp Lys Val Leu Glu Asn Asn Ile Leu Phe Gly
275 280 285

Tyr Gly Ile Ser Glu Tyr Ser Val Thr Gly Thr Trp Leu Gly Ser His
290 295 300

Ser Gly Tyr Ile Ser Phe Phe Tyr Lys Ser Gly Ile Val Gly Leu Ile
305 310 315 320

Leu Leu Met Phe Ser Phe Phe Tyr Val Ile Lys Lys Ser Tyr Gly Val
325 330 335

Asn Gly Glu Thr Ala Leu Phe Tyr Phe Thr Ser Leu Ala Ile Phe Phe

340
 Ile Tyr Glu Thr Ile Asp Pro Ile Ile Ile Ile Leu Val Leu Phe Phe
 355 360 365
 Ser Ser Ile Gly Ile Trp Asn Asn Ile Asn Phe Lys Lys Asp Met Glu
 370 375 380
 Thr Lys Asn Glu
 385
 <210> 34
 <211> 322
 <212> PRT
 <213> Streptococcus suis
 <220>
 <221> misc_feature
 <223> CPSII
 <400> 34
 Met Asn Asp Leu Ile Ser Val Ile Val Pro Ile Tyr Asn Val Gln Asp
 1 5 10 15
 Tyr Leu Asp Lys Cys Ile Asn Ser Ile Ile Asn Gln Thr Tyr Thr Asn
 20 25 30
 Leu Glu Val Ile Leu Val Asn Asp Gly Ser Thr Asp Asp Ser Glu Lys
 35 40 45
 Ile Cys Leu Asn Tyr Met Lys Asn Asp Gly Arg Ile Lys Tyr Tyr Lys
 50 55 60
 Lys Ile Asn Gly Gly Leu Ala Asp Ala Arg Asn Phe Gly Leu Glu His
 65 70 75 80
 Ala Thr Gly Lys Tyr Ile Ala Phe Val Asp Ser Asp Asp Tyr Ile Glu

85 90 95

Val Ala Met Phe Glu Arg Met His Asp Asn Ile Thr Glu Tyr Asn Ala
100 105 110

Asp Ile Ala Glu Ile Asp Phe Cys Leu Val Asp Glu Asn Gly Tyr Thr
115 120 125

Lys Lys Lys Arg Asn Ser Asn Phe His Val Leu Thr Arg Glu Glu Thr
130 135 140

Val Lys Glu Phe Leu Ser Gly Ser Asn Ile Glu Asn Asn Val Trp Cys
145 150 155 160

Lys Leu Tyr Ser Arg Asp Ile Ile Lys Asp Ile Lys Phe Gln Ile Asn
165 170 175

Asn Arg Ser Ile Gly Glu Asp Leu Leu Phe Asn Leu Glu Val Leu Asn
180 185 190

Asn Val Thr Arg Val Val Val Asp Thr Arg Glu Tyr Tyr Tyr Asn Tyr
195 200 205

Val Ile Arg Asn Ser Ser Leu Ile Asn Gln Lys Phe Ser Ile Asn Asn
210 215 220

Ile Asp Leu Val Thr Arg Leu Glu Asn Tyr Pro Phe Lys Leu Lys Arg
225 230 235 240

Glu Phe Ser His Tyr Phe Asp Ala Lys Val Ile Lys Glu Lys Val Lys
245 250 255

Cys Leu Asn Lys Met Tyr Ser Thr Asp Cys Leu Asp Asn Glu Phe Leu
260 265 270

Pro Ile Leu Glu Ser Tyr Arg Lys Glu Ile Arg Arg Tyr Pro Phe Ile
275 280 285

Lys Ala Lys Arg Tyr Leu Ser Arg Lys His Leu Val Thr Leu Tyr Leu
290 295 300

Met Lys Phe Ser Pro Lys Leu Tyr Val Met Leu Tyr Lys Lys Phe Gln
305 310 315 320

Lys Gln

<210> 35

<211> 322

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1J

<400> 35

Met Asp Lys Ile Ser Val Ile Val Pro Val Tyr Asn Val Asp Lys Tyr
1 5 10 15

Leu Ser Ser Cys Ile Glu Ser Ile Ile Asn Gln Asn Tyr Lys Asn Ile
20 25 30

Glu Ile Leu Leu Ile Asp Asp Gly Ser Val Asp Asp Ser Ala Lys Ile
35 40 45

Cys Lys Glu Tyr Glu Lys Asp Lys Arg Val Lys Ile Phe Phe Thr Asn
50 55 60

His Ser Gly Val Ser Asn Ala Arg Asn His Gly Ile Lys Arg Ser Thr
65 70 75 80

Ala Glu Tyr Ile Met Phe Val Asp Ser Asp Asp Val Val Asp Ser Arg
85 90 95

Leu Val Glu Lys Leu Tyr Phe Asn Ile Ile Lys Ser Arg Ser Asp Leu
100 105 110

Ser Gly Cys Leu Tyr Ala Thr Phe Ser Glu Asn Ile Asn Asn Phe Glu
115 120 125

Val Asn Asn Pro Asn Ile Asp Phe Glu Ala Ile Asn Thr Val Gln Asp
130 135 140

Met Gly Glu Lys Asn Phe Met Asn Leu Tyr Ile Asn Asn Ile Phe Ser
145 150 155 160

Thr Pro Val Cys Lys Leu Tyr Lys Lys Arg Tyr Ile Thr Asp Leu Phe
165 170 175

Gln Glu Asn Gln Trp Leu Gly Glu Asp Leu Leu Phe Asn Leu His Tyr
180 185 190

Leu Lys Asn Ile Asp Arg Val Ser Tyr Leu Thr Glu His Leu Tyr Phe
195 200 205

Tyr Arg Arg Gly Ile Leu Ser Thr Val Asn Ser Phe Lys Glu Gly Val
210 215 220

Phe Leu Gln Leu Glu Asn Leu Gln Lys Gln Val Ile Val Leu Phe Lys
225 230 235 240

Gln Ile Tyr Gly Glu Asp Phe Asp Val Ser Ile Val Lys Asp Thr Ile
245 250 255

Arg Trp Gln Val Phe Tyr Tyr Ser Leu Leu Met Phe Lys Tyr Gly Lys
260 265 270

Gln Ser Ile Phe Asp Lys Phe Leu Ile Phe Arg Asn Leu Tyr Lys Lys
275 280 285

Tyr Tyr Phe Asn Leu Leu Lys Val Ser Asn Lys Asn Ser Leu Ser Lys
290 295 300

Asn Phe Cys Ile Arg Ile Val Ser Asn Lys Val Phe Lys Lys Ile Leu
305 310 315 320

Trp Leu

<210> 36

<211> 278

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS1K

<400> 36

Met Asp Thr Ile Ser Lys Ile Ser Ile Ile Val Pro Ile Tyr Asn Val
1 5 10 15

Glu Lys Tyr Leu Ser Lys Cys Ile Asp Ser Ile Val Asn Gln Thr Tyr
 20 25 30

Lys His Ile Glu Ile Leu Leu Val Asn Asp Gly Ser Thr Asp Asn Ser
 35 40 45

Glu Glu Ile Cys Leu Ala Tyr Ala Lys Lys Asp Ser Arg Ile Arg Tyr
 50 55 60

Phe Lys Lys Glu Asn Gly Gly Leu Ser Asp Ala Arg Asn Tyr Gly Ile
65 70 75 80

Ser Arg Ala Lys Gly Asp Tyr Leu Ala Phe Ile Asp Ser Asp Asp Phe
 85 90 95

Ile His Ser Glu Phe Ile Gln Arg Leu His Glu Ala Ile Glu Arg Glu
 100 105 110

Asn Ala Leu Val Ala Val Ala Gly Tyr Asp Arg Val Asp Ala Ser Gly
 115 120 125

His Phe Leu Thr Ala Glu Pro Leu Pro Thr Asn Gln Ala Val Leu Ser
 130 135 140

Gly Arg Asn Val Cys Lys Lys Leu Leu Glu Ala Asp Gly His Arg Phe
145 150 155 160

Val Val Ala Cys Asn Lys Leu Tyr Lys Lys Glu Leu Phe Glu Asp Phe

120

165 170 175

Arg Phe Glu Lys Gly Lys Ile His Glu Asp Glu Tyr Phe Thr Tyr Arg
180 185 190

Leu Leu Tyr Glu Leu Glu Lys Val Ala Ile Val Lys Glu Cys Leu Tyr
195 200 205

Tyr Tyr Val Asp Arg Glu Asn Ser Ile Thr Thr Ser Ser Met Thr Asp
210 215 220

His Arg Phe His Cys Leu Leu Glu Phe Gln Asn Glu Arg Met Asp Phe
225 230 235 240

Tyr Glu Ser Arg Gly Asp Lys Glu Leu Leu Leu Glu Cys Tyr Arg Ser
245 250 255

Phe Leu Ala Phe Ala Val Leu Phe Leu Gly Lys Tyr Asn His Trp Leu
260 265 270

Ser Lys Gln Gln Lys Lys
275

<210> 37

<211> 4519

<212> DNA

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS9

<400> 37

aagcttatcg tcaaggtgtt cgctatatcg tggcgacatc tcatagacga aaagggatgt 60

ttgaaacacc agaaaaagtt atcatgacta actttcttca atttaaagac gcagtagcag 120

bioRxiv preprint doi: <https://doi.org/10.1101/014000>; this version posted October 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

aagtttatcc tgaaatacga ttgtgctatg gtgctgaatt gtattatagt aaagatatat 180
 taagcaaact tgaaaaaaag aaagtaccca cacttaatgg ctgcgctat attcttttgg 240
 agttcagtag tgatactcct tggaagaga ttcaagaagc agtgaacgaa gtgacgctac 300
 ttgggctaac tcccgtactt gcccatatag aacgatatga cggcctagcg ttcatgcag 360
 agagagtaga agagttaatt gacaagggat gctatactca ggtaaatagt aatcatgtgc 420
 tgaagcccac ttaattggt gatcgagcaa aagaatttaa aaaacgtact cggatatttt 480
 tagagcagga ttagtacat tgtgttgcta gcgatatgca taatttatct agtagacctc 540
 cgtttatgag ggaggettat aagttgctaa cagaggaatt tggcaaagat aaagcgaaag 600
 cgttgctaaa aaagaatcct cttatgctat taaaaacca ggcgatttaa actggttact 660
 ctagattgtg gagagaaaaa tggatttagg aactgttact gataaactgt tagaacgcaa 720
 cagtaaacga ttgatactcg tgtgcatgga tacgtgtctt cttatagttt ccatgatttt 780
 gagcagactg ttttggatg ttattattga cataccagat gaacgettca ttctgcagt 840
 ttattcgtat tcaattttat atttgattct atcgtttaga ttaaagtct ttcattaat 900
 tacgcgttac acagggtatc agagttagt aaaaatagga cttagttaa tatctgcgca 960
 ttcatgttt ttaattatct caatggtgtt gtggcaggct ttagttatc gttcatctt 1020
 agtatcccta ttttgtcgt atgtaatgct cattactccg aggattgtt ggaaagtctt 1080
 acatgagacg agaaaaaatg ctatccgtaa gaaggatagc ccactaagaa tcttagtagt 1140
 aggtgctgga gatggtggtg atattttat caatactgtc aaagatcgaa aattgaattt 1200
 tgaaattgtc ggtatcgtg atcgtgatcc aaataaactt ggaacattta tccgtacggc 1260
 taaagttta ggaaaccgta atgatattcc acgactggtg gaggaattag ctgttgacca 1320
 agtgacgatt gccatccctt cttaaatgg taaggagcga gagaagattg ttgaaatctg 1380
 taacactaca ggagtgaccg tcaataatat gccgagtatt gaagacatta tggcggggaa 1440

catgtctgtc agtgcctttc aggaaattga cgtagcagac cttcttggtc gaccagaggt 1500
 tgttttggat caggatgaat tgaatcagtt ttccaaggg aaaacaatcc ttgtcacagg 1560
 agcaggtggc tctatcggtt cagagctatg tcgtcaaatt gctaagtta cgcctaaacg 1620
 cttgttgttg cttggacatg gagaaaattc aatctatctc attcatcgag agttactgga 1680
 aaagtaccaa ggtaagattg agttgggtccc tctcattgca gatattcaag atagagaatt 1740
 gatttttagc ataatggctg aatatcaacc cgatgttgtt tatcatgctg cagcacataa 1800
 gcatgttcct ttgatggaat ataatccaca tgaagcagtg aagaataata tttttggaac 1860
 gaagaatgtg gctgaggcgg ctaaaactgc aaaggttgcc aaatttgta tggtttcaac 1920
 agataaagct gtaatccac caaatgtcat gggagcgact aaacgtgttg cagaaatgat 1980
 tgttacaggt ttaacgagc caggtcagac tcaatttgcg gcagtccggt ttgggaatgt 2040
 tctaggtagt cgtggaagtg ttgtccgct attcaaagag caaattagaa aaggtggacc 2100
 tgttacggtt accgacttta ggatgactcg ttatttcattg acgattcctg aggcaagtcg 2160
 ttgtgttatt caagctggac atttgcaaaa aggtggagaa atatttgtct tggatatggg 2220
 cgagccagta caaatcctgg aattggcaag aaaagtattc ttgtaagtg gacacacaga 2280
 ggaagaaatc gggattgtag aatctggaat cagaccaggc gagaaactct acgaggaatt 2340
 attatcaaca gaagaacgtg tcagcgaaca gattcatgaa aaaatattg tgggtcgcgt 2400
 tacaataag cagtcggaca ttgtcaattc atttatcaat ggattactcc aaaaagatag 2460
 aaatgaatta aaaaatatgt tgattgaatt tgcaaaacaa gaataagaaa gtaaaaaata 2520
 ttttacttt cctagagttt aaacgatgtt taagttctag gaaggttaga atacctaatt 2580
 aacaacaata ttactattta ttaagagtca gataatagca actaagtgt acaaactatc 2640
 ttataataa gtatatttgg tcaaaaggga gatgtgaaat gtatccaatt tgtaaacgta 2700
 ttttagcaat tattatctca gggattgcta ttgtgttct gagtccaatt ttattattga 2760

ttgcattggc aattaaatta gattctaaag gtccggtatt atttaaaca aagcgggttg 2820
 gtaaaaaaca gtcatacttt atgatttata aattccgttc tatgtacgtt gacgcaccaa 2880
 gtgatatgcc gactcatcta ttaaaggatc ctaaggcgat gattaccaag gtgggcgcgt 2940
 ttctcagaaa aacaagtta gatgaactgc cacagctttt taatattttt aaaggtgaaa 3000
 tggcgattgt tggccacgc ccagccttat ggaatcaata tgacttaatt gaagagcgag 3060
 ataaatatgg tgcaaatgat attcgtcctg gactaaccgg ttgggtcaa attaatggc 3120
 gtgatgaatt ggaaattgat gaaaagtcaa aattagatgg atattatgtt caaaatatga 3180
 gtctaggttt ggatattaaa tgtttcttag gtacattcct cagtgtagcc agaagcgaag 3240
 gtgttgtga aggtggaaca gggcagaaag gaaaaggatg aaatttcag tattaatgtc 3300
 ggtctatgag aaagaaaaac cagagtttct tagggaatct ttggaaagca tccttgtcaa 3360
 tcaaacaatg attccaacgg aggttgtctt ggtagaggat gggccactca atcagagctt 3420
 atatatgtatt ttagaagaat taaaagtgc attttcattt ttaaaacga tagccttga 3480
 aaagaattcg ggtttaggaa ttgcactgaa tgaaggttg aaacattgta attatgagt 3540
 ggtttgcacg aaatggattc tgatgatgtt gcatatacat acacgttttg aaaagcaagt 3600
 taactttata aaacaaaacc cgactataga tattgagata gatgagttct taaattctac 3660
 tagtgaaata gtttctcata aaaatgttc aaccagcac gatgaaatat taaagatggc 3720
 aaggcgggag aaatccatgt gccacatgac tgtaatgtt aaaaagaaaa gtgtcgagag 3780
 agcagggggg tatcaaacac ttccgtacgt agaagattat ttctttggg tgcgcatgat 3840
 tgcttcagga tcgaaattg caaacattga tgaacacta gttcttgcac gtgttgaaa 3900
 tgggatgttc aataggaggg ggaacagaga acaattaac agttggacat tactaattga 3960
 atttatgtta getcaaggaa ttgttacacc actagatgta tttattaac aaatttacat 4020
 tagggctttt gtttatatgc caacttgat aaagaaactc atttatggaa aaatcttaag 4080

<210> 38

<211> 215

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS9D

<400> 38

Lys Gly Met Phe Glu Thr Pro Glu Lys Val Ile Met Thr Asn Phe Leu
20 25 30

Tyr Gly Ala Glu Leu Tyr Tyr Ser Lys Asp Ile Leu Ser Lys Leu Glu

50 55 60
 Lys Lys Lys Val Pro Thr Leu Asn Gly Ser Arg Tyr Ile Leu Leu Glu
 65 70 75 80
 Phe Ser Ser Asp Thr Pro Trp Lys Glu Ile Gln Glu Ala Val Asn Glu
 85 90 95
 Val Thr Leu Leu Gly Leu Thr Pro Val Leu Ala His Ile Glu Arg Tyr
 100 105 110
 Asp Ala Leu Ala Phe His Ala Glu Arg Val Glu Glu Leu Ile Asp Lys
 115 120 125
 Gly Cys Tyr Thr Gln Val Asn Ser Asn His Val Leu Lys Pro Thr Leu
 130 135 140
 Ile Gly Asp Arg Ala Lys Glu Phe Lys Lys Arg Thr Arg Tyr Phe Leu
 145 150 155 160
 Glu Gln Asp Leu Val His Cys Val Ala Ser Asp Met His Asn Leu Ser
 165 170 175
 Ser Arg Pro Pro Phe Met Arg Glu Ala Tyr Lys Leu Leu Thr Glu Glu
 180 185 190
 Phe Gly Lys Asp Lys Ala Lys Ala Leu Leu Lys Lys Asn Pro Leu Met
 195 200 205
 Leu Leu Lys Asn Gln Ala Ile
 210 215

<210> 39

<211> 608

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<400> 39

Arg Leu Ile Leu Val Cys Met Asp Thr Cys Leu Leu Ile Val Ser Met
20 25 30

Arg Phe Ile Leu Ala Val Leu Phe Val Ser Ile Leu Tyr Leu Ile Leu
50 55 60

Gln Ser Tyr Val Lys Ile Gly Leu Ser Leu Ile Ser Ala His Ser Leu
85 90 95

Ile Leu Val Ser Leu Phe Leu Ser Tyr Val Met Leu Ile Thr Pro Arg
115 120 125

Lys Asp Ser Pro Leu Arg Ile Leu Val Val Gly Ala Gly Asp Gly Gly
145 150 155 160

Asn Ile Phe Ile Asn Thr Val Lys Asp Arg Lys Leu Asn Phe Glu Ile
165 170 175

Val Gly Ile Val Asp Arg Asp Pro Asn Lys Leu Gly Thr Phe Ile Arg
180 185 190

Thr Ala Lys Val Leu Gly Asn Arg Asn Asp Ile Pro Arg Leu Val Glu
195 200 205

Glu Leu Ala Val Asp Gln Val Thr Ile Ala Ile Pro Ser Leu Asn Gly
210 215 220

Lys Glu Arg Glu Lys Ile Val Glu Ile Cys Asn Thr Thr Gly Val Thr
225 230 235 240

Val Asn Asn Met Pro Ser Ile Glu Asp Ile Met Ala Gly Asn Met Ser
245 250 255

Val Ser Ala Phe Gln Glu Ile Asp Val Ala Asp Leu Leu Gly Arg Pro
260 265 270

Glu Val Val Leu Asp Gln Asp Glu Leu Asn Gln Phe Phe Gln Gly Lys
275 280 285

Thr Ile Leu Val Thr Gly Ala Gly Gly Ser Ile Gly Ser Glu Leu Cys
290 295 300

Arg Gln Ile Ala Lys Phe Thr Pro Lys Arg Leu Leu Leu Leu Gly His
305 310 315 320

Gly Glu Asn Ser Ile Tyr Leu Ile His Arg Glu Leu Leu Glu Lys Tyr
325 330 335

Gln Gly Lys Ile Glu Leu Val Pro Leu Ile Ala Asp Ile Gln Asp Arg
340 345 350

Glu Leu Ile Phe Ser Ile Met Ala Glu Tyr Gln Pro Asp Val Val Tyr
355 360 365

His Ala Ala Ala His Lys His Val Pro Leu Met Glu Tyr Asn Pro His
370 375 380

Glu Ala Val Lys Asn Asn Ile Phe Gly Thr Lys Asn Val Ala Glu Ala
385 390 395 400

Ala Lys Thr Ala Lys Val Ala Lys Phe Val Met Val Ser Thr Asp Lys
405 410 415

Ala Val Asn Pro Pro Asn Val Met Gly Ala Thr Lys Arg Val Ala Glu
420 425 430

Met Ile Val Thr Gly Leu Asn Glu Pro Gly Gln Thr Gln Phe Ala Ala

435 440 445
 Val Arg Phe Gly Asn Val Leu Gly Ser Arg Gly Ser Val Val Pro Leu
 450 455 460
 Phe Lys Glu Gln Ile Arg Lys Gly Gly Pro Val Thr Val Thr Asp Phe
 465 470 475 480
 Arg Met Thr Arg Tyr Phe Met Thr Ile Pro Glu Ala Ser Arg Leu Val
 485 490 495
 Ile Gln Ala Gly His Leu Ala Lys Gly Gly Glu Ile Phe Val Leu Asp
 500 505 510
 Met Gly Glu Pro Val Gln Ile Leu Glu Leu Ala Arg Lys Val Ile Leu
 515 520 525
 Leu Ser Gly His Thr Glu Glu Glu Ile Gly Ile Val Glu Ser Gly Ile
 530 535 540
 Arg Pro Gly Glu Lys Leu Tyr Glu Glu Leu Leu Ser Thr Glu Glu Arg
 545 550 555 560
 Val Ser Glu Gln Ile His Glu Lys Ile Phe Val Gly Arg Val Thr Asn
 565 570 575
 Lys Gln Ser Asp Ile Val Asn Ser Phe Ile Asn Gly Leu Leu Gln Lys
 580 585 590
 Asp Arg Asn Glu Leu Lys Asn Met Leu Ile Glu Phe Ala Lys Gln Glu
 595 600 605

<210> 40

<211> 200

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS9F

<400> 40

Met Tyr Pro Ile Cys Lys Arg Ile Leu Ala Ile Ile Ile Ser Gly Ile

1 5 10 15

Ala Ile Val Val Leu Ser Pro Ile Leu Leu Leu Ile Ala Leu Ala Ile

20 25 30

Lys Leu Asp Ser Lys Gly Pro Val Leu Phe Lys Gln Lys Arg Val Gly

35 40 45

Lys Asn Lys Ser Tyr Phe Met Ile Tyr Lys Phe Arg Ser Met Tyr Val

50 55 60

Asp Ala Pro Ser Asp Met Pro Thr His Leu Leu Lys Asp Pro Lys Ala

65 70 75 80

Met Ile Thr Lys Val Gly Ala Phe Leu Arg Lys Thr Ser Leu Asp Glu

85 90 95

Leu Pro Gln Leu Phe Asn Ile Phe Lys Gly Glu Met Ala Ile Val Gly

100 105 110

Pro Arg Pro Ala Leu Trp Asn Gln Tyr Asp Leu Ile Glu Glu Arg Asp

115 120 125

Lys Tyr Gly Ala Asn Asp Ile Arg Pro Gly Leu Thr Gly Trp Ala Gln

130 135 140

Ile Asn Gly Arg Asp Glu Leu Glu Ile Asp Glu Lys Ser Lys Leu Asp

145 150 155 160

Gly Tyr Tyr Val Gln Asn Met Ser Leu Gly Leu Asp Ile Lys Cys Phe

165 170 175

Leu Gly Thr Phe Leu Ser Val Ala Arg Ser Glu Gly Val Val Glu Gly

180 185 190

Gly Thr Gly Gln Lys Gly Lys Gly

195 200

P02230"TH029260

<210> 41

<211> 269

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS2G

<400> 41

Met Lys Phe Ser Val Leu Met Ser Val Tyr Glu Lys Glu Lys Pro Glu
 1 5 10 15

Phe Leu Arg Glu Ser Leu Glu Ser Ile Leu Val Asn Gln Thr Met Ile
 20 25 30

Pro Thr Glu Val Val Leu Val Glu Asp Gly Pro Leu Asn Gln Ser Leu
 35 40 45

Tyr Ser Ile Leu Glu Glu Phe Lys Ser Arg Phe Ser Phe Phe Lys Thr
 50 55 60

Ile Ala Leu Glu Lys Asn Ser Gly Leu Gly Ile Ala Leu Asn Glu Gly
 65 70 75 80

Leu Lys His Cys Asn Tyr Glu Trp Val Cys Thr Lys Trp Ile Leu Met
 85 90 95

Met Leu His Ile His Thr Arg Phe Glu Lys Gln Val Asn Phe Ile Lys
 100 105 110

Gln Asn Pro Thr Ile Asp Ile Glu Ile Asp Glu Phe Leu Asn Ser Thr
 115 120 125

Ser Glu Ile Val Ser His Lys Asn Val Pro Thr Gln His Asp Glu Ile
 130 135 140

Leu Lys Met Ala Arg Arg Glu Lys Ser Met Cys His Met Thr Val Met
145 150 155 160

Phe Lys Lys Lys Ser Val Glu Arg Ala Gly Gly Tyr Gln Thr Leu Pro
165 170 175

Tyr Val Glu Asp Tyr Phe Leu Trp Val Arg Met Ile Ala Ser Gly Ser
180 185 190

Lys Phe Ala Asn Ile Asp Glu Thr Leu Val Leu Ala Arg Val Gly Asn
195 200 205

Gly Met Phe Asn Arg Arg Gly Asn Arg Glu Gln Ile Asn Ser Trp Thr
210 215 220

Leu Leu Ile Glu Phe Met Leu Ala Gln Gly Ile Val Thr Pro Leu Asp
225 230 235 240

Val Phe Ile Asn Gln Ile Tyr Ile Arg Val Phe Val Tyr Met Pro Thr
245 250 255

Trp Ile Lys Lys Leu Ile Tyr Gly Lys Ile Leu Arg Lys
260 265

<210> 42

<211> 143

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS9H

<400> 42

Met Ile Thr Val Leu Met Ala Thr Tyr Asn Gly Ser Pro Phe Ile Ile

1 5 10 15
 Lys Gln Leu Asp Ser Ile Arg Asn Gln Ser Val Ser Ala Asp Lys Val
 20 25 30
 Ile Ile Trp Asp Asp Cys Ser Thr Asp Asp Thr Ile Lys Ile Ile Lys
 35 40 45
 Asp Tyr Ile Lys Lys Tyr Ser Leu Asp Ser Trp Val Val Ser Gln Asn
 50 55 60
 Lys Ser Asn Gln Gly His Tyr Gln Thr Phe Ile Asn Leu Thr Lys Leu
 65 70 75 80
 Val Gln Glu Gly Ile Val Phe Phe Ser Asp Gln Asp Asp Ile Trp Asp
 85 90 95
 Cys His Lys Ile Glu Thr Met Leu Pro Ile Phe Asp Arg Glu Asn Val
 100 105 110
 Ser Met Val Phe Cys Lys Ser Arg Leu Ile Asp Glu Asn Gly Asn Ile
 115 120 125
 Ile Ser Ser Pro Asp Thr Ser Asp Arg Ile Asn Thr Tyr Ser Leu
 130 135 140

<210> 43

<211> 3738

<212> DNA

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS7

<400> 43

ctgcagcaca taagcatgtt ccattgatgg aatataatcc acatgaagca gtgaagaata 60

atatttttgg aacgaagaat gtggctgagg cggctaaaac tgcaaagggt gccaaatttg 120

ttatggttgc aacagataaa gctgttaatc cgccaaatgt catgggagcg actaaacgtg 180

ttgcagaaat gattgtaaca ggtttaaagc agccagggtc gactcaattt gcggcagtc 240

gttttgggaa tgttctaggt agtcgtggaa gtgttgttcc gctattcaaa gagcaaatta 300

gaaaagggtg acctgttacg gttaccgact ttaggatgac tcgttatttc atgacgattc 360

ctgaggcaag tcgtttggtt atccaagctg gacatttggc aaaagggtgga gaaatctttg 420

tcttgatat ggggtgagcca gtacaaatcc tggaattggc aagaaaagtt atcttgtaa 480

gcggacatac agaggaagaa atcgggattg tagaatctgg aatcagacca ggcgagaaac 540

tctacgagga attgttatca acagaagaac gtgtcagcga acagattcat gaaaaaatat 600

ttgtgggtcg cggtacaaat aagcagtcgg acattgtcaa ttcatttate aatggattac 660

tccaaaaaga tagaaatgaa ttaaagata tgttgattga attgcaaaa caagaataag 720

aaagtaaaaa atatttttac ttcttagag tttaacgat gttaagttc taggaagggtt 780

ggaattgctt tcgtggagggt gatagataga aacctatata ttgtagaag aaaggatatt 840

aaactaaagg tgaatcgga cataaagttt agatagagtt ggtatttaat gccaaacagg 900

tgaatgcac ctcctgctcg ttactaagca ggagatagta aagttgcttg aaagagagtt 960

tgtaaatcag tataagtagg ctaaagttag aatatatc tattattatc ggtaatgata 1020

ctattattga gaattattgt agtggggata aaaataattt ttggtgattt tatcgtccga 1080

ctaaagggtg gggttaaaaa gtacttatat tcttttagaa ttgatgaaaa atatggggga 1140

atataatatt tataggagat acgatgacta gagtagagtt gattactaga gaattttta 1200

agaagaatga agcaaccagt aaatatttc agaagataga atcaagaaga ggtgaattat 1260

ttattaaatt cttatggat aagtacttg cgctatcct attattgcta ttatcccag 1320

taatcattat attagctatt tggataaaat tagatagtaa ggggccaaatt tttatcgcc 1380

aagaacgtgt tacgagatat ggtcgaattt ttagaatatt taagtttaga acaatgattt 1440
ctgatgcgga taaagtcgga agtcttgta cagtcggtca agataatcgt attacgaaag 1500
tcggtcacat tatcagaaaa tatcggctgg acgaagtgcc ccaactttt aatgttttaa 1560
tgggggatat gagctttgta ggtgtaagac cagaagtaca aaaatatgta aatcagtata 1620
ctgatgaaat gttgcgacg ttacttttac ctgcaggaat tacttcacca gcgagtattg 1680
catataagga tgaagatatt gttttagaag aatattgttc tcaaggctat agtcctgatg 1740
aagcatatgt tcaaaaagta ttaccagaaa aaatgaagta caatttgaa tatatcagaa 1800
actttggaat tatttctgat tttaaagtaa tgattgatac agtaattaa gtaataaaat 1860
aggagattaa aatgacaaaa agacaaaata ttccatttc accaccagat attaccaag 1920
ctgaaattga tgaagtatt gacacactaa aatctggtg gattacaaca ggaccaaaga 1980
caaaagagct agaacgtcgg ctatcagtat ttacaggaac caataaaact gtgtgtttaa 2040
attctgctac tgcaggattg gaactagtct tacgaattct tgggtgttga cccggagatg 2100
aagttattgt tctgctatg acctatactg cctcatgtag tgtcattact catgtaggag 2160
caactcctgt gatggtgat attcaaaaa acagcttga gatggaatat gatgcttgg 2220
aaaaagcgat tactccgaaa acaaaagta tcattcctgt tgatctagct ggtattcctt 2280
gtgattatga taagatttat accatcgtag aaacaaaacg ctctttgtat gttgcttctg 2340
ataataaatg gcagaaactt tttggcgag ttattatcct atctgatagt gcacactcac 2400
taggtgctag ttataaggga aaaccagcgg gttccctagc agattttacc tcattttctt 2460
tccatgcagt taagaatttt acaactgctg aaggaggtag tgtgacatgg agatcacatc 2520
ctgatttga tgacgaagag atgtataaag agtttcagat ttactctctt catggtcaga 2580
caaaggatgc attagctaag acacaattag ggtcatggga atatgacatt gttattcctg 2640
gttacaagtg taatatgaca gatattatgg caggtatcgg tcttggtcaa ttagaacgtt 2700

acccatcttt gttgaatcgt cgcagagaaa tcattgagaa atacaatgct ggctttgagg 2760
 ggacttcgat taagccgttg gtacacctga cggaagataa acaatcgtct atgcacttgt 2820
 atatcacgca tctacaaggc tatactttag aacaacgaaa tgaagtcatt caaaaaatgg 2880
 ctgaagcagg tattgcgtgc aatgttctact acaaaccatt acctcttctc acagcctaca 2940
 agaatcttgg tttgaaatg aaagatttct cgaatgccta tcagtatttt gaaaatgaag 3000
 ttactgcc tctcatacc aactgagtg atgaagatgt ggagtatgtg atagaaatgt 3060
 ttttaaaat tgtagtaga gattagtat tttggaagga gatatggtgg aaagagatat 3120
 ggtggaaaga gacacgttgg tatctataat aatgcctcg tggaatacag ctaagtatat 3180
 atctgaatca atccagtcag tgttgacca aacacaccaa aattgggaac ttataatcgt 3240
 tgatgattgt tctaatgacg aaactgaaaa agttgttctg catttcaaag attcaagaat 3300
 aaagttttt aaaaattcga ataatttagg ggcagctcta acacgaaata aggcactaag 3360
 aaaagctaga ggtaggtgga ttgcgttctt ggattcagat gatttatggc acccgagtaa 3420
 gctagaaaaa cagcttgaat ttatgaaaaa taatggatat tcattactt atcacaattt 3480
 tgaaaagatt gatgaatcta gtcagtcttt acgtgtcctg gtgtcaggac cagcaattgt 3540
 gactagaaaa atgatgtaca attacggcta tccaggtgtt ttgactttca tgtatgatgc 3600
 agacaaaatg gggttaattc agataaaaga tataaagaaa aataacgatt atgcgatatt 3660
 acttcaattg tgtaagaagt atgactgtta tcttttaaat gaaagtttag cttcgtatcg 3720
 aattagaaaa aaatcgat 3738

<210> 44

<211> 238

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS7E

<400> 44

Ala Ala His Lys His Val Pro Leu Met Glu Tyr Asn Pro His Glu Ala
1 5 10 15

Val Lys Asn Asn Ile Phe Gly Thr Lys Asn Val Ala Glu Ala Ala Lys
 20 25 30

Thr Ala Lys Val Ala Lys Phe Val Met Val Ser Thr Asp Lys Ala Val
 35 40 45

Asn Pro Pro Asn Val Met Gly Ala Thr Lys Arg Val Ala Glu Met Ile
 50 55 60

Val Thr Gly Leu Asn Glu Pro Gly Gln Thr Gln Phe Ala Ala Val Arg
65 70 75 80

Phe Gly Asn Val Leu Gly Ser Arg Gly Ser Val Val Pro Leu Phe Lys
 85 90 95

Glu Gln Ile Arg Lys Gly Gly Pro Val Thr Val Thr Asp Phe Arg Met
 100 105 110

Thr Arg Tyr Phe Met Thr Ile Pro Glu Ala Ser Arg Leu Val Ile Gln
 115 120 125

Ala Gly His Leu Ala Lys Gly Gly Glu Ile Phe Val Leu Asp Met Gly
 130 135 140

Glu Pro Val Gln Ile Leu Glu Leu Ala Arg Lys Val Ile Leu Leu Ser
145 150 155 160

Gly His Thr Glu Glu Glu Ile Gly Ile Val Glu Ser Gly Ile Arg Pro
 165 170 175

Gly Glu Lys Leu Tyr Glu Glu Leu Leu Ser Thr Glu Glu Arg Val Ser
 180 185 190

Glu Gln Ile His Glu Lys Ile Phe Val Gly Arg Val Thr Asn Lys Gln
 195 200 205

Ser Asp Ile Val Asn Ser Phe Ile Asn Gly Leu Leu Gln Lys Asp Arg
 210 215 220

Asn Glu Leu Lys Asp Met Leu Ile Glu Phe Ala Lys Gln Glu
 225 230 235

<210> 45

<211> 232

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS7F

<400> 45

Met Thr Arg Val Glu Leu Ile Thr Arg Glu Phe Phe Lys Lys Asn Glu
 1 5 10 15

Ala Thr Ser Lys Tyr Phe Gln Lys Ile Glu Ser Arg Arg Gly Glu Leu
 20 25 30

Phe Ile Lys Phe Phe Met Asp Lys Leu Leu Ala Leu Ile Leu Leu Leu
 35 40 45

Leu Leu Ser Pro Val Ile Ile Ile Leu Ala Ile Trp Ile Lys Leu Asp
 50 55 60

Ser Lys Gly Pro Ile Phe Tyr Arg Gln Glu Arg Val Thr Arg Tyr Gly
 65 70 75 80

Arg Ile Phe Arg Ile Phe Lys Phe Arg Thr Met Ile Ser Asp Ala Asp
85 90 95

Lys Val Gly Ser Leu Val Thr Val Gly Gln Asp Asn Arg Ile Thr Lys
100 105 110

Val Gly His Ile Ile Arg Lys Tyr Arg Leu Asp Glu Val Pro Gln Leu
115 120 125

Phe Asn Val Leu Met Gly Asp Met Ser Phe Val Gly Val Arg Pro Glu
130 135 140

Val Gln Lys Tyr Val Asn Gln Tyr Thr Asp Glu Met Phe Ala Thr Leu
145 150 155 160

Leu Leu Pro Ala Gly Ile Thr Ser Pro Ala Ser Ile Ala Tyr Lys Asp
165 170 175

Glu Asp Ile Val Leu Glu Glu Tyr Cys Ser Gln Gly Tyr Ser Pro Asp
180 185 190

Glu Ala Tyr Val Gln Lys Val Leu Pro Glu Lys Met Lys Tyr Asn Leu
195 200 205

Glu Tyr Ile Arg Asn Phe Gly Ile Ile Ser Asp Phe Lys Val Met Ile
210 215 220

Asp Thr Val Ile Lys Val Ile Lys
225 230

<210> 46

<211> 404

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS7G

<400> 46

Met Thr Lys Arg Gln Asn Ile Pro Phe Ser Pro Pro Asp Ile Thr Gln
 1 5 10 15

Ala Glu Ile Asp Glu Val Ile Asp Thr Leu Lys Ser Gly Trp Ile Thr
 20 25 30

Thr Gly Pro Lys Thr Lys Glu Leu Glu Arg Arg Leu Ser Val Phe Thr
 35 40 45

Gly Thr Asn Lys Thr Val Cys Leu Asn Ser Ala Thr Ala Gly Leu Glu
 50 55 60

Leu Val Leu Arg Ile Leu Gly Val Gly Pro Gly Asp Glu Val Ile Val
 65 70 75 80

Pro Ala Met Thr Tyr Thr Ala Ser Cys Ser Val Ile Thr His Val Gly
 85 90 95

Ala Thr Pro Val Met Val Asp Ile Gln Lys Asn Ser Phe Glu Met Glu
 100 105 110

Tyr Asp Ala Leu Glu Lys Ala Ile Thr Pro Lys Thr Lys Val Ile Ile
 115 120 125

Pro Val Asp Leu Ala Gly Ile Pro Cys Asp Tyr Asp Lys Ile Tyr Thr
 130 135 140

Ile Val Glu Asn Lys Arg Ser Leu Tyr Val Ala Ser Asp Asn Lys Trp
 145 150 155 160

Gln Lys Leu Phe Gly Arg Val Ile Ile Leu Ser Asp Ser Ala His Ser
 165 170 175

Leu Gly Ala Ser Tyr Lys Gly Lys Pro Ala Gly Ser Leu Ala Asp Phe
 180 185 190

Thr Ser Phe Ser Phe His Ala Val Lys Asn Phe Thr Thr Ala Glu Gly
 195 200 205

Gly Ser Val Thr Trp Arg Ser His Pro Asp Leu Asp Asp Glu Glu Met

210 215 220

Tyr Lys Glu Phe Gln Ile Tyr Ser Leu His Gly Gln Thr Lys Asp Ala
225 230 235 240

Leu Ala Lys Thr Gln Leu Gly Ser Trp Glu Tyr Asp Ile Val Ile Pro
245 250 255

Gly Tyr Lys Cys Asn Met Thr Asp Ile Met Ala Gly Ile Gly Leu Val
260 265 270

Gln Leu Glu Arg Tyr Pro Ser Leu Leu Asn Arg Arg Arg Glu Ile Ile
275 280 285

Glu Lys Tyr Asn Ala Gly Phe Glu Gly Thr Ser Ile Lys Pro Leu Val
290 295 300

His Leu Thr Glu Asp Lys Gln Ser Ser Met His Leu Tyr Ile Thr His
305 310 315 320

Leu Gln Gly Tyr Thr Leu Glu Gln Arg Asn Glu Val Ile Gln Lys Met
325 330 335

Ala Glu Ala Gly Ile Ala Cys Asn Val His Tyr Lys Pro Leu Pro Leu
340 345 350

Leu Thr Ala Tyr Lys Asn Leu Gly Phe Glu Met Lys Asp Phe Pro Asn
355 360 365

Ala Tyr Gln Tyr Phe Glu Asn Glu Val Thr Leu Pro Leu His Thr Asn
370 375 380

Leu Ser Asp Glu Asp Val Glu Tyr Val Ile Glu Met Phe Leu Lys Ile
385 390 395 400

Val Ser Arg Asp

<210> 47

<211> 210

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> CPS7H

<400> 47

Met Val Glu Arg Asp Met Val Glu Arg Asp Thr Leu Val Ser Ile Ile
1 5 10 15

Met Pro Ser Trp Asn Thr Ala Lys Tyr Ile Ser Glu Ser Ile Gln Ser
20 25 30

Val Leu Asp Gln Thr His Gln Asn Trp Glu Leu Ile Ile Val Asp Asp
35 40 45

Cys Ser Asn Asp Glu Thr Glu Lys Val Val Ser His Phe Lys Asp Ser
50 55 60

Arg Ile Lys Phe Phe Lys Asn Ser Asn Asn Leu Gly Ala Ala Leu Thr
65 70 75 80

Arg Asn Lys Ala Leu Arg Lys Ala Arg Gly Arg Trp Ile Ala Phe Leu
85 90 95

Asp Ser Asp Asp Leu Trp His Pro Ser Lys Leu Glu Lys Gln Leu Glu
100 105 110

Phe Met Lys Asn Asn Gly Tyr Ser Phe Thr Tyr His Asn Phe Glu Lys
115 120 125

Ile Asp Glu Ser Ser Gln Ser Leu Arg Val Leu Val Ser Gly Pro Ala
130 135 140

Ile Val Thr Arg Lys Met Met Tyr Asn Tyr Gly Tyr Pro Gly Cys Leu
145 150 155 160

Thr Phe Met Tyr Asp Ala Asp Lys Met Gly Leu Ile Gln Ile Lys Asp
165 170 175

Ile Lys Lys Asn Asn Asp Tyr Ala Ile Leu Leu Gln Leu Cys Lys Lys
 180 185 190

Tyr Asp Cys Tyr Leu Leu Asn Glu Ser Leu Ala Ser Tyr Arg Ile Arg
 195 200 205

Lys Lys
 210

<210> 48

<211> 101

<212> DNA

<213> Streptococcus suis

<220>

<221> misc_feature

<222> (1)..(101)

<223> N may be any nucleotide

<220>

<221> misc_feature

<223> 100 base pair repeat between CPS2G and CPS2H

<400> 48
 aagggcacct ctataaactc ccaaaattgc gaatttgag ttacgaaagc cttgttaa 60

caancatttt aaattttaga aaattagttt ttagagctcc c 101

<210> 49

<211> 101

<212> DNA

<213> Streptococcus suis

<220>

<221> misc_feature

<222> (1)..(101)

<223> N may be any nucleotide

<220>

<221> misc_feature

<223> 100 base pair repeat within CPS2M

<400> 49

ggcgccacct ctataaatc ccaaaattgc gaattcgag ttacgaaagc cttgttaa 60

caancatctt aaattttaga aaattagttt ttagaggtcc c 101

<210> 50

<211> 101

<212> DNA

<213> Streptococcus suis

<220>

<221> misc_feature

<223> 100 base pair repeat between CPS2O and CPS2P

<400> 50

aagggcacct ctataaactc ccaaaattgc gaattcgag ttacgaaagc cttgttaa 60

caaacatttt aaattttaga aaattagttt ttagaggtcc c 101

<210> 51

<211> 120

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> N-terminal part of CPS2J

<400> 51

Met Ala Lys Val Ser Ile Ile Val Pro Ile Phe Asn Thr Glu Lys Tyr

1 5 10 15

Leu Arg Glu Cys Leu Asp Ser Ile Ile Ser Gln Ser Tyr Thr Asn Leu

20 25 30

Glu Ile Leu Leu Ile Asp Asp Gly Ser Ser Asp Ser Ser Thr Asp Ile

35 40 45

Cys Leu Glu Tyr Ala Glu Gln Asp Gly Arg Ile Lys Leu Phe Arg Leu

50 55 60

Pro Asn Gly Gly Val Ser Asn Ala Arg Asn Tyr Gly Ile Lys Asn Ser

65 70 75 80

Thr Ala Asn Tyr Ile Met Phe Val Asp Ser Asp Asp Ile Val Asp Gly

85 90 95

Asn Ile Val Glu Ser Leu Tyr Thr Cys Leu Lys Glu Asn Asp Ser Asp

100 105 110

Leu Ser Gly Gly Leu Leu Ala Thr

115 120

<210> 52

<211> 120

<212> PRT

<213> Streptococcus suis

<220>

<221> misc_feature

<223> N-terminal part of CPS2K

<220>

<221> misc_feature

<222> (1)..(120)

<223> Xaa may be any amino acid

<400> 52

Met Ile Asn Ile Ser Ile Ile Val Pro Ile Tyr Asn Val Glu Gln Tyr

1 5 10 15

Leu Ser Lys Cys Ile Asn Ser Ile Val Asn Gln Thr Tyr Lys His Ile

20 25 30

Glu Leu Leu Val Asn Asp Gly Ser Ser Thr Asp Asn Ser Glu Glu Ile

35 40 45

Cys Leu Ala Tyr Ala Lys Lys Asp Ser Arg Ile Arg Tyr Phe Lys Lys

50 55 60

Glu Asn Gly Gly Leu Ser Asp Ala Arg Asn Tyr Gly Ile Ser Arg Ala

65 70 75 80

Lys Gly Asp Tyr Leu Ala Phe Ile Asp Ser Asp Asp Phe Ile His Ser

85 90 95

Glu Phe Ile Gln Arg Leu Xaa His Glu Ala Ile Glu Arg Glu Asn Ala

100 105 110

Leu Xaa Xaa Val Ala Val Ala Gly

115 120

<210> 53

<400> 53

1 5 10 15

20 25 30

35 40 45

50 55 60

65 70 75 80

85 90 95

100 105 110

115 120 125

130 135 140

145 150 155 160

Gly Lys Thr Glu Ile Leu Ile Glu Asn Pro Thr Tyr Ser Arg Met Ile
165 170 175

Glu Leu Ile Arg His Gln Gly Ile Pro Tyr Gln Thr Ile Glu Arg Asn
180 185 190

Leu Asp Gly Ile Asp Leu Glu Glu Leu Glu Ser Ile Phe Gln Thr Gly
195 200 205

Lys Ile Lys Phe Phe Tyr Thr Ile Pro Arg Leu His Asn Pro Leu Gly
210 215 220

Ser Thr Tyr Asp Ile Ala Thr Lys Thr Ala Ile Val Lys Leu Ala Lys
225 230 235 240

Gln Tyr Asp Val Tyr Ile Ile Glu Asp Asp Tyr Leu Ala Asp Phe Asp
245 250 255

Ser Ser His Ser Leu Pro Leu His Tyr Leu Asp Thr Asp Asn Arg Val
260 265 270

Ile Tyr Ile Lys Ser Phe Thr Pro Thr Leu Phe Pro Ala Leu Arg Ile
275 280 285

Gly Ala Ile Ser Leu Pro Asn Gln Leu Arg Asp Ile Phe Ile Lys His
290 295 300

Lys Ser Leu Ile Asp Tyr Asp Thr Asn Leu Ile Met Gln Lys Ala Leu
305 310 315 320

Ser Leu Tyr Ile Asp Asn Gly Met Phe Ala Arg Asn Thr Gln His Leu
325 330 335

His His Ile Tyr His Ala Gln Trp Asn Lys Ile Lys Asp Cys Leu Glu
340 345 350

Lys Tyr Ala Leu Asn Ile Pro Tyr Arg Ile Pro Lys Gly Ser Val Thr
355 360 365

Phe Gln Leu Ser Lys Gly Ile Leu Ser Pro Ser Ile Gln His Met Phe
370 375 380

Gly Lys Cys Tyr Tyr Phe Ser Gly Gln Lys Ala Asp Phe Leu Gln Ile

148

385

390

395

400

Phe Phe Glu Gln Asp Phe Ala Asp Lys Leu Glu Gln Phe Val Arg Tyr
405 410 415

Leu Asn Glu

FOOTNOTES

TABLE 1. Bacterial strains and plasmids

strain/plasmid	relevant characteristics	source/reference
Strain		
<i>E. coli</i>		
CC118	PhoA ⁻	(28)
XL2 blue	Stratagene	
<i>E. coli</i>		
XL2 blue	Stratagene	
<i>S. suis</i>		
10	virulent serotype 2 strain	(49)
3	serotype 2	(63)
17	serotype 2	(63)
735	reference strain serotype 2	(63)
T15	serotype 2	(63)
6555	reference strain serotype 1	(63)
6388	serotype 1	(63)
6290	serotype 1	(63)
5637	serotype 1	(63)
5673	serotype 1/2	(63)
5679	serotype 1/2	(63)
5928	serotype 1/2	(63)
5934	serotype 1/2	(63)
5209	reference strains serotype 1/2	(63)
5218	reference strain serotype 9	(63)
5973	serotype 9	(63)
6437	serotype 9	(63)
6207	serotype 9	(63)
reference strains	serotypes 1-34	(9, 56, 14)
<i>S. suis</i>		
10	virulent serotype 2 strain	(51)
10cpsB	isogenic cpsB mutant of strain 10	this work
10cpsEF	isogenic cpsEF mutant of strain 10	this work
Plasmid		
pKUN19	replication functions pUC, Amp ^R	(23)
pGEM7Zf(+)	replication functions pUC, Amp ^R	Promega Corp.
pIC19R	replication functions pUC, Amp ^R	(29)
pIC20R	replication functions pUC, Amp ^R	(29)
pIC-spc	pIC19R containing spc ^R gene of pDL282	labcollection

pDL282	replication functions of pBR322 and pVT736-1, Amp ^R , Spc ^R	(43)
pPHOS2	pIC-spc containing the truncated <i>phoA</i> gene of pPHO7 as a <i>PstI</i> - <i>BamHI</i> fragment	this work
pPHO7	contains truncated <i>phoA</i> gene	(15)
pPHOS7	pPHOS2 containing chromosomal <i>S. suis</i> DNA	this work
pCPS6	pKUN19 containing 6 kb <i>HindIII</i> fragment of <i>cps</i> operon	this work (Fig.1)
pCPS7	pKUN19 containing 3,5 kb <i>EcoRI</i> - <i>HindIII</i> fragment of <i>cps</i> operon	this work (Fig.1)
pCPS11	pCPS7 in which 0.4 kb <i>PstI</i> - <i>BamHI</i> fragment of <i>cpsB</i> gene is replaced by Spc ^R gene of pIC-spc	this work (Fig.1)
pCPS17	pKUN19 containing 3.1 kb <i>KpnI</i> fragment of <i>cps</i> operon	this work (Fig.1)
pCPS18	pKUN19 containing 1.8 kb <i>SnaBI</i> fragment of <i>cps</i> operon	this work (Fig.1)
pCPS20	pKUN19 containing 3.3 kb <i>XbaI</i> - <i>HindIII</i> fragment of <i>cps</i> operon	this work (Fig.1)
pCPS23	pGEM7Zf(+) containing 1.5 kb <i>MluI</i> fragment of <i>cps</i> operon	this work (Fig.1)
pCPS25	pIC20R containing 2.5 kb <i>KpnI</i> - <i>SalI</i> fragment of pCPS17	this work (Fig.1)
pCPS26	pKUN19 containing 3.0 kb <i>HindIII</i> fragment of <i>cps</i> operon	this work (Fig.1)
pCPS27	pCPS25 containing 2.3 kb <i>XbaI</i> (blunt)- <i>ClaI</i> fragment of pCPS20	this work (Fig.1)
pCPS28	pCPS27 containing the 1.2 kb <i>PstI</i> - <i>XhoI</i> Spc ^R gene of pIC-spc	this work (Fig.1)
pCPS29	pKUN19 containing 2.2 kb <i>SacI</i> - <i>PstI</i> fragment of <i>cps</i> operon	this work (Fig.1)
pCPS1-1	pKUN19 containing 5 kb <i>EcoRV</i> fragment of <i>cps</i> operon of type 1	this work (Fig.1)
pCPS1-2	pKUN19 containing 2.2 kb <i>HindIII</i> fragment of <i>cps</i> operon of type 1	this work (Fig.1)
pCPS9-1	pKUN19 containing 1 kb <i>HindIII</i> - <i>XbaI</i> fragment of <i>cps</i> operon of serotype 9	this work (Fig.1)
pCPS9-2	pKUN19 containing 4.0 kb <i>XbaI</i> - <i>XbaI</i> fragment of <i>cps</i> operon of serotype 9	this work (Fig.1)

Amp^R: ampicillin resistant
Spc^R: spectinomycin resistant
cps: capsular polysaccharide

Table 1 continued

Table 2. Properties of Orfs in the *cps* locus of *S. suis* serotype 2 and similarities to gene product other bacteria

ORF	nucleotide position in sequence	number of amino acids	GC%	proposed function of gene product ¹	similar gene product (% identity)
Orf2Z	1 -719	240	44	Unknown	<i>B. subtilis</i> YitS (26%)
Orf2Y	2079-822	419	38	Transcription regulation	<i>B. subtilis</i> YcxD (39%)
Orf2X	2202-2934	244	39	Unknown	<i>H. influenzae</i> YAAA (24%)
Cps2A	3041-4484	481	39	Regulation	<i>S. pneumoniae</i> Cps19fA (58%)
Cps2B	4504-5191	229	40	Chain length determination	<i>S. pneumoniae</i> type 3 Orf1 (58%)
Cps2C	5203-5878	225	40	Chain length determination/Export	<i>S. pneumoniae</i> Cps23fD (63%)
Cps2D	5919-6648	243	38	Unknown	<i>S. pneumoniae</i> CpsB (62%)
Cps2E	6675-8052	459	33	Glycosyltransferase	<i>S. pneumoniae</i> Cps14E (56%)
Cps2F	8089-9256	389	32	Glycosyl transferase	<i>S. pneumoniae</i> Cps23fT
Cps2G	9262-10417	385	36	Glycosyltransferase	<i>S. thermophilus</i> EpsF (25%)
Cps2H	10808-12176	457	31	Glycosyltransferase	<i>S. mutans</i> RGPEC, ^N (29%)
Cps2I	12213- 13443	410	29	CP polymerase	<i>S. pneumoniae</i> Cps23fI (48%)
Cps2J	13583-14579	332	29	Glycosyltransferase	<i>S. pneumoniae</i> Cps14J (31%)
Cps2K	14574-15576	334	37	Glycosyltransferase	<i>S. pneumoniae</i> Cps14J (40%)

Table 2 continued

"Cps2L"	15618-16635	103	37	Unknown	-
"Cps2M"	16811-17322	-	38	-	<i>S. agalactiae</i> CpsF ^N (77%) <i>E. coli</i> NeuA ^N (47%)
"Cps2N"	17559-18342	-	39	-	<i>S. agalactiae</i> CpsJ (43%)
Cps20	18401-19802	476	40	Repeat unit transporter	<i>S. agalactiae</i> CpsK (41%)
Cps2P	20327-21341	338	39	Sialic acid synthesis	<i>S. agalactiae</i> NeuB (80%) <i>E. coli</i> NeuB (59%)
Cps2Q	21355-21865	170	42	Sialic acid synthesis	<i>S. agalactiae</i> NeuC ^N (61%) <i>E. coli</i> NeuC ^N (54%)
Cps2R	21933-22483	184	40	Sialic acid synthesis	<i>S. agalactiae</i> NeuC ^C (55%) <i>E. coli</i> NeuC ^C (40%)
Cps2S	22501-23125	208	42	Sialic acid synthesis	<i>E. coli</i> NeuD (32%)
Cps2T	23136-24366	395	40	CMP-NeuNAC synthetase	<i>S. agalactiae</i> CpsF (49%) <i>E. coli</i> NeuA (34%)
"Orf2U"	24566-25488	168	42	Transposase	<i>S. thermophilus</i> IS1194 (51%)
"Orf2V"	25691-26281	116	37	Transposase	<i>S. pneumoniae</i> orf1 (85%)

¹ Predicted by sequence similarity

^N Similarity refers to the amino-terminal part of the gene product

^C Similarity refers to the carboxy-terminal part of the gene product

ORFs between " " are truncated or non-functional as the result of frame-shift or point mutations

TABLE 3. Properties of ORFs in the *cps* genes of *S. suis* serotypes 1 and 9 and similarities to gene products of other bacteria

ORF	nucleotide position in sequence	G + C%	number of amino acids	predicted mol. mass (kDa)	predicted pI	proposed function of gene product ¹	similar gene product (% identity)	reference/ accession nr.
Cps1E ² (48%)	1-1363	34%	454	52.2	8.0	Glucosyltransferase	Streptococcus suis Cps2E (86%) Streptococcus pneumoniae Cps14E (12%)	(26)
Cps1F	1374-1821	33%	149	17.3	8.2	Unknown	Streptococcus pneumoniae Cps14F (83%)	(14)
Cps1G	1823-2315	25%	164	19.5	7.5	Glycosyltransferase	Streptococcus pneumoniae Cps14G (50%) (14)	
Cps1H	3035-4202	24%	389	45.5	8.4	CP polymerase	Streptococcus pneumoniae Cps14H (30%)	(14)
Cps1I	4197-					Glycosyltransferase	Streptococcus pneumoniae Cps14J (38%) Lactococcus lactis EpsG (31%) Streptococcus thermophilus EpsI (33%)	(13) (29) (28)
Cps1J						Glycosyltransferase	Streptococcus pneumoniae Cps14J ()	

Table 3 continued

Cps1K ³	37%	278	32.5	7.8	Glycosyltransferase	(13)
						<i>Streptococcus pneumoniae</i> Cps14J (44%)
Cps9D ²	37%	215	24.9	8.1	Unknown	(26)
						<i>Streptococcus suis</i> Cps2D (89%)
Cps9E					Glycosyltransferase	(18)
						<i>Staphylococcus aureus</i> Cap1D (27%)
Cps9F	36%	200	22.3	8.2	Glycosyltransferase	(17)
						<i>Staphylococcus aureus</i> Cap5M (52%)
Cps9G	35%	269	31.5	8.0	Unknown	(43%)
						<i>Actinobacillus actinomycetemcomitans</i> (AB002668_4)
						<i>Haemophilus influenzae</i> Lsg (43%)
						(005081)
Cps9H ³	30%	143	16.5	7.2	Unknown	(33)
						<i>Yersinia enterocolitica</i> Rfbb (28%)

¹ Predicted by sequence similarity

² N-terminal part of protein is lacking

³ C-terminal part of protein is lacking

Table 4.

[illegible]

DNA probes

[illegible]

TABLE 6. Virulence of wild type and capsular mutant *S. suis* strains in germfree pigs

<i>S. suis</i> strains ¹	pigs/ group [n]	mortality ² [%]	morbidity ³ [%]	clinical index of the group	fever index ⁷	leuco- cyte index ⁸	isolation of <i>S. suis</i> in pigs [n] per group in	CNS	serosae	joints
10	4	100	100	11	88	43	44	2	3	4
10cpsB	4	0	0	0	10	1	3	1	3	2
10cpsEF	4	0	0	0	0	1	0	1	3	2

¹ strain10 in the wild type strain, strains 10cpsB and 10cpsEF are isogenic capsular mutant strains

² piglets which died spontaneously or had to be killed for animal welfare reasons

³ only considering pigs with specific symptoms

⁴ clinical index: % of observations which matched the described criteria

⁵ specific symptoms: ataxia, lemeness on at least one joint, stiffness

⁶ non-specific symptoms: inappetance, depression

⁷ % of observations in the experimental group with a body temperature > 40° C

⁸ % of blood samples in the group in which number of granulocytes > 10¹⁰/l

TABLE 7

Table 7. Bacterial strains and plasmids

strain/plasmid	relevant characteristics
Strain	
<i>E. coli</i>	
XL2 blue	
<i>S. suis</i>	
reference strains	serotypes 1-34
5667	serotype 7, tonsil (1993)
7037	serotype 7, organs (1994)
7044	serotype 7, brains (1994)
7068	serotype 7 (1994)
7646	serotype 7 (1994)
7744	serotype 7, lungs (1996)
7759	serotype 7, joints (1996)
8169	serotype 7 (1997)
15913	serotype 7, meninges (1998)
Plasmid	
pKUN19	replication functions pUC, Amp ^R
pGEM7zf(+)	replication functions pUC, Amp ^R
pCPS9-1	pKUN19 containing 1 kb <i>HindIII</i> - <i>XbaI</i> fragment of <i>cps</i> operon of serotype 9
pCPS9-2	pKUN19 containing 4.0 kb <i>XbaI</i> - <i>XbaI</i> fragment of <i>cps</i> operon of serotype 9
pCPS7-1	pKUN19 containing 1.6-kb <i>PstI</i> fragment of <i>cps</i> operon of type 7
pCPS7-2	pGEM7 containing 2.7-kb <i>ScaI</i> - <i>ClaI</i> fragment of <i>cps</i> operon of type 7

*Amp^R: ampicillin resistant
cps: capsular polysaccharide

Table 8. Properties of Orfs in the cps genes of *S. suis* serotype 7 and similarities to gene products of other bacteria

Orf	nucleotide position in sequence	proposed function of gene product	similar gene product (% identity)
Cps7E	1-719	Glycosyltransferase	<i>Streptococcus suis</i> Cps9E (99%)
Cps7F	1164-1863	Glycosyltransferase	<i>Bordetella pertussis</i> Bp1G ¹ (43%) <i>Streptococcus suis</i> Cps2E ¹ (33%)
Cps7G	1872-3086	Biosynthesis amino sugar	<i>Bordetella pertussis</i> Bp1F (48%)
Cps7H	3104-3737	Glycosyltransferase	<i>Escherichia coli</i> WbdN (35%) <i>Streptococcus suis</i> Cps2K ² (31%)

¹similarity refers to the C-terminal part of the gene product

²similarity refers to the N-terminal part of the gene product

Table 9.

[illegible]

REFERENCES

1. Arends, J. P., and H. C. Zanen. 1988. Meningitis caused by *Streptococcus suis* in humans. Rev. Infect. Dis. 10:131-137.
2. Arrecubieta, C., E. Garcia, and R. Lopez. 1995. Sequence and transcriptional analysis of a DNA region involved in the
5 production of capsular polysaccharide in *Streptococcus pneumoniae* type 3. Gene 167: 1-7
3. Arrecubieta, C., R. Lopez, and E. Garcia. 1994. Molecular characterization of *cap3A*, a gene from the operon required for the synthesis of the capsule of *Streptococcus pneumoniae*
10 type 3: sequencing of mutations responsible for the unencapsulated phenotype and localization of the capsular cluster on the pneumococcal chromosome. J. Bacteriol. 176: 6375-6383.
4. Clifton-Hadley, F.A. 1983. *Streptococcus suis* type 2
15 infections. Br. Vet. J. 139:1-5.
5. Charland, N., J. Harel, M. Kobisch, S. Lacasse, and M. Gottschalk. 1998. *Streptococcus suis* serotype 2 mutants deficient in capsular expression. Microbiol. 144:325-332.
6. Cross, A. S. 1990. The biological significance of
20 bacterial encapsulation. Curr. Top. Microbiol. Immunol. 150: 87-95.
7. Elliott, S. D. and J. Y. Tai . 1978. The type specific polysaccharide of *Streptococcus suis*. J. Exp. Med. 148: 1699-1704.
- 25 8. Feder, I., M. M. Chengappa, B. Fenwick, M. Rider and J. Staats. 1994. Partial characterization of *Streptococcus suis* type 2 hemolysin. J. Clin. Microbiol. 32:1256-1260.
9. Gottschalk, M., R. Higgins, M. Jacques, M. Beaudoin, and J. Henrichsen. 1991. Characterization of six new capsular
30 types (23 through 28) of *Streptococcus suis*. J. Clin. Microbiol. 29:2590-2594.
10. Gottschalk, M., S. Lacouture, and J. D. Dubreuil. 1995. Characterization of *Streptococcus suis* type 2 haemolysin.

Microbiology 141:189-195.

11. Gottschalk, M., A. Lebrun, M. Jacques, and R. Higgins. 1990. Haemagglutination properties of *Streptococcus suis*. J. Clin. Microbiol. 28: 2156-2158.
- 5 12. Guidolin, A., J. M. Morona, R. Morona, D. Hansman, and J. C. Paton. 1994. Nucleotide sequence analysis of genes essential for capsular polysaccharide biosynthesis in *Streptococcus pneumoniae* type 19F. 1994. Infect. Immun. 62: 5384-5396.
- 10 13. Guitierrez, C., and J. C. Devedjian. 1989. Plasmid facilitating *in vitro* construction of PhoA fusions in *Escherichia coli*. Nucl. Acid. Res. 17: 3999.
14. Higgins, R., M. Gottschalk, M. Boudreau, A. Lebrun, and J. Henrichsen. 1995. Description of six new capsular types (28 through 34) of *Streptococcus suis*. J. Vet. Diagn. Invest. 7:405-406
- 15 15. Jacobs, A. A., P. L. W. Loeffen, A. J. G. van den Berg, and P. K. Storm. 1994. Identification, purification and characterization of a thiol-activated hemolysin (suilysin) of *Streptococcus suis*. Infect. Immun. 62: 1742-1748.
- 20 16. Jacques, M., M. Gottschalk, B. Foiry B. and R. Higgins. 1990. Ultrastructural study of surface components of *Streptococcus suis*. J. Bacteriol. 172:2833-2838.
17. Klein P., M. Kanehisa and C. DeLisi. 1985. The detection and classification of membrane spanning proteins. Biochim. Biophys. Acta. 851: 468-476.
- 25 18. Kolkman, M. A. B., D. A. Morrison, B. A. M. van der Zeijst, and P. J. M. Nuijten. 1996. The capsule polysaccharide synthesis locus of *Streptococcus pneumoniae* serotype 14: identification of the glycosyl transferase gene *cps14E*. J. Bacteriol. 178: 3736-3541.
- 30 19. Kolkman, M. A. B., W. Wakarchuk, P. J. M. Nuijten, and B. A. M. van der Zeijst. 1997. Capsular polysaccharide synthesis in *Streptococcus pneumoniae* serotype 14: molecular analysis of the complete *cps* locus and identification of genes encoding glycosyltransferases required for the biosynthesis of the
- 35

09604-0330
F022T0" F049260

- tetrasaccharide subunit. Mol. Microbiol. 26: 197-208.
20. Kolkman, M. A. B., B. A. M. van der Zeijst and P. J. M. Nuijten. 1997. Functional analysis of glycosyltransferases encoded by the capsular polysaccharide biosynthesis locus of *Streptococcus pneumoniae* serotype 14. J. Biol. Chem. 272: 19502-19508.
21. Konings, R. N. H., E. J. M. Verhoeven, and B. P. H. Peeters. 1987. pKUN vectors for the separate production of both DNA strands of recombinant plasmids. Methods Enzymol. 153: 12-34.
22. Korolik, V., B. N. Fry, M. R. Alderton, B. A. M. van der Zeijst, and P. J. Coloe. 1997. Expression of *Campylobacter hyoilei* lipo-oligosaccharide (LOS) antigens in *Escherichia coli*. Microbiol. 143: 3481-3489.
23. Leij, P. C. J., R. van Furth, and T. L. van Zwet. 1986. In vitro determination of phagocytosis and intracellular killing of polymorphonuclear and mononuclear phagocytes. In Handbook of Experimental Immunology, vol. 2. Cellular Immunology, pp. 46.1-46.21. Edited by D. M. Weir, L. A. Herzenberg, C. Blackwell and L. A. Herzenberg. Blackwell Scientific Publications, Oxford.
24. Lin, W. S., T. Cunneen, and C. Y. Lee. 1994. Sequence analysis and molecular characterization of genes required for the biosynthesis of type 1 capsular polysaccharide in *Staphylococcus aureus*. J. Bacteriol. 176: 7005-7016.
25. Liu, D., A. M. Haase, L. Lindqvist, A.A. Lindberg, and P. R. Reeves. 1993. Glycosyl transferases of O-antigen biosynthesis in *Salmonella enteritica*: Identification and characterization of transferase genes of group B, C2, and E1. J. Bacteriol. 175: 3408-3413.
26. Manoil, C., and J. Beckwith. 1985. A transposon probe for protein export signals. Proc. Natl. Acad. Sci. USA 82: 8129-8133.
27. Marsh, J. L., M. Erfle, and E. J. Wykes. 1984. The pIC plasmid and phage vectors with versatile cloning sites for recombinant selection by insertional inactivation. Gene

- 32:481-485.
28. Miller, J. 1972. Experiments in Molecular Genetics. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
29. Morona, J. K., R. Morona, and J. C. Paton. 1997.
- 5 Characterization of the locus encoding the *Streptococcus pneumoniae* type 19F capsular polysaccharide biosynthesis pathway. Mol. Microbiol. 23: 761-763.
30. Muñoz, R., M. Mollerach, R. López and E. Garcia. 1997. Molecular organization of the genes required for the synthesis
- 10 of type 1 capsular polysaccharide of *Streptococcus pneumoniae*; formation of binary encapsulated pneumococci and identification of cryptic dTDP-rhamnose biosynthesis genes. Mol. Microbiol. 25: 79-92.
31. Pearce B. J., Y. B. Yin, and H. R. Masure. 1993. Genetic
- 15 identification of exported proteins in *Streptococcus pneumoniae*. Mol. Microbiol. 9: 1037-1050.
32. Roberts, I. S. 1996. The biochemistry and genetics of capsular polysaccharide production in bacteria. Ann. Rev. Microbiol. 50: 285-315.
- 20 33. Rossbach, S., D. A. Kulpa, U. Rossbach, and F. J. de Bruin. 1994. Molecular and genetic characterization of the rhizopine catabolism (mocABRC) genes of *Rhizobium meliloti* L5-30. Mol. Gen. Genet. 245: 11-24.
34. Rubens, C. E., L. M. Heggen, R. F. Haft, and R. M. Wessels. 1993. Identification of *cpsD*, a gene essential for
- 25 type III capsule expression in group B streptococci. Mol. Microbiol. 8: 843-855.
35. Rubens, C. E., L. M. R. Wessels, L. M. Heggen, and D. L. Kasper. 1987. Transposon mutagenesis of type III group B
- 30 *Streptococcus*: correlation of capsule expression with virulence. Proc. Natl. Acad. Sci. USA 84:7208-7212.
36. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning. A laboratory manual. Second edition. Cold Spring Harbor Laboratory Press. Cold Spring Harbor. New York.
- 35 37. Smith, H. E., U. Vecht, H. J. Wisselink, N. Stockhofe-Zurwieden, Y. Biermann, and M. A. Smits. 1996. Mutants of

- Streptococcus suis* types 1 and 2 impaired in expression of muramidase-released protein and extracellular protein induce disease in newborn germfree pigs. Infect Immun. 64: 4409-4412.
38. Smith, H. E., H. J. Wisselink, U. Vecht, A. L. J. Gielkens and M. A. Smits. 1995. High-efficiency transformation and gene inactivation in *Streptococcus suis* type 2. Microbiol. 141: 181-188.
39. Sreenivasan, P. K., D. L. LeBlanc, L. N. Lee, and P. Fives-Taylor. 1991. Transformation of *Actinobacillus actinomycetemcomitans* by electroporation, utilizing constructed shuttle plasmids. Infect. Immun. 59: 4621-4627.
40. Stringele F., J.-R. Neeser, and B. Mollet. 1996. Identification and characterization of the *eps* (exopolysaccharide) gene cluster from *Streptococcus thermophilus* Sfi6. J. Bacteriol. 178: 1680-1690.
41. Stockhofe-Zurwieden, N., U. Vecht, H. J. Wisselink, H. van Lieshout, and H. E. Smith. 1996. Comparative studies on the pathogenicity of different *Streptococcus suis* serotype 1 strains. In Proceedings of the 14th IPVS Congress. pp. 299.
42. van Kranenburg, R., J. D. Marugg, I. I. van Swam, N. J. Willem and W. M. de Vos. 1997. Molecular characterization of the plasmid-encoded *eps* gene cluster essential for exopolysaccharide biosynthesis in *Lactococcus lactis* Mol. Microbiol. 24: 387-397.
43. van Leengoed, L. A., E. M. Kamp, and J. M. A. Pol. 1989. Toxicity of *Haemophilus pleuropneumoniae* to porcine lung macrophages. Vet. Microbiol. 19: 337-349.
44. van Leengoed, L. A. M. G., U. Vecht, and E. R. M. Verheyen. 1987. *Streptococcus suis* type 2 infections in pigs in The Netherlands (part two). Vet Quart. 9, 111-117.
45. Vecht, U., J. P. Arends, E. J. van der Molen, and L. A. M. G. van Leengoed. 1989. Differences in virulence between two strains of *Streptococcus suis* type 2 after experimentally induced infection of newborn germfree pigs. Am. J. Vet. Res. 50:1037-1043.
46. Vecht, U., L. A. M. G. van Leengoed, and E. R. M.

- Verheyen. 1985. *Streptococcus suis* infections in pigs in The Netherlands (part one). Vet. Quart. 7:315-321
47. Vecht, U., H. J. Wisselink, M. L. Jellema, and H. E. Smith. 1991. Identification of two proteins associated with virulence of *Streptococcus suis* type 2. Infect. Immun. 59:3156-3162.
48. Vecht, U., H. J. Wisselink, N. Stockhofe-Zurwieden, and H. E. Smith. 1996. Characterization of virulence of the *Streptococcus suis* serotype 2 reference strain Henrichsen S 735 in newborn gnotobiotic pigs. Vet. Microbiol. 51:125-136.
49. Vecht, U., H. J. Wisselink, J. E. van Dijk, and H. E. Smith. 1992. Virulence of *Streptococcus suis* type 2 strains in newborn germfree pigs depends on phenotype. Infect. Immun. 60:550-556.
50. Wagenaar, F., G. L. Kok, J. M. Broekhuijsen-Davies, and J. M. A. Pol. 1993. Rapid cold fixation of tissue samples by microwave irradiation for use in electron microscopy. Histochemical J. 25: 719-725.
51. Wessels, M. R. and M. S. Bronze. 1994. Critical role of the group A streptococcal capsule in pharyngeal colonization and infection in mice. Proc. Natl. Acad. Sci. USA 91: 12238-12242.
52. Wessels, M. R., A. E. Moses, J. B. Goldberg, and T. J. DiCesare. 1991. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc. Natl. Acad. Sci. USA. 88: 8317-8321.
53. Yamane, K., M. Kumamano, and K. Kurita. 1996. The 25⁰-36⁰ region of the *Bacillus subtilis* chromosome: determination of the sequence of a 146 kb segment and identification of 113 genes. Microbiol. 142: 3047-3056.
54. Butler, J. C., R. F. Breiman, H. B. Lipman, J. Hofmann, and R. R. Facklam. 1995. Serotype distribution of *Streptococcus pneumoniae* infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J. Infect. Dis. 171: 885-889.
55. Charland, N., M. Jacques, S. Lacoutre and M. Gottschalk.

1997. Characterization and protective activity of a monoclonal antibody against a capsular epitope shared by *Streptococcus suis* serotypes 1, 2 and 1/2. *Microbiol.* 143:3607-3614.
56. Gottschalk, M., R. Higgins, M. Jacques, K. R. Mittal, and J. Henrichsen. Description of 14 new capsular types of *Streptococcus suis*. *J. Clin. Microbiol.* 27:2633-2636.
57. Heath, P. J., B. W. Hunt, and J. P. Duff. 1996. *Streptococcus suis* serotype 14 as a cause of pig disease in the UK. *Vet. Rec.* 2:450-451.
- 10 58. Hommez, J., L. A. Devrieze, J. Henrichsen, and F. Castryck. 1986. Identification and characterization of *Streptococcus suis*. *Vet. Microbiol.* 16:349-355.
59. Killper-Balz, R., and K. H. Schleifer. 1987. *Streptococcus suis* sp. nov. nom. rev. *Int. J. Syst. Bacteriol.* 15 37:160-162.
60. Kolkman, M. A. B., B. A. M. van der Zeijst, and P. J. M. Nuijten. 1998. Diversity of capsular polysaccharide synthesis gene clusters in *Streptococcus pneumoniae*. Submitted for publication.
- 20 61. Lee, J. C., S. Xu, A. Albus, and P. J. Livolsi. 1994. Genetic analysis of type 5 capsular polysaccharide expression by *Staphylococcus aureus*. *J. Bacteriol.* 176:4883-4889.
62. Reek, F. H., M. A. Smits, E. M. Kamp, and H. E. Smith. 1995. Use of multiscreen plates for the preparation of 25 bacterial DNA suitable for PCR. *BioTechniques* 19: 282-285.
63. Sau, S., N. Bhasin, E. R. Wann, J. C. Lee, T. J. Foster, and C. Y. Lee. 1997. The *Staphylococcus aureus* allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. *Microbiol.* 143: 2395-30 2405.
64. Sau, S., and C. Y. Lee. 1996. Cloning of type 8 capsule genes and analysis of gene clusters for the production of different capsular polysaccharides in *Staphylococcus aureus*. *J. Bacteriol.* 178: 2118-2126.
- 35 65. Sau, S., and C. Y. Lee. 1997. Molecular characterization and transcriptional analysis of type 8 capsule genes in

- Staphylococcus aureus*. J. Bacteriol. 179:1614-1621.
66. Smith, H. E., M. Rijnsburger, N. Stockhofe-Zurwieden, H. J. Wisselink, U. Vecht, and M. A. Smits. 1997. Virulent strains of *Streptococcus suis* serotype 2 and highly virulent strains of *Streptococcus suis* serotype 1 can be recognized by a unique ribotype profile. J. Clin. Microbiol. 35:1049-1053.
67. Yamazaki, M., L. Thorne, M. Mikolajczak, R. W. Armentrout, and T. J. Pollock. 1996. Linkage of genes essential for synthesis of a polysaccharide capsule in *Sphingomonas* strain S88. J. Bacteriol. 178:2676-2687.
68. Zhang, L., A. Al-Hendy, P. Toivanen, and M. Skurnik. 1993. Genetic organization and sequence of the *rfb* gene cluster of *Yersinia enterocolitica* serotype O:3: similarities to the dTDP-L-rhamnose biosynthesis pathway of *Salmonella* and to the bacterial polysaccharide transport systems. Mol. Microbiol. 9:309-321.
69. Clifton-Hadley, F.A. (1983). *Streptococcus suis* type 2 infections. Br. Vet. J. 139, 1-5.
70. Vecht, U., van Leengoed, L. A. M. G. and Verheyen, E. R. M. (1985). *Streptococcus suis* infections in pigs in The Netherlands (part one). Vet. Quart. 7, 315-321.
71. Arends, J. P. and Zanen, H. C. (1988). Meningitis caused by *Streptococcus suis* in humans. Rev. Infect. Dis. 10, 131-137.
72. Hommez, J., Devrieze, L.A., Henrichsen, J. and Castryck, F. (1986). Identification and characterization of *Streptococcus suis*. Vet. Microbiol. 16, 349-355.
73. Killper-Balz, R. and Schleifer, K. H. (1987). *Streptococcus suis* sp. nov. nom. rev. Int. J. Syst. Bacteriol. 37, 160-162.
74. Gottschalk, M., Higgins, R. and Jacques, M. (1993). Production of capsular material by *Streptococcus suis* serotype 2 under different conditions. Can. J. Vet. Res. 57, 49-52.
75. Higgins, R. and Gottschalk, M. (1990). An update on *Streptococcus suis* identification. J. Vet. Diagn. Invest. 2, 249-252.

- 76 Gottschalk, M., Higgins, R., Jacques, M., Beaudoin, M.
and Henrichsen, J. (1991). Characterization of six new
capsular types (23 through 28) of *Streptococcus suis*. J. Clin.
Microbiol. 29, 2590-2594.
- 5 77 Gottschalk, M., Higgins, R., Jacques, M., Mittal, K. R.
and Henrichsen, J. (1989) Description of 14 new capsular types
of *Streptococcus suis*. J. Clin. Microbiol. 27, 2633-2636.
- 78 Higgins, R., Gottschalk, M., Boudreau, M., Lebrun, A. and
Henrichsen, J. (1995). Description of six new capsular types
10 (28 through 34) of *Streptococcus suis*. J. Vet. Diagn. Invest.
7, 405-406
- 79 Aarestrup, F. M., Jorsal, S. E. and Jensen, N. E. (1998).
Serological characterization and antimicrobial susceptibility
of *Streptococcus suis* isolates from diagnostic samples in
15 Denmark during 1995 and 1996. Vet. Microbiol. 15, 59-66.
- 80 MacLennan, M., Foster, G., Dick, K., Smith, W. J. and
Nielsen, B. (1996). *Streptococcus suis* serotypes 7, 8 and 14
from diseased pigs in Scotland. Vet Rec. 139, 423-424.
- 81 Sihvonen, L., Kurl, D. N. and Henrichsen, J. (1988).
20 *Streptococcus suis* isolates from pigs in Finland. Acta Vet.
Scand. 29, 9-13.
- 82 Boetner, A. G., Binder, M. and Bille-Hansen, V. (1987).
Streptococcus suis infections in Danish pigs and experimental
infection with *Streptococcus suis* serotype 7. Acta Path.
25 Microbiol. Immunol. Scand. Sect. B, 95, 233-239.
- 83 Smith, H. E., Veenbergen, V., van der Velde, J., Damman,
M., Wisselink, H. J. and Smits, M. A. (1999). The cps genes of
Streptococcus suis serotypes 1, 2 and 9: development of rapid
serotype-specific PCR assays. J. Clin. Microbiol. submitted
- 30 84 Smith, H. E., Damman, M., van der Velde, J., Wagenaar,
F., Wisselink, H. J., Stockhofe-Zurwieden, N. and Smits, M. A.
(1999). Identification and characterization of the cps locus
of *Streptococcus suis* serotype 2: the capsule protects against
phagocytosis and is an important virulence factor. Infect.
35 Immun. 67, 1750-1756.
- 85 Miller, J. (1972). Experiments in Molecular Genetics.

- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- 86 Sambrook, J., E. F. Fritsch, and T. Maniatis. (1989).
Molecular cloning: a laboratory manual. Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY.
- 5 87 Allen, A. and Maskell, D. (1996). The identification,
cloning and mutagenesis of a genetic locus required for
lipopolysaccharide biosynthesis in *Bordetella pertussis*. *Mol.*
Microbiol. 19, 37-52.
- 88 Wang, L. and Reeves, P. R. (1998). Organization of
10 *Escherichia coli* O157 O antigen gene cluster and
identification of its specific genes. *Infect. Immun.* 66, 3545-
3551.
- 89 Wisselink, H. J., Reek, F. H., Vecht, U., Stockhofe-
Zurwieden, N., Smits, M. A. and Smith, H. E. (1999).
- 15 Detection of virulent strains of *Streptococcus suis* type 2 and
highly virulent strains of *Streptococcus suis* type 1 in
tonsillar specimens of pigs by PCR. *Vet. Microbiol.* 67, 143-
157.
- 90 Konings, R. N. H., Verhoeven, E. J. M. and Peeters, B. P.
20 H. (1987). pKUN vectors for the separate production of both
DNA strands of recombinant plasmids. *Methods Enzymol.* 153, 12-
34.

0976704-0304
F02270-740260